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Summary 
 
              Drug development is aimed at therapeutic agents that possess desirable 
pharmacological properties, which include pharmacokinetic, pharmacodynamic and 
toxicological profiles. Historically, inappropriate pharmacological properties have been 
one of the primary reasons for the failure of drug candidates in the later stages of drug 
development. Thus tools for predicting pharmacological properties in early drug 
discovery stages are desirable for fast elimination of agents with undesirable properties so 
that development efforts can be focused on the most promising candidates. As part of the 
efforts for developing such tools, computational approaches have been explored for 
predicting various pharmacological properties of pharmaceutical agents. In particular, 
statistical learning methods (SLMs) have shown promise for these tasks by statistically 
analyzing the correlation between chemical structures and a specific property to derive 
statistical models or rules for predicting whether an agent possesses a specific property or 
not. 
 
              Previously, pharmacological property prediction models were frequently built 
upon limited number of structurally related compound sets and by using linear regression 
methods. Hence they may not be suitable for the prediction of pharmacological properties 
of structurally diverse compounds and for pharmacological properties that are regulated 
by multiple mechanisms. Moreover, some pharmacological properties, which are 
pharmacologically and clinically important, are insufficiently studied by different 
computational approaches. Thus it is of interest and necessary to examine the potential of 
using enlarged and more diverse groups of compounds and non-linear SLMs in 
improving the quality of pharmacological property prediction models and in applying the 
SLMs on those important but insufficiently studied pharmacological properties. This 
   ix 
work aims at studying the applicability of SLMs, such as support vector machine (SVM), 
probabilistic neural network (PNN), k nearest neighbor (k-NN), C4.5 decision tree (C4.5 
DT), linear discriminate analysis (LDA) and logistic regression (LR) to classify 
compounds of diverse structures into different pharmacological property categories. 
Specifically, the pharmacokinetic models explored in this work are activators for 
pregnane X receptor (PXR) and blood brain barrier (BBB) agents. The pharmacodynamic 
model studied in this work is agonists of estrogen receptor (ER) and the toxicity models 
studied are genotoxicity (GT) and Tetrahymena pyriformis toxicity (TPT) agents.  
 
               A set of 199 molecular descriptors are used to describe the molecular 
pysicochemical properties of those pharmaceutical agents studied in this work. A feature 
selection method, recursive feature elimination (RFE), is incorporated to improve the 
prediction performance. The results show that SLMs could improve the quality of these 
pharmacological property prediction models by using enlarged and more diverse groups 
of compounds. RFE is able to identify a group of relevant molecular descriptors that 
reflect the pharmacological property of studied models and are consistent to quantitive 
structure activity relationship (QSAR), pharmacophore and X-ray crystallographic 
studies. In addition, selection of appropriate molecular descriptors can lead to 
substantially more balanced prediction accuracies and enhance the overall accuracies. 
Moreover, SLMs are found to be useful for developing prediction models and 
characterizing relevant physicochemical features for PXR activators and ER agonists, 
which are very important pharmacological properties of drug candidates but insufficiently 
explored in previous studies.  
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Chapter 1 Introduction 
 
 
Statistical learning methods (SLMs) have been successfully applied in many 
diverse fields with numerous applications such as medical decision making, protein 
function prediction, speech recognition, detection of oil spills and micro-array gene 
expression analysis. Because of their success in these fields, SLMs are increasingly 
employed to reduce the time and cost needed for evaluating the pharmacological 
properties of drug candidates. The most common SLMs are traditional linear 
statistical methods such as linear regression and multiple linear regressions. Non-
linear SLMs such as support vector machine (SVM) and artificial neural networks 
(ANN) have been evaluated for their usefulness for the prediction of pharmacological 
properties. In this chapter, an overview for drug discovery and pharmacological 
properties of pharmaceutical agents (section 1.1) and current available SLMs used to 
study and to predict pharmacological behaviour of a drug or pharmaceutical agent 
are given (section 1.2). A subsection is presented to illustrate how molecular 
properties of a drug or pharmaceutical agent can be described by molecular 
descriptors (section 1.3). These descriptors will serve as input for all SLMs mentioned. 
Brief description for feature selection method used in this work is also given (section 
1.4). The significance of all the pharmacological property models studied in current 
work was provided (section 1.5). Finally, the objectives and outline of this work are 
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1.1 Drug discovery and pharmacological properties of 
pharmaceutical agents  
 
 
Pharmacology is the study of the effects of chemical compounds on the 
function of living systems [Rang et al. 2003]. Although the motivation of 
pharmacology comes from clinical practice, it can only be built on the basis of various 
biological sciences such as physiology, pathology, molecular cell biology as well as 
other sciences such as chemistry, physics, computational science and bioinformatics. 
Since proteins are major products of genes and are key players in regulating a myriad 
of biological events from cell division, differentiation to cell death, most of the drug 
targets are proteins although some drugs target RNA or DNA. Mutations of these 
essential proteins in cells may lead to disorders in living organisms. For years 
countless of efforts have been devoted to developing more sophisticated approaches 
and techniques to identify disease-related proteins. For decades, researchers hope to 
develop small compounds that behave as “magic bullets” or drugs that target these 
proteins specifically and hence to moderate their functions. Therefore, a very first step 
in drug discovery process is to identify a disease-causing protein target before the 
drug leads or drug candidates are discovered. A validated target is usually an effector 
of a therapeutic compound that, when modulates in human, will provide 
pharmacological effect. High throughput screening (HTS) approaches for finding 
potential therapeutic compounds on validated targets have been established [Ohlstein 
et al. 2000]. Compounds of diverse structure from a chemical library are then used in 
HTS to screen against these validated targets [Drews 2000]. 
 
Even if a compound shows high selectivity and specificity to a disease-causing 
protein, there is no guarantee that the compound can succeed as a drug in clinical 
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phase. This is due to several important aspects in pharmacology: pharmacokinetics, 
pharmacodynamics and toxicity. Pharmacokinetic properties of a substance refer to its 
rate and extent of absorption, distribution, metabolism, and excretion when it enters a 
living body. These processes are normally called ADME in short. Pharmacodynamics, 
on the other hand, refers to how a compound interacts with a target protein at the 
molecular level, such as inhibiting or activating the protein function, altering or 
modulating the biological pathway behaviors, side effects, or even toxicities. Hence, 
toxicity is the side effects that can be caused by the multiple targets of the drug 
candidates through interfering cells normal functions. 
 
The drug discovery process is typically a lengthy and costly process. As 
shown in Figure 1.1, in modern drug design process the average time required for a 
drug to proceed from initial design effort to market approval is about 13 years. The 
estimated average development cost of a new drug is about US$802 million, with the 
preclinical phase and clinical phase costing about US$335 million and US$467 
million respectively [DiMasi et al. 2003]. Traditionally, pharmacokinetic and toxicity 
profiles of pharmacological properties of drug candidates have primarily been 
evaluated during later downstream stages, particularly in the expensive animal tests 
and clinical trials [van de Waterbeemd et al. 2003]. According to a recent report, 
approximatedly 40% of all drug failures during the clinical phase are due to poor 
pharmacokinetics (7%) or poor pharmacodynamics and unacceptable toxicities (33%) 
[Kubinyi 2003]. To increase the efficiency and reduce the cost and time of 
pharmaceutical research and development, there has been a paradigm shift such that 
pharmacological properties are now considered and evaluated in the less costly, 
earlier stages of drug discovery process, such as lead identification and optimization. 
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This enables all the pharmacological properties to be optimized simultaneously, thus 
resulting in cost and time savings. This strategy has been widely accepted in the 
pharmaceutical industry now. Thus methods for predicting pharmacological 
properties of drug candidates with diverse structures, particularly in the early phase of 
drug discovery and safety evaluation, are useful and desirable for facilitating durg 
discovery and safety evaluation [Drews 2000; Ekins et al. 2000b; White 2000]. 














In summary, drug development is aimed at the finding of therapeutic agents 
that possess desirable pharmacodynamic, pharmacokinetic properties and low 
toxicological profiles [Caldwell et al. 1995; Drews 2000; Park et al. 2000]. 
Historically, inappropriate pharmacokinetic properties [Prentis et al. 1988; Spalding 
et al. 2000; Bugrim et al. 2004], pharmacodynamic properties and toxicity [Bugrim et 
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al. 2004] have been the primary reasons for the failure of drug candidates in later 
stages of drug development. Tools for predicting pharmacokinetic and 
pharmacodynamic properties as well as toxicological properties in the early drug 
design stages are needed for fast elimination of agents with undesirable properties so 
that development efforts can be focused on the most promising candidates [Drews 
2000; Ekins et al. 2000b; White 2000]. As part of the efforts for developing such tools, 
computational methods have been explored for predicting various pharmacological 
properties of pharmaceutical agents. SLMs are the computational approaches that are 
increasingly used for in silico HTS of compounds with diverse structures in early drug 
discovery stage. 
 
1.2 Statistical learning methods for characterization of 
pharmacological properties of pharmaceutical agents 
 
With the advancemet in computational technologies, SLMs have become 
increasingly important in the drug discovery and development process.  SLMs are 
procedures used in the study of computer predictions, classifications or analysis of 
algorithms where the learning process may improve automatically through experience 
[Vapnik 1995].  SLMs have been successfully used in many diverse fields with 
numerous applications such as pharmacological properties predictions [Czerminski et 
al. 2001; Livingstone et al. 2003], medical decision making [Veropoulos 2001], 
protein function prediction [Cai et al. 2003], speech recognition [Burges 1998], 
detection of oil spills [Kubat et al. 1998], and micro-array gene expression analysis 
[Guyon et al. 2002]. The reason for the widespread adoption of SLMs in different 
fields is that they do not make any assumption about the nature of the relationship 
between the property to be predicted and the factors affecting that property. This 
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enables complex relationships to be modeled accurately and thus improves the 
prediction accuracy of these models. 
 
             As part of the efforts to accelerate and reduce the cost of drug discovery 
processes, SLMs have been explored for predicting various pharmacokinetic, 
pharmacodynamic and toxicological properties of pharmaceutical agents [Katritzky et 
al. 1997; Manallack et al. 1999; van de Waterbeemd et al. 2003; Hansch et al. 2004]. 
These include drug properties such as bioavailability [Nandagere et al. 2003], cellular 
permeability [van de Waterbeemd et al. 2003], skin permeability [Abraham et al. 
1999], first pass effect [Watari et al. 1988], intestinal absorption [Xue et al. 2004b], 
active transport processes [Ekins et al. 2000c], blood-brain barrier penetration [Liu et 
al. 2001a; Ecker et al. 2004], serum protein binding [Votano et al. 2006], P450 
isoenzyme substrates and inhibitors [Molnar et al. 2002b; Ekins et al. 2003], 
genotoxicity [He et al. 2003], carcinogenicity [Morales et al. 2006] and mutagenicity  
[Simon-Hettich et al. 2006].  Therefore SLMs have shown promise for performing 
these tasks by statistically analyzing the correlation between chemical structures and a 
specific property to derive statistical models or rules for predicting, whether an agent 
possesses a specific property and, in some cases, the activity level of the agent 
[Manallack et al. 1999; Burbidge et al. 2001; Liu et al. 2001b; Trotter et al. 2003].  
 
The earliest explorations of  SLMs are in drug development regression-based 
quantitative structure activity relationship (QSAR) [Katritzky et al. 1997; Hansch et 
al. 2004], in which the activity of an agent can be modeled and predicted from a 
selected set of structure-derived structural and physicochemical features by using a 
statistically derived mathematical equation. These methods have been extensively 
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reviewed elsewhere [Katritzky et al. 1997; Hansch et al. 2004]. Table 1.1 summarizes 
the performance of several regression-based SLMs for predicting pharmaceutical 
agents of specific pharmacokinetic, pharmacodynamic or toxicological property. The 
performances of these studies are primarily measured by the r2 value, which measures 
the explained variance between the computed activities and experimentally measured 
activities. Furthermore, q2 values, RMSE values and average-fold errors for an 
independent validation set are also frequently computed to further evaluate the 
predictive capability of these statistical models. The computed r2 values of these 
regression-based SLMs listed in Table 1.1 are in the range from 0.51 to 0.95 [Ertl et 
al. 2000; Yamazaki et al. 2004], which are at a level useful for predicting the activity 
values of compounds of particular pharmacological properties. 
 
In an attempt to develop pharmacological property prediction models that 
cover more diverse ranges of structures and properties than those described by the 
available QSAR models, nonlinear supervised learning methods such as support 
vector machines (SVM) [Burbidge et al. 2001; Trotter et al. 2003; Li et al. 2005b; 
Yap et al. 2005] and artificial neural networks (ANN) [Manallack et al. 1999; 
Doniger et al. 2002; Yap et al. 2004b] have recently been explored for predicting the 
property and the activity of an agent from its structural and chemical features by using 
an in-explicit statistical model or classifier. In contrast to QSAR methods, these 
recently explored SLMs derive in-explicit statistical models to classify agents into 
two classes, one possessing and the other not possessing a specific property 
[Manallack et al. 1999; Burbidge et al. 2001; Trotter et al. 2003; Xue et al. 2004c; Li 
et al. 2005b; Yap et al. 2005]. Table 1.2 summarizes the reported performances by 
using classification-based SLMs for predicting pharmaceutical agents of specific 
CHAPTER 1 INTRODUCTION                                                                                            8
pharmacokinetic, pharmacodynamic or toxicological property. The number of 
compounds in many of the studies listed in Table 1.2 is in the range of hundreds or 
even thousands of compounds, which is significantly higher than the tens or sometime 
hundreds of compounds typically used in QSAR studies [Grover et al. 2000] and 
closer to those used for developing structure-based [Shoichet 2004; Ghosh et al. 2006] 
and ligand-based [Lengauer et al. 2004; Oprea et al. 2004] virtual screening systems. 
The computed positive accuracies are in the range of 53% ~ 100%, with the majority 
concentrating in the range of 80%~96%. The computed negative accuracies are 
distributed in the range of 67% ~ 100%, with the majority concentrating in the range 
of 80%~99%. These results suggest that the SLMs reviewed here have certain level of 
capability for distinguishing between compounds of a particular pharmacological 
property and those without that property.  
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Table 1.1 Performance of regression-based statistical learning methods for predicting compounds of specific pharmacokinetic, 
pharmacodynamic or toxicological property. The relevant literature references are given in the method column. 




Molecular descriptors Validation methoda Reported prediction 
statistics 
E-state Training set (84) 
10% CV (84) 
Validation set (10) 
r2=0.77, q2=0.70,  
r2=0.68 




ELE, TOP, information-content, spatial, 
structural, thermodynamic 
Training set (84) 












CON, TOP, GEO, electrostatic, Q-C Training set (84) 






ki et al. 2004] 
Log P Training set (226) 





ner et al. 
2005] 
Log P Training set 1 (84) 
Training set 2 (44) 







fb ANN[Klein et 
al. 2002] 
Atom and functional group counts, 
connectivity index differences, 
connectivity index quotients, charge 
indices, vertex counts, ramifications, 
Wiener number, MW, Log P 




a et al. 2005] 
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hERG potassium 
channel blockers 
pIC50 PLS[Yao et al. 
2005] 
GRIND descriptors Training set (332) 
Validation set (16) 
Training set (518) 




PSA Training set (45) r2=0.95 
MW, molecular lipoaffinity Training set (55) 
Validation set (11) 









al. 2001; Liu 
et al. 2001b] Hydrogen bonding, molecular volume, 
solvent-accessible surface area 






Physicochemical, structural fragment Training set (417) 





PLS [Oprea et 
al. 1999] 
 
Log P, molecular size, H-bond, counts Training set (16) 








et al. 1999] 
 
MolSurf Training set (13) 









et al. 2004] 
Atom and functional group counts, 
connectivity index differences, 
connectivity index quotients, charge 
indices, vertex counts, ramifications, 
Wiener number, MW, Log P 
Validation set (6) r2=0.731 
Abbreviations:  HIA – human intestinal absorption; hERG – human ether-a-go-go-related gene; MLR – multiple linear regression; GRNN – general regression neural 
network; SVR – support vector regression; LSSVM – least square support vector machine; DRAGON – (an application for the calculation of molecular descriptors); ELE – 
electronical; MW – molecular weight; SIBAR – similarity based structure activity relationship; GRIND – grid independent descriptors;  a – number in parenthesis denotes 















Table 1.1 Continued 
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Table 1.2 Performance of classification-based statistical learning methods for predicting compounds of specific pharmacokinetic, 
pharmacodynamic or toxicological property. The relevant literature references are given in the method column. 
Reported prediction 
accuracy 
Property Method and 
reference of 
reported study 







Method (No of 
compounds) a Pp (%) Pn (%) P(%) 
5HT reuptake 
inhibitors 
SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
371/2498 Validation set 
(374/27971) 
70.9 97.5 -- 
Adenosine receptor 
A1 agonists 
SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
126/2498 Validation set 
(130/27971) 
67.7 99.5 -- 
Adenosine receptor 
A2 agonists 
SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
143/2498 Validation set 
(146/27971) 
71.9 97.9 -- 
CRF antagonists SVM[Zuegge et 
al. 2002] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
198/2498 Validation set 
(203/27971) 
88.2 99.2 -- 
PLS[Molnar et al. 
2002a] 
CATS, TOP, ELE, count, 
structural, atom types 
311 Validation set 1 (50) 







ANN[Yap et al. 
2005] 
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partitioning[Yap 
et al. 2005] 
keys, 1D similarity scores 
Consensus 
SVM[Yap et al. 
2005] 
DRAGON 602 Validation set (100) 90.0 95.0 94.0 
CYP2C9 inhibitors Consensus 
SVM[Yap et al. 
2005] 
DRAGON 602 Validation set (100) 88.9 96.3 95.0 
CYP2D6 substrates Consensus 
SVM[Yap et al. 
2005] 
DRAGON 602 Validation set (100) 98.2 90.9 95.0 
CYP3A4 substrates Consensus 
SVM[Yap et al. 
2005] 
DRAGON 602 Validation set (100) 96.6 94.4 95.0 
CYP2C9 substrates Consensus 
SVM[Fujishima 
et al. 2004] 




ANN[Lepp et al. 
2006] 
Topological Structural 
Fragment based on the 
enumeration of all possible 
substructure from a chemical 
structure and the numerical 
characterization of them 
1227 Validation Set (137) - - 81 
Dopamine D1 
antagonists 
SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
87/2498 Validation set 
(92/27971) 
57.6 99.8 -- 
Dopamine D2 
antagonists 
SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
241/2498 Validation set 
(243/27971) 














Table 1.2 Continued 
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Dopamine reuptake 
inhibitors 
SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
83/2498 Validation set 
(89/27971) 
52.8 99.8 -- 
HT1A agonists SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
489/2498 Validation set 
(497/27971) 
79.7 95.2 -- 
HT1A antagonists SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
489/2498 Validation set 
(261/27971) 
67.4 98.8 -- 
HT1C agonists SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
68/2498 Validation set 
(71/27971) 
80.3 99.6 -- 
HT1D agonists SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
310/2498 Validation set 
(314/27971) 
88.9 97.9 -- 
HT2A agonists SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
321/2498 Validation set 
(328/27971) 
80.8 96.2 -- 
HT2B antagonists SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
53/2498 Validation set 
(56/27971) 
73.2 99.1 -- 
HT2C antagonists SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
115/2498 Validation set 
(120/27971) 
55.8 99.4 -- 
HT3 antagonists SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
419/2498 Validation set 
(426/27971) 
84.5 96.9 -- 
MAO A inhibitors SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
44/2498 Validation set 
(49/27971) 















Table 1.2 Continued 
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acceptor 
MAO B inhibitors SVM[Lepp et al. 
2006] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
56/2498 Validation set 
(60/27971) 
58.3 99.9 -- 
Norepinephrine 
reuptake inhibitors 
SVM[Xue et al. 
2004c] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
109/2498 Validation set 
(114/27971) 
80.8 99.2 -- 
P-gp substrates SVM[Manallack 
et al. 2002] 
Simple molecular properties, 
molecular connectivity and 
shape, E-state, Q-C, GEO 






NN[Lepp et al. 
2006] 
20 standard BCUT 
descriptors 




et al. 2002] 
Atom types, chain, ring, 
rotatable bond, H-bond 
acceptor 
643/2498 Validation set 
(980/27971) 
82.0 96.6 -- 
Agents acting at 
class A rhodopsin-




21 standard BCUT 
descriptors 
2736 Ensemble of 100 
Networks (2736) 
80.9 82.1 81.5 
Agents acting at 
class A rhodopsin-
like peptide binding 
GPCRs 
Consensus 
NN[Hall et al. 
2003] 
21 standard BCUT 
descriptors 
1400 Ensemble of 100 
Networks (1400) 
87 89.3 88.1 
Abbreviations: HIA – human intestinal absorption; P-gp – p-glycoprotein; MAO – mono amino oxidase; CRF – corticotrophin releasing factor; CYP – cytochrome protein; 
LDA – linear discriminant analysis; ANN – artificial neural network; NN –  neural network; SVM – support vector machine; PLS – partial least squares; DRAGON – (an 
application for the calculation of molecular descriptors); BCUT – Burden-CAS- University of Texas; GEO – geometrical; H-bond – hydrogen bond; E-state – electronically 















Table 1.2 Continued 
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1.3 Describing molecular properties using molecular descriptors 
 
Converting descriptions of molecular physicochemical properties such as size, 
shape, connectivity, dipole moment, hydrogen bonding, and electrostatic interactions into 
digital values that serve as input for SLMs is an important step in the success of applying 
SLMs in the computational study of pharmacological properties of diverse set of 
compounds. Hence, proper representation of the structural and physicochemical features 
of chemical agents is the key to the successful application of SLMs and to the elucidation 
of the underlying molecular mechanism of a particular pharmacokinetic, 
pharmacodynamic or toxicological property from the derived statistical models [Xue et al. 
2004b; Li et al. 2005b]. Currently, over 3,700 molecular descriptors have been used for 
representing structural and physicochemical features of chemical agents based on their 
1D, 2D or 3D structures. These descriptors range from constitutional descriptors such as 
molecular weight to more complex 2D and 3D descriptors representing different 
geometric, connectivity, and physicochemical properties [Hopfinger 1980; Cruciani et al. 
2000; Hall et al. 2002; Xue et al. 2004b; Todeschini et al. 2005; Wegner 2005]. Efforts 
have been directed at the development of additional molecular descriptors for 
representing agents of more complex structures and for modeling more extensive sets of 
properties. Detailed description of molecular descriptors will be presented in Chapter 2. 
 
1.4 Feature selection methods 
 
In practice, not all of those molecular descriptors are needed for representing 
features of a particular class of agents. Among the descriptors some are irrelevant or 
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negligible to a specific pharmacological property of the compounds. Feature selection 
methods have been explored and are being improved for finding appropriate sets of 
structural and physicochemical features for predicting a specific property [Iyer et al. 2002; 
Serra et al. 2003; Weston et al. 2003; Liu 2004; Venkatraman et al. 2004; Xue et al. 
2004b; Li et al. 2005b; Walters et al. 2005] and for improving computation speed, 
performance and interpretability of pharmacological properites predicton models. 
Features useful for agents of a particular property can be selected either by intuition as in 
the typical cases of QSAR studies, or by using subjective feature selection methods. The 
commonly used feature selection methods include recursive feature eliminations (RFE) 
[Guyon et al. 2002], genetic algorithm-based approach [Lucasius et al. 1993], and 
simulated annealing-based approach [Sutter et al. 1993]. Some of these methods, 
particularly RFE,  have gained popularity due to their effectiveness for discovering 
informative features in the analysis of drug activities [Guyon et al. 2002; Yu et al. 2003] 
and pharmacokinetic and toxicological properties [Iyer et al. 2002; Serra et al. 2003; Xue 
et al. 2004b; Xue et al. 2004c; Li et al. 2005a; Li et al. 2005b]. Detailed description of 
feature selecton and RFE feature selection method will be provided in Chapter 2.  
 
1.5 Models studied in this work and the importance of these models 
 
 
The pharmacological properties of a pharmaceutical agent are pharmacokinetics, 
pharmacodynamics, and toxicity. It is thus reasonable to divide the computational 
prediction models into these three categories. However, due to the diverse range of 
activities in each category, we focused our attention on a limited number of the current 
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properties and developed prediction models for these properties in the current work based 
on either the model’s clinical importance or novelties. The pharmacokinetic models 
studied are pregnane X receptor (PXR) activators and blood brain barrier (BBB) agents. 
The pharmacodynamic model studied is the agonists for estrogen receptor (ER) and the 
toxicological models studied are genotoxicity and Tetrahymena pyriformis toxicity (TPT) 
agents. This work does not serve as a complete study to all aspects of pharmacological 
properties of pharmaceutics but as a preliminary attempt to use SLMs, in particular SVM, 
as computation tools to facilitate drug discovery process. Detailed descriptions, results 
and discussions of each model are given in Chapter 3, Chapter 4 and Chapter 5 
respectively. 
 
1.5.1 Pregnane X Receptor (PXR) activators 
 
PXR plays important roles in the metabolism of xenobiotics and drug-drug 
interactions by regulating the expression of metabolizing enzymes such as cytochrome 
P450 enzymes (CYP3A4, CYP2B6, CYP2C8/9), and glutathione-S-transferases [Kliewer 
et al. 2002]. It also regulates the expression of important drug transporters such as P-
glycoprotein [Ekins 2004; Xie et al. 2004]. Therefore, drugs capable of activating PXR 
may have significant impacts on their own metabolism, transport and interaction with 
other drugs. Identification of PXR activators is important for analyzing metabolism and 
pharmacokinetic profiles of drug candidates and for detecting potential drug-drug 
interactions. 
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Most of the drug metabolism prediction efforts have been directed at the 
development of computational tools for predicting CYP substrates and inhibitors [Ekins 
et al. 2000a; Doniger et al. 2002]. However, significantly less efforts have been devoted 
to the development of computational approaches for identifying PXR activators. Because 
of the importance of PXR in drug metabolism and drug-drug interactions, more efforts 
are needed to explore additional computational methods for predicting a broader 
spectrum of PXR activators than those covered by existing studies.  
 
1.5.2 Blood brain barrier (BBB) agents 
 
 
Good pharmacokinetic properties are required to achieve sufficient drug 
concentration at a target site while possibly limiting its distribution elsewhere to reduce 
potential side effects [Butina et al. 2002]. One important pharmacokinetic property of a 
drug is its ability or inability to penetrate the blood-brain barrier [Norinder et al. 2002]. 
BBB-penetration (BBB+) is important for drugs that target receptors in the brain. For 
drugs not directed at targets in the brain, BBB+ is undesirable to avoid unwanted central 
nervous system (CNS) related side effects.  
 
Previous results of BBB binary classification SLM models indicate that a more 
balanced prediction with an improved BBB non-penetration (BBB-) accuracy is needed 
for facilitating the prediction of BBB- agents as well as for reducing the false positive 
rate of the prediction of BBB+ agents. It is therefore of interest to examine whether 
proper selection of molecular descriptors by using RFE feature selection method could 
improve the BBB- accuracy and the overall BBB+/BBB- accuracy of SLMs.  
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1.5.3 Estrogen receptor (ER) agonists 
 
Estrogen receptors are members of nuclear receptor family that playing important 
roles in cell growth, development, and homeostasis processes in various tissues. ER 
ligands are classified into three types: agonists, antagonists and selective ER modulators 
[MacGregor et al. 1998]. In particular, ER agonists have been used as drugs for hormone 
replacement therapy, contraception, prevention of osteoporosis [Coelingh 2004], and for 
the treatment of metastatic prostate cancer [Oh 2002]. Apart from these beneficial effects, 
exposure to environmental ER agonists and partial agonists has been proposed to be risk 
factor for the interference of reproductive system development and tumorigenesis in 
humans [Hileman 1997].  
 
A few SLMs have been used for the prediction of ER binders [Fang et al. 2001; 
Hu et al. 2003; Asikainen et al. 2004; Tong et al. 2004b]. However, prediction of ER 
binders does not automatically enable the identification of ER agonists which are 
important therapeutic drug candidates. So it is critical to evaluate the capability of the 
most widely used SLMs for predicting ER agonists specifically by using a significantly 
larger number and more diverse range of ER agonists and non-agonists. 
 
1.5.4 Genotoxicity agents 
 
Genotoxicity is one of the adverse drug reactions (ADRs) closely evaluated in 
drug discovery and approval processes. The molecular mechanisms of genotoxicity 
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include DNA intercalation by aromatic ring of a drug, DNA methylation, DNA adduct 
formation and strand breakage, and unscheduled DNA synthesis [Bolzan et al. 2002].  
 
Computational tools for fast and efficient prediction of drug genotoxic potential 
have been developed [Kramer 1998; Schwetz et al. 1998]. However, the performance of 
these methods is practically limited by the quality of molecular descriptors, diversity of 
training and testing data, and the efficiency of SLMs. Therefore, there is a need to 
examine if a similar or even better level of accuracy can be achieved for the more diverse 
set of molecules. It is also of interest to determine if the genotoxic agents (GT+) 
prediction accuracy can be further improved by a training set composed of a more diverse 
set of GT+ agents. Moreover, other SLMs such as SVM and C4.5 DT have shown 
promising potential and it is useful to evaluate these methods on genetoxicity prediction. 
. 
1.5.5 Tetrahymena pyriformis toxicity (TPT) agents 
 
Toxicological tests and safety evaluations are essential and have been used for 
assessing the toxic potential of chemical compounds and investigational drugs, many of 
which have been tested with Tetrahymena pyriformis [Sauvant et al. 1995; Wu et al. 
1997; Sauvant et al. 1999; Darcy et al. 2002; Bonnet et al. 2003].  
 
 SLMs incorporated QSAR regression models have been explored for developing 
TPT agents prediction systems for both individual chemical groups [Serra et al. 2001; 
Netzeva et al. 2003b; Ren 2003b; Schuurmann et al. 2003; Melagraki et al. 2005; 
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Spycher et al. 2005] and multiple chemical groups [Niculescu et al. 2000; Gini et al. 
2004]. These methods achieve impressive predictive performance, but their practical 
application potential is not fully understood because of the limited diversity of training 
data, quality of molecular descriptors, and the efficiency of SLMs. Because of the 
diversity of compounds and mechanisms of toxic actions, it is desirable to explore 
additional SLMs such as SVM, k-NN and C4.5 DT. Instead of focusing on specific 
structural features or a particular group of related molecules, it is desirable to classify 
diverse sets of compounds into TPT and non-TPT agents based on their general structural 
and physicochemical properties irrespective of their structural and chemical affiliations. 
 
1.6 Objectives and outline of this work 
 
Overall, there are three major objectives for this work. The first objective is to 
construct computational classification models for some pharmacological properties that 
are clinically and pharmacologically important, but have not been sufficiently explored 
by computational methods. One of the examples is the PXR activators, which is 
important for analyzing metabolism and pharmacokinetic profiles of drug candidates and 
for detecting potential drug-drug interactions. However, no SLMs models have been built 
for PXR activators so far. Another example is the estrogen receptor (ER) agonists, which 
are potential drug candidate for beneficial therapeutic application. Although many 
computation models such as QSAR and pharmacophores had been built for ER binders, 
no SLM models for ER agonists, which are important to evaluate the estrogenic property 
of a compound, are built so far. Therefore, in this work we attempt to develop 
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computational SLMs classification models for these two less extensively studied, but 
clinically and pharmacologically important receptors. 
 
The second objective of this work is to improve the performance of previous 
pharmacological property prediction models. In this work, several strategies are used to 
achieve this objective. The first strategy is to apply newer SLMs, such as SVM and PNN, 
for the development of pharmacological property prediction models. These methods have 
shown promising potential for predicting pharmacological properties of drug candidates. 
It is of interest to compare the SLMs with previous computational approaches for the 
prediction of pharmacological properties. The second strategy is to use a larger number 
and more diverse groups of compounds for developing pharmacological property 
prediction models. Some of the previous pharmacological property models have been 
built using datasets with a limited number of related compounds and thus may not be 
suitable for predicting of pharmacological properties of diverse group of compounds. It is 
necessary to use more diverse and large data set to build more robust pharmacological 
property prediction systems. The third strategy is to use RFE feature selection method to 
properly select relevant molecular descriptors for facilitating a more balanced and 
improved overall prediction performance. 
 
The last objective is to improve on the interpretability of pharmacological 
property prediction models developed by SLMs. A common problem with these models 
is that they are often complex with multiple parameters and weights. Thus it is difficult to 
determine which physiochemical and structural properties of a compound are important 
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in determining its pharmacological properties. Hence it will be useful to have a method 
that can identify the important physicochemical and structural properties. The molecular 
descriptors selected by the feature selection method, particularly the RFE method, may 
provide specific structural information to identify the characteristics of the 
pharmacological properties of pharmaceutical agents, which may be very useful for high 
throughput drug screening of compounds from diverse structure dataset during the early 
stage of drug discovery process to identify novel pharmaceutical agents. 
 
In summary, this work is aimed at predicting and investigating pharmacological 
properties, including pharmacokinetics, pharmacodynamics and toxicological properties 
of pharmaceutical agents by using statistical learning methods. More specifically, the 
study seeks to predict and characterize PXR activators, BBB agents, ER agonists, 
genotoxic agents and TPT agents computationally. The present study may shed some 
light on the capability of statistical learning methods to the prediction of pharmacological 
properties of pharmaceutical agents, which could help in the lead discovery and 
optimization. 
 
The complete outline of this thesis is as follows: In Chapter 1, an introduction to 
drug discovery process is described and the pharmacological properties of pharmaceutical 
agents are defined. Specifically, the importance of pharmacological property prediction 
models such as PXR activators, BBB agents, ER agonists, genotoxicity agents and TPT 
agents is presented.  
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In Chapter 2, methods used in this work are described. In particular, the dataset 
quality analysis, the statistical molecular design, the molecular descriptors, the feature 
selection method, all the statistical learning methods used in this work, and the model 
evaluation methods are presented in more detail.  
 
 In Chapter 3, the models related to the prediction models of pharmacokinetic 
properties are given. In particular, PXR activator and BBB agent models are presented. 
With regards to the PXR activator model, PXR and hPXR activator prediction systems 
were developed by using SVM, PNN, and k-NN, which were trained and tested by using 
a significantly higher number of compounds than those used in previous studies. RFE 
was used to extract molecular descriptors associated with PXR activation. For the BBB 
model several SLMs were tested in this work. RFE was used for selecting molecular 
descriptors relevant to the prediction of BBB+ and BBB- agents. Analysis of the RFE 
selected descriptors and comparisons with other classification studies were also provided. 
 
Chapter 4 is devoted to pharmacodynamic property prediction. In particular, the 
model of ER agonists was the focus of the sutdy. The capability of the most widely used 
SLMs for predicting ER agonists by using a significantly larger number and more diverse 
range of ER agonists and non-agonists than in previous studies were evaluated. RFE was 
used for selecting molecular descriptors relevant to the prediction of ER agonists and 
non-agonists.  
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In Chapter 5, the models for the prediction of toxicological properties were 
provided. In particular, the genotoxicity and TPT models were the points of discussion. 
For the two toxicological prediction models, several SLMs were evaluated by using 
significantly larger number and more diverse range of pharmaceutical agents than in 
previous studies. In particular, SVM was studied because of its good performance in a 
number of classification problems. RFE was used in this work for selecting the molecular 
descriptors relevant to the classification of genotixic and non-genotoxic agents, including 
TPT and non-TPT agents.  
 
Finally, in the last chapter, Chapter 6, major findings and contributions of current 
work to the progress of using SLMs for predicting pharmacological properties of 
pharmaceutical agent were discussed. Limitations and suggestions for future studies were 
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Chapter 2 Methods 
 
  
 A pharmacological property prediction model will normally consist of three main 
components: (1) pharmaceutical agent datasets (section 2.1), (2) physicochemical and 
structural descriptions of the compounds in the dataset (section 2.2 and section 2.3) and 
(3) a statistical learning technique used to correlate the first two components (section 
2.4). In this chapter, these three components are described and all the methods used in 
this work for developing pharmacological properties prediction models are featured. 
Methods that are used for checking the validity and usefulness of pharmacological 




2.1.1 Quality analysis  
 
The development of reliable pharmacological property calssification models 
depends on the availability of high quality pharmacological property descriptor data with 
low experimental errors [Cronin et al. 2003]. Ideally, these pharmacological properties 
descriptors should be measured by a single protocol so that different compounds can be 
reliably compared with each other. However, some pharmacological properties 
descriptors have been measured only for a limited number of compounds and these data 
are rarely determined by the same protocol. Thus data selection has been primarily based 
on comparison of data of compounds commonly studied by different protocols, and 
incorporation of additional experimental information. 
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For this work, several methods are adopted to ensure that inter-laboratory 
variations in experimental protocols do not significantly affect the quality of the training 
sets. The sources for the pharmacological property descriptor data for each compound 
were investigated to ensure that there were no wide variations in experimental protocol 
from those of the majority of the compounds in the training set. Compounds that were 
investigated in more than one source are used to estimate the quality of each source. It is 
assumed that the most common range of the pharmacological properties descriptor data 
for the compounds investigated in more than one source was used to select compounds 
for the different classes [Susnow et al. 2003b]. 
 




                 
The use of an external independent validation set, which has been collected 
independently from the training set, is widely regarded as the best way to assess the 
quality of a pharmacological property model [Wold et al. 1995]. However, it is usually 
difficult to find additional sources of pharmacological property data to construct an 
independent validation set and thus the typical method is to split the original dataset into 
two different sets, a training set for developing the model and a validation set for 
evaluating the model performance [Gramatica et al. 2004]. The training set should 
contain compounds of diverse structures that can adequately represent all of the 
compounds that possess a particular pharmacological property [Rajer-Kanduc et al.; 
Schultz et al. 2003].  
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There are a number of approaches for creating diverse training sets and 
representative validation sets from the original dataset. A summary is given in Table 2.1. 
These include random selection, cluster-based methods, dissimilarity-based methods, 
cell-based methods, stochastic techniques, statistical experimental designs and neural 
networks [Daszykowski et al. 2002; Leach et al. 2003]. Studies have shown that 
dissimilarity-based methods, such as Kennard and Stone algorithm and removal-until-
done algorithm, are more effective than other algorithms in selecting diverse training sets 
and representative validation sets for developing and validating pharmacological property 
prediction models [Rajer-Kanduc et al.; Snarey et al. 1997]. Thus these two methods are 
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Single linkage [Leach et al. 2003] K-means [Forgy 1965] 
Complete linkage [Leach et al. 2003] Jarvis-Patrick clustering [Jarvis et al. 1973] 
Group average [Leach et al. 2003] DBSCAN [Ester et al. 1996] 
Wards method [Leach et al. 2003] OPTICS [Ankrest et al. 1999] 
Centroid method [Leach et al. 2003] DENCLUE [Han et al. 2001] 
Median method [Leach et al. 2003]  
 
Dissimilarity-based methods 
MaxSum [Snarey et al. 1997] OptiSim [Clark 1997] 
Kennard and Stone algorithm [Kennard et 
al. 1969] 
IcePick [Mount et al. 1999] 
Removal-until-done [Hobohm et al. 1002] Minimum spanning tree error function 
[Waldman et al. 2000] 
Sphere exclusion [Hudson et al. 1996]  
 
Cell-based methods 
Cummins algorithm [Cummins et al. 1996] 
Menard algorithm [Menard et al. 1998] 
Uniform cell coverage [Lam et al. 2002] 
 
Stochastic techniques 
Techniques using Monte Carlo sampling [Agrafiotis 1996; Hassan et al. 1996] 
Techniques using genetic algorithms [Sheridan et al. 2000; Gillet et al. 2002] 
 
Statistical experimental designs 
D-optimal design [Mitchell 1974] 




Kohonen’s self-organizing map [Kohonen 1995] 
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2.1.2.2 Kennard and Stone algorithm 
 
Two compounds with the largest Euclidean distance apart were initially selected 
for the training set. The remaining compounds for the training set were selected by 
maximizing the minimum distance between the compounds in the training set and the rest 
of the compounds in the dataset. This selection process would continue until the desired 
number of compounds was selected for the training set. The remaining compounds in the 
dataset would be used as the validation set [Kennard et al. 1969]. 
 
2.1.2.3 Removal-until-done algorithm 
 
Compounds are sequentially removed from the dataset in pairs and placed in the 
training and validation sets until a defined similarity threshold or desired number of 
compounds was selected for the validation set. The selection of the compounds to be 
removed was based on their distribution in the chemical space. Here, chemical space is 
defined by the structural and chemical descriptors used to represent a compound and each 
descriptor value is a point in a multidimensional space [Todeschini et al. 2000]. Each 
compound would occupy a particular location in this chemical space. All possible pairs of 
the compounds in the dataset were generated and a similarity score was computed for 
each pair. These pairs were then ranked in terms of their similarity scores, based on 
which compounds of similar structural and chemical features were evenly assigned into 
the training and validation sets. For those compounds without enough structurally and 
chemically similar counterparts, they were assigned to the training set. 
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2.1.3 Diversity and representativity of datasets 
  
 The diversity of a dataset can be measured by using the diversity index (DI) 
value, which is the average value of the similarity between pairs of compounds in a 
dataset [Perez 2005]: 








= = ≠= −
∑ ∑
                                                (2-1)                                   
 
where sim(i,j) is a measure of the similarity between compound i and j, and N is the 
number of compounds in the dataset. The structural diversity of a dataset increases with 
decreasing DI value. In this work, sim(i,j) is computed by using the Tanimoto coefficient 
[Potter et al. 1998; Willett et al. 1998; Molnar et al. 2002b]: 




















                     (2-2)
 
where l is the number of descriptors computed for the molecules in the dataset. The mean 
maximum Tanimoto coefficient of the compounds in dataset A and those in dataset B 
could be used as a representative index (RI) to measure the extent to which dataset B is 
representative of dataset A. Dataset B is more representative of dataset A if the RI value 
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2.2 Molecular descriptors 
 
2.2.1 Types of molecular descriptors 
 
 
Molecular descriptors have been routinely used in quantitative description of 
structural and physicochemical properties of molecules in statistical studies of drugs and 
small molecules [Katritzky et al. 1993; Karelson M et al. 1996; Kier et al. 1999; Cruciani 
et al. 2000; Todeschini et al. 2000]. A descriptor is “the final result of a logical and 
mathematical procedure which transforms chemical information encoded within a 
symbolic representation of a compound into an useful number or the result of some 
standardized experiment” [Todeschini et al. 2000]. There are currently over 3,700 types 
of descriptors, which are classified into three broad categories: 1D, 2D and 3D 
descriptors that encode chemical composition, topology, and 3D shape and functionality 
respectively [Todeschini et al. 2000; Farnum et al. 2003]. A descriptor can be simple, 
like molecular volume, which encode only one feature of a compound, or can be 
complex, like 3D-MoRSE, which encode multiple physicochemical and structural 
properties of a compound. Examples of the most popularly used and internet accessible 
descriptor calculation programs are DRAGON [Todeschini et al. 2005], Molconn-Z [Hall 
et al. 2002], and MODEL [Li et al. 2006c].   
 
In this study, a set of 199 molecular descriptors were selected from the more than 
1,000 descriptors described in the literature by eliminating those descriptors that are 
obviously redundant or unrelated to the problem studied here. These descriptors, listed in 
Table 2.2, include 18 descriptors in the class of simple molecular properties, 28 
CHAPTER 2 METHODS 33
descriptors in the class of molecular connectivity and shape, 97 descriptors in the class of 
electro-topological state, 31 descriptors in the class of quantum chemical properties, and 
25 descriptors in the class of geometrical properties. They were computed from the 3D 
structure of each compound using our own designed molecular descriptor computing 
program. The remaining redundant and un-related descriptors were further reduced by 
using a feature selection method [Degroeve et al. 2002; Yu et al. 2003; Xue et al. 2004b; 
Li et al. 2005b].  
 
Examples of topological descriptors include numbers of rings and rotatable bonds, 
numbers of hydrogen bond acceptors and donors, molecular connectivity chi indices, 
molecular shape Kappa indices, electrotopological state indices, and atom type 
electrotopological state indices. Molecular connectivity chi indices and shape Kappa 
indices encode information about molecular size, shape, branching, unsaturation, 
heteroatom content and cyclicity [Kier et al. 1986; Hall et al. 1991a]. The 
electrotopological state indices are numerical values computed for each atom in a 
molecule, which encode information about both the topological environment of that atom 
and the electronic interactions due to all other atoms in the molecule [Hall et al. 1991b; 
Hall et al. 1995]. 
 
Quantum chemical descriptors are used to describe electrostatic and electronic 
properties of a molecule. These descriptors are calculated using molecular orbital 
energies and wave functions of electronic motion in a molecule, which can be obtained 
by solving the Schrödinger equation of electronic motion [Dewar et al. 1985]. The 
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computed quantum chemical descriptors include partial atomic charges, the highest 
occupied and lowest unoccupied molecular orbital energies, dipole moment, 
polarizability and other descriptors derived from them [Thanikaivelan et al. 2000]. 
Geometric descriptors encode the 3D-structural features of molecules. These include the 
van der Waals volume, solvent accessible surface area, molecular surface area, van der 
Waals surface area, and the related properties from combining them with partial atomic 
charges [Hopfinger 1980; Tsodikov et al. 2002]. 
 
In this work, descriptors were computed from the 3D structure of the compounds. 
The 2D structure of each of the compounds was generated by using ChemDraw 
[CambridgeSoft Corporation 2002] and DS ViewerPro 5.0 [Accelrys 2005] and was 
subsequently converted into 3D structure by using CONCORD [Pearlman] followed by 
geometrical optimization using the clean structure module of DS Viewer Pro. All the 
generated geometries had been fully optimized without symmetry restrictions. The 3D 
structure of each compound was manually inspected to ensure that the chirality of each 
chiral agent was properly generated. All salts and elements, such as sodium or calcium, 
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Table 2.2 Molecular descriptors used in this work 






18 Molecular weight, Number of rings, rotatable 





28 Molecular connectivity indices, Valence 
molecular connectivity indices, Molecular shape 





97 Electrotopological state indices, and Atom type 
electrotopological state indices, Weiner Index, 
Centric Index, Altenburg Index, Balaban Index, 
Harary Number, Schultz Index, PetitJohn R2 
Index, PetitJohn D2 Index,     Mean Distance 
Index, PetitJohn I2 Index, Information Weiner, 




      31 Polarizability index, Hydrogen bond acceptor 
basicity (covalent HBAB), Hydrogen bond donor 
acidity (covalent HBDA), Molecular dipole 
moment, Absolute hardness, Softness, Ionization 
potential, Electron affinity, Chemical potential, 
Electronegativity index, Electrophilicity index, 
Most positive charge on H, C, N, O atoms, Most 
negative charge on H, C, N, O atoms, Most 
positive and negative charge in a molecule, Sum 
of squares of charges on H,C,N,O and all atoms, 
Mean of positive charges, Mean of negative 
charges, Mean absolute charge, Relative positive 
charge, Relative negative charge 




    25 Length vectors (longest distance, longest third 
atom, 4th atom), Molecular van der Waals volume, 
Solvent accessible surface area, Molecular surface 
area, van der Waals surface area, Polar molecular 
surface area, Sum of solvent accessible surface 
areas of positively charged atoms, Sum of solvent 
accessible surface areas of negatively charged 
atoms, Sum of charge weighted solvent accessible 
surface areas of positively charged atoms, Sum of 
charge weighted solvent accessible surface areas 
of negatively charged atoms, Sum of van der 
Waals surface areas of positively charged atoms, 
Sum of van der Waals surface areas of negatively 
charged atoms, Sum of charge weighted van der 
Waals surface areas of positively charged atoms, 
Sum of charge weighted van der Waals surface 
areas of negatively charged atoms, Molecular 
rugosity, Molecular globularity, Hydrophilic 
region, Hydrophobic region, Capacity factor, 
Hydrophilic-Hydrophobic balance, Hydrophilic 







Molecular descriptors are usually scaled before they are used for modelling. This 
is to ensure that all descriptors have equal potential to affect the pharmacological 
property prediction models [Livingstone 1995]. There are four main types of descriptor 
scaling: auto-scaling, range scaling, feature weighting [Livingstone 1995] and Pareto 
scaling [Eriksson et al. 2001]. Auto-scaling and range scaling are the two most common 
types of descriptor scaling methods used in pharmacological properties modellings and 
are chosen in this work. 
 
Table 2.2 Continued
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2.2.2.1 Auto-scaling 
 
In auto-scaling, the mean is subtracted from the descriptor values and the resultant 
values are divided by the standard deviation: 






−−='                                                                    (2-3) 
where 'ijX  is the new scaled value for descriptor j of compound i, and jX
−
 and jσ  are the 
mean and standard deviation of descriptor j respectively. The auto-scaled descriptors 
have a mean of zero and a standard deviation of one. The advantage of auto-scaling is 
that it is less susceptible to effects of compounds with extreme values because they are 
mean-centred. In addition, variance of one is useful in variance-related methods since 
they each will contribute one unit of variance to the overall variance of a dataset. 
 
 
2.2.2.2 Range scaling (Normalization) 
 
In range scaling, the minimum value of a descriptor is subtracted from the 
descriptor values and the resultant values are divided by the range: 









X                                                             (2-4) 
Where min,jX  and max,jX are the minimum and maximum values of descriptor j 
respectively. The range-scaled descriptors have a minimum and maximum value of -1 
and 1 respectively. Range scaling can be carried out over any preferred range by 
multiplication of the range-scaled values by a factor. The disadvantage of range scaling is 
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that it is dependent on the minimum and maximum values of the descriptors, which 
makes it very sensitive to outliers. 
 
2.3 Feature selection method 
 
The purpose of feature selection is to remove descriptors that are irrelevant or 
negligible to a pharmacological property of the compounds, so as to improve 
computation speed, performance and interpretability of predictive models. Irrelevant and 
redundant descriptors are removed either by using a filter or a wrapper approach or a 
combination of these approaches. The filter approach is independent of the in silico 
methods and is frequently used to remove redundant descriptors or descriptors of low 
information content. Descriptors are chosen or removed based on one or more of the 
following considerations: prior knowledge of factors affecting a particular 
pharmacological property, the properties of the descriptors (e.g. variance), the correlation 
between different descriptors, and the distribution of the descriptor values in different 
data classes. In the wrapper approach, a descriptor selection algorithm is incorporated 
into an in silico classification method such as support vector machine [Guyon et al. 
2003]. 
 
In many cases, it is difficult to uniquely select an optimum set of descriptors due 
to the high redundancy and overlapping of many descriptors [Gramatica et al. 2004]. 
Separate sets of descriptors containing different members of redundant descriptor classes 
have been found to give similar prediction accuracies [Izrailev et al. 2004]. The 
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interpretation of the prediction results in these cases should be more appropriately 
conducted at the descriptor class level where redundant and overlapping descriptors are 
grouped into one class. Table 2.3 gives a list of the common descriptor selection methods 
used in pharmacological properties classification studies. 
Table 2.3 Common descriptor selection methods used in pharmacological properties 
classification studies 
Filter Methods Wrapper Methods 
Remove descriptors with low variance Forward selection [Xu et al. 2001] 
Remove highly correlated descriptors Backward elimination [Xu et al. 2001] 
CORCHOP [Livingstone et al. 1989] Stepwise regression [Xu et al. 2001] 
Decision tree [Cardie 1993] Branch and bound [Narendra et al. 1977] 
FOCUS [Almuallim et al. 1994] Floating search [Pudil et al. 1994] 
LVF [Brassard et al. 1996] Adaptive floating search [Somol et al. 
1999] 
RELIEF [Kononenko 1994] Oscillating search [Somol et al. 2000] 
Discrimination scores [Guyon et al. 2002] Tabu search [Glover 1989] 
Information gain [Liu 2004] Simulated annealing [Sutter et al. 1993] 
Mutual information [Liu 2004] Genetic algorithm [Siedlecki et al. 1989] 
2χ - test [Liu 2004] Recursive feature elimination [Guyon et al. 
2002] 
Odds ratio [Liu 2004]  
GSS coefficient [Liu 2004]  
 
2.3.1 Recursive feature elimination (RFE) 
 
 
The feature selection method used in this work is the recursive feature elimination 
method, which has gained popularity due to its effectiveness for discovering informative 
features or attributes in the analysis of drug activity [Guyon et al. 2002; Yu et al. 2003] 
and pharmacokinetic and toxicological properties [Xue et al. 2004b; Xue et al. 2004c]. 
Here, an agent is represented by a vector xi, with its molecular descriptors (or features) as 
the components. The task of selecting appropriate molecular descriptors can be conducted 
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by ranking and selecting those with higher contributions to a particular pharmacological 
property classification problem.  
 
It has been suggested that the ranking criterion for feature selection can be based 
on the change in the objective function upon removing each feature [Kohavi et al. 
1997b]. To improve the efficiency of SVM training, this objective function is represented 
by a cost function J computed for the ith feature, and it is computed by using training set 
only. When the ith feature is removed or its weight wi reduced to zero, DJ(i) as the 










∂=                                       (2-5) 
where wi is the weight of the feature i, and the change in weight Dwi = wi → 0 
corresponds to the removal of feature i. In the corresponding linear SVM classifier, the 
cost function is IwJ Tα−= 2)2/1( , where I is an m dimensional identity vector (m is 
the number of compounds in training set). Therefore 2)2/1()( iwiDJ =  and 2iw  can be 
used as a feature ranking criterion.  
 
RFE with polynomial kernels of a nonlinear SVM classification system has been 
applied on the prediction of drug activity [Yu et al. 2003]. However, because of the 
diversity and complexity of the compounds to be classified, the use of linear and 
polymial kernels may not always be sufficient for accurate prediction of various 
pharmacological properties. Thus, in this work, SVM classification systems of Guassian 
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kernels are used.  In this case, the cost functions to be minimized, under the constraints  







0α  is: 
IHJ TT ααα −= )2/1(                                      (2-6)   
where H is the matrix with elements such as that of y i y j exp(-||xi - xj|| 2/(2σ2)) in the 
support vector machine algorithm. To compute the variation in cost function caused by 
removing input component i, the α is kept unchanged and the matrix H is re-computed. 
The resulting ranking coefficient is: 
αααα )()2/1()2/1()( iHHiDJ TT −−=                                      (2-7) 
where H(-i) is the matrix computed by the same method as matrix H but with its ith 
component removed. One or more of features with the smallest DJ(i) are thus eliminated.  
 
2.3.2 The procedure of RFE 
 
As illustrated in Figure 2.1, the RFE feature selection computation procedure  is 
outlined as follows [Xue et al. 2004b]: the prediction accuracy of a statistical learning 
prediction system during the training process was evaluated by means of N-fold cross 
validation. In the first step, for a fixed parameter, the statistical learning prediction 
system is trained by using the complete set of features (molecular descriptors) described 
in the previous section. The second step is to compute the ranking criterion score DJ(i) 
for each feature in the current set by using equation (2-5). All of the computed DJ(i) are 
subsequently ranked in descending order. The third step is to remove the m features with 
the smallest criterion scores. In this work, m was chosen to be 5 as that used in earlier 
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studies [Yu et al. 2003]. In the fourth step, the prediction system is retrained by using the 
remaining set of features, and the corresponding prediction accuracy is computed by 
means of N-fold cross validation. The first to fourth steps are then repeated for other 
parameter values. After the completion of these procedures, the set of features and 
parameters that give the best prediction accuracy are selected.  
Figure 2.1 Schematic diagrams illustrating the process of using feature selection method 
for selecting molecular descriptors most appropriate in the prediction of compounds of a 
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2.4.1.1 Logistic regression (LR) 
 
LR [Hosmer et al. 1989] is based on the assumption that a logistic relationship 
exists between the probability of class membership with one or more descriptors:  
( 0 1 1 2 2 )
1
1 X X kXk
Y
e β β β β− + + + +
= + K                (2-8) 
where Y is the probability that vector x belongs to the positive class, β0 is the regression 
model constant, β1 to βk are the coefficients corresponding to the descriptors X1 to Xk. A 
Y value of 0.5 or greater indicates that the vector x belongs to the positive class while a 
value below 0.5 classifies vector x as negative. 
 
2.4.1.2 Linear discriminate analysis (LDA) 
 
As illustrated in Figure 2.2, LDA [Huberty 1994] separates two different classes 





L w x=∑                     (2-9) 
 where L is the resultant classification score and wi is the weight associated with the 
corresponding descriptor xi. A positive or negative L value indicates that the vector x 
belongs to the positive or negative class respectively. 
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Figure 2.2 Schematic diagrams illustrating the process of the prediction of 
pharmaceutical agents with a particular pharmacological property from its structure by 
using a statistical learning method — linear discriminant analysis (LDA). Feature vectors 
(hj, pj, vj,…) represent such structural and physicochemical properties as hydrophobicity, 
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 2.4.1.3 C4.5 decision trees (DT) 
 
C4.5 DT is a branch-test-based classifier [Quinlan 1993], which is illustrated in 
Figure 2.3. A branch of the decision tree corresponds to a group of classes and a leaf 
represents a specific class. A decision node specifies a test on a single attribute value, 
with one branch and its subsequent classes as possible outcomes. C4.5 decision tree uses 
recursive partitioning to examine every attribute of the data and rank them according to 
their ability to partition the remaining data, thereby constructing a decision tree. A vector 
x is classified by starting at the root of the tree and moving through the tree until a leaf is 
encountered. At each non-leaf decision node, a test is conducted to move into a branch. 
Upon reaching the destination leaf, the class of the vector x is predicted to be that of the 
leaf. This process continues to allow the tree to grow to the full size, which is then pruned 
back to an appropriate size based on the evaluation of its overall prediction performance. 
 
The estimation criterion in the decision tree algorithm is the selection of an 
attribute to test at each decision node in the tree. The goal is to select the attribute that is 
most useful for classifying examples. A good quantitative measure of the worth of an 












SsEntropyASGain that measures how well a given 








2log)( , S is called entropy that characterizes the purity or 
impurity of an arbitrary collection of examples, pi is the proportion of S belonging to 
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class I, values A is the set of all possible values for attribute A, and Sv is the subset of S 
for which attribute A has value v (i.e., })(|{ vsASIsSv ==
∧
). 
Figure 2.3 Schematic diagram illustrating a decision tree process for the prediction of 
pharmaceutical agents of a particular pharmacological property from their structure by 
using a statistical learning method – C4.5 decision tree. A, B: feature vectors of agents 
with the property; E, F: feature vectors of agents without the property; feature vectors (hj, 
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2.4.1.4 k-nearest neighbor (k-NN)  
 
As illustrated in Figure 2.4, k-NN measures the Euclidean distance between a to-
be-classified vector x and each individual vector xi in the training set [Johnson et al. 
1982] . The Euclidean distances for the vector pairs are calculated using the following 
formula: 
  2|||| ixxD −=                                                                      (2-10) 
 
A total of k number of vectors nearest to the vector x are used to determine its class, f(x): 








))(,(maxarg)( δ                                            (2-11) 
where ( , ) 1 if  and ( , ) 0 if a b a b a b a bδ δ= = = ≠ , argmax is the maximum of the function, 
V is a finite set of vectors {v1,…vs} and )(
^
xf  is an estimation of )(xf . Here estimation 
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Figure 2.4 Schematic diagrams illustrating the process of the prediction of 
pharmaceutical agents with a particular pharmacological property from its structure by 
using a statistical learning method — k-nearest neighbors (k-NN). Feature vectors (hj, pj, 
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2.4.1.5 Probabilistic neural network (PNN) 
 
As illustrated in Figure 2.5, PNN is a form of neural network designed for 
classification through the use of Bayes’ optimal decision rule [Specht 1990] 
 )()( xfchxfch jjjiii >                                     (2-12) 
where hi and hj are the prior probabilities, ci and cj are the costs of misclassification and 
fi(x) and fj(x) are the probability density function for class i and j respectively. An 
unknown vector x is classified into population i if the product of all the three terms is 
greater for class i than for any other class j (not equal to i). In most applications, the prior 
probabilities and costs of misclassifications are treated as being equal. The probability 
density function for each class for a univariate case can be estimated by using the 
Parzen’s nonparametric estimator [Parzen 1962] 











(1)( σσ               (2-13)  
where n is the sample size, σ is a scaling parameter which defines the width of the bell 
curve that surrounds each sample point, W(d) is a weight function which has its largest 
value at d = 0 and (x – xi) is the distance between the unknown vector and a vector in the 
training set. The Parzen’s nonparametric estimator was later expanded by Cacoullos 
[Cacoullos 1966] for the multivariate case. 
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The Gaussian function is frequently used as the weight function because it is well 
behaved, easily calculated and satisfies the conditions required by Parzen’s estimator. 
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Figure 2.5 Schematic diagrams illustrating the process of the prediction of 
pharmaceutical agents with a particular pharmacological property from its structure by 
using a statistical learning method — probabilistic neural networks (PNN). A, B, E, F and 
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The network architectures of PNN are determined by the number of compounds 
and descriptors in the training set. As shown in Figure 2.6, there are 4 layers in a PNN. 
The input layer provides input values to all neurons in the pattern layer and has as many 
neurons as the number of descriptors in the training set. The number of pattern neurons is 
determined by the total number of compounds in the training set. Each pattern neuron 
computes a distance measurement between the input and the training case represented by 
that neuron and then subjects the distance measurement to the Parzen’s nonparameteric 
estimator. The summation layer has a neuron for each class and the neurons sum all the 
pattern neurons’ output corresponding to members of that summation neuron’s class to 
obtain the estimated probability density function for that class. The single neuron in the 
output layer then estimates the class of the unknown vector x by comparing all the 
probability density function from the summation neurons and choosing the class with the 
highest probability density function.  
Figure 2.6 PNN four layers architecture 
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2.4.1.6 Support vector machine (SVM) 
 
The theory of SVM has been extensively described in the literature [Vapnik 1995; 
Burges 1998]. Thus only a brief description is given here. As illustrated in Figure 2.7, 
SVM is based on the structural risk minimization principle from statistical learning 
theory [Vapnik 1995]. In linearly separable cases, SVM constructs a hyper-plane to 
separate two classes of molecules with a maximum margin. A molecule is represented by 
a vector ix , with the structural and physicochemical descriptors of this molecule as its 
components. Separation of the two classes of molecules is conducted by finding a vector 
w and another parameter b that minimizes 2|||| w  and satisfies the following conditions: 
 1±≥+⋅ bxw i  for 1+=iy  Class 1 (D+)                      (2-16) 
 1±≤+⋅ bxw i  for 1−=iy      Class 2  (D-)                      (2-17) 
where yi is the class index, w is a vector normal to the hyperplane, ||||/|| wb  is the 
perpendicular distance from the hyperplane to the origin and 2|||| w  is the Euclidean norm 
of w. After the determination of w and b, a given vector xi can be classified by: 
  ])[( bxwsign +⋅                (2-18) 
 
In nonlinearly separable cases, SVM maps the feature vectors into a higher 
dimensional feature space by using a kernel function K(xi, xj). Table 2.4 lists three 
different types of kernel functions which are commonly used. An example of the kernel 
function is the Gaussian radial basis kernel function which has been extensively used in 
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different studies with good results [Burbidge et al. 2001; Czerminski et al. 2001; Trotter 
et al. 2001]. 
 
22 2/||),( σji xxji exxK
−−=                (2-19) 
Table 2.4 Commonly used kernel functions 
Kernel Equation 
Gaussian radian basis function 
(RBF) 
22 2/||),( σji xxji exxK
−−=  
Polynomial p
jiji xxxxK )1(),( +⋅=  
Sigmoidal )tanh(),( δ−⋅= jiji xkxxxK  
 
Linear support vector machine algorithm is then applied to the vectors in this 









0 )),(()( α                          (2-20) 
where the coefficients αi0 and b are determined by maximizing the following 
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under the following conditions:  







0α                                           (2-22)    
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where C is a penalty for training errors. A positive or negative value from equation (2-20) 
indicates that the vector x belongs to the positive (D+) or negative (D-) class respectively.  
Figure 2.7 Schematic diagram illustrating the process of the prediction of pharmaceutical 
agents with a particular pharmacological property from its structure by using a statistical 
learning method — support vector machines (SVM). A, B, E, F and (hj, pj, vj,…) are 
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2.4.2 Parameters optimization 
 
Different SLMs have types of parameters that must be optimized. In this work 
SVM is trained by using a Gaussian radian basis kernel function which has an adjustable 
parameterσ . For PNN, the only parameter to be optimized is a scaling parameterσ . In 
kNN, the optimum number of nearest neighbors, k, needs to be derived for each training 
set.  
 
Optimization of the parameter for each of these SLMs is conducted by scanning 
the parameter through a range of values. The set of parameters that produces the best 
pharmacological property prediction model, which is determined by using cross-
validation methods, such as 5-fold cross-validation, 10-fold cross-validation or a 
modeling testing set, is used to construct a final pharmacological property prediction 
model which is then further validated to ensure that it is valid and useful for the 
pharmacological property prediction study. 
 
2.5 Model validation 
 
2.5.1 Performance evaluation of a pharmacological property prediction model 
 
 One of the objectives of modeling is to allow prediction of the pharmacological 
properties of compounds which have not been clinically and biologically tested. Thus it is 
important to determine the ability of the derived pharmacological property prediction 
models to predict the properties of compounds that are not present in the training set. 
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Several validation methods have been used for training, testing, and estimating 
generalization errors of a pharmacological property model based on a "re-sampling" 
strategy [Weiss et al. 1991; Shao et al. 1995; Wold et al. 1995]. The commonly used 
validation methods include N-fold cross validation, leave one out, leave v out, jack-
knifing, and bootstrapping. In N-fold cross validation, compounds are randomly divided 
into N subsets of approximately equal size. N-1 subsets are used as a training set for 
developing a model; the remaining one is used as a test set for evaluating the prediction 
performance of that model. This process is repeated N times such that every subset is 
used as a testing set once. The average accuracy of the N time models is used for 
measuring the generalization capability of that method. When N equals to the number of 
compounds, the method is called “leave one out” as every compound is used for testing a 
model trained by using all of the other compounds. "Leave-v-out" is a more elaborate and 
expensive version of the “leave something out” cross-validation that involves leaving out 
all possible combinations of v compounds as a test set. In jack-knifing, compounds are 
distributed and used for training and testing the models in the same way as that of “leave 
one out” method, but the generalization error of the derived models is estimated based on 
the comparison of the average accuracy of subsets and that of all sets of these models. In 
bootstrapping, different combinations of randomly selected subsets of compounds are 
separately used for training models, each of which is tested by using the compounds not 
included in the respective training set. 
 
  There are reports of the lack of correlation between cross-validation methods 
and the prediction capability of a pharmacological property prediction model [Golbraikh 
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et al. 2002; Kozak et al. 2003; Reunanen 2003; Olsson et al. 2004]. Moreover, cross-
validation methods have a tendency of underestimating the prediction capability of a 
classification model, especially if important molecular features are present in only a 
minority of the compounds in the training set [Mosier et al. 2002; Hawkins 2004]. Thus a 
model having low cross-validation accurary can still be predictive [Mosier et al. 2002]. 
This lead to some studies which suggest that an independent validation set may provide a 
more reliable estimate of the prediction capability of a pharmacological property model 
[Wold et al. 1995; Golbraikh et al. 2002]. Despite these disadvantages, cross-validation 
methods are still useful for assessing pharmacological properties prediction models 
during optimization of parameters of SLMs and during feature selection process. 
 
 A validation set should ideally be obtained independently from the training set. 
It is even better if the validation set is composed of newly published experimentally 
validated chemical compounds with a particular pharmacological property. However, 
validation sets are usually constructed by using statistical molecular design because of the 
limited availability of high-quality pharmaceutical property data. Regardless of the 
method used to obtain a validation set, a good validation set should be representative of 
the training set so that it can properly assess the prediction capabilities of the 
pharmacological property model [Tropsha et al. 2003].  
 
 2.5.2 Performance evaluation methods 
 
 As in the case of all discriminative methods [Baldi et al. 2000; Roulston 2002], 
the performance of SLMs can be evaluated by the quantity of true positives TP 
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(pharmaceutical agents possessing a specific pharmacological property), true negatives 
TN (pharmaceutical agents not possessing a specific pharmacological property), false 
positives FP (pharmaceutical agents not possessing a specific pharmacological property 
but predicted as agents possessing the specific pharmacological property), false negatives 
FN (pharmaceutical agents possessing a specific pharmacological property but predicted 
as agents not possessing the specific pharmacological property). Sensitivity and 
specificity are the prediction accuracy for pharmaceutical agents possessing a specific 
pharmacological property and agents not possessing that pharmacological property 
respectively. The overall prediction accuracy (Q) and Matthews correlation coefficient 
(C) [Matthews 1975] are used to measure the overall prediction performance: 
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A shortcoming of the overall accuracy is that an imbalance in the data classes may 
result in a high overall accuracy even if sensitivity or specificity is low. For example, a 
classification model which has a sensitivity of 100% and specificity of 0% will have an 
overall accuracy of 90% for a validation set that has 9 times more compounds in the 
positive data class than compounds in the negative data class. Thus Matthews correlation 
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coefficient, which is a weighted measure, is increasingly being chosen to measure the 
predictive capability of pharmacological property classification models.  A Matthews 
correlation coefficient value of 1 indicates that the classification model can predict the 
data classes of unknown compounds perfectly, a Matthews correlation coefficient of 0 is 
expected for a classification model that is not better than random guessing, and a 
Matthews correlation coefficient value of -1 indicates a total disagreement between the 
predicted data classes and the actual data classes. For the above mentioned example, the 
Matthews correlation coefficient will give a value of 0, which is more accurate to 




          A frequently used method for checking whether a prediction system is overfitted is 
to compare the prediction accuracies determined by using cross validation methods with 
those determined by using independent validation sets [Hawkins 2004]. Since descriptor 
selection normally is performed by using the cross validation method as the modeling 
testing sets, an over-fitted classification system is expected to have much higher 
prediction accuracy for the cross validation sets than that for the independent validation 
sets.  
 
It is not sufficient for a pharmacological property prediction model to have good 
predictive capability. A second requirement for a high quality pharmacological property 
prediction model is that it must not suffer from overfitting. There are two main types of 
overfitting: (1) using a model that is more flexible than it needs to be and (2) using a 
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model that includes irrelevant descriptors [Hawkins 2004]. There are various methods 
that can be used to prevent or to check for these two types of overfitting. 
 
A number of different pharmacological property prediction models can be 
developed using SLMs of varying complexities. The pharmacological property prediction 
model with the best balance between complexity of SLM used and its predictive 
capability is the one that is most suitable for predicting the pharmacological property of 
interest. This method prevents the use of a pharmacological property prediction model 
that is more flexible than is necessary. 
 
Although cross-validation methods tend to give a pessimistic estimate of the 
predictive capability of a pharmacological property prediction model, a model that is not 
overfitted should not have large differences in the estimation of its predictive capability 
between cross-validation methods and independent validation sets. 
 
              Y-randomization is commonly used to determine the probability of chance 
correlation during descriptor selection [Manly 1997; Leardia et al. 1998]. In classification 
problems, a portion of positive class compounds in the training set is randomly 
exchanged with negative class compounds in the training set, creating new training sets 
with false positive class and false negative class compounds. The SLM is trained using 
this “scrambled” training set. The randomization is repeated a number of times and 
prediction capabilities of the new scrambled model from each run are compared to that of 
the original model. If the scrambled training set gives significantly lower prediction 
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capabilities than the original training set, it can be concluded that the original model was 
relevant and unlikely to arise as a result of chance correlation. 
 
In order to determine whether a selected set of descriptors of the original model 
include those irrelevant for the prediction of a pharmacological property, different groups 
of pharmacological property predicton models, each containing different number of 
descriptors, can be generated by using the descriptor selection method. Each group 
contains a fixed number of pharmacological property prediction models having the same 
number of descriptors. The prediction capabilities of the pharmacological property 
models in each group are determined and the average prediction capabilities of all the 
groups are compared and used to determine the optimal number of descriptors for the 
particular pharmacological property. If the optimal number of descriptors coincide with 
the number of descriptors in the original pharmacological property prediction model, the 
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Chapter 3 Prediction of pharmacokinetics properties of 
pharmaceutical agents 
 
 Optimization of pharmacokinetic properties of a drug candidate is an important 
consideration in drug design process. Good pharmacokinetic properties are required to 
achieve sufficient drug concentration at a target site while possibly limiting its 
distribution elsewhere to reduce potential side effects. This chapter studies two important 
pharmacokinetic prediction models by using SLMs. One is the activator for pregnane X 
receptor (PXR) that corresponds to promiscuity of drug metabolism due to the fact that 
activation of PXR induces expression of a number of drug metabolizing enzymes such as 
CYP3A4 (section 3.1). The other one is a blood brain barrier agent model that 
corresponds to transport and permeability of a drug across blood brain barrier to enter 
to brain (section 3.2). 
 
 




Pregnane X receptor (PXR) is a nuclear receptor known to be activated by many 
structurally diverse xenobiotics and endogenous compounds [Lehmann et al. 1998; Jones 
et al. 2000; Ekins 2004]. PXR plays important roles in the metabolism of xenobiotics and 
drug-drug interactions by regulating the expression of some metabolizing enzymes such 
as cytochrome P450 enzymes (CYP3A4, CYP2B6, CYP2C8/9), and glutathione-S-
transferases [Kliewer et al. 2002]. It also regulates the expression of important drug 
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transporters such as P-glycoprotein [Ekins 2004; Xie et al. 2004]. Therefore, drugs 
capable of activating PXR may have significant impact on their own metabolism, 
transport and interaction with other drugs. Identification of PXR activators is important 
for analyzing metabolism and pharmacokinetic profiles of drug candidates and for 
detecting potential drug-drug interactions. 
 
Most of the drug metabolism prediction efforts have been directed at the 
development of tools for predicting CYP substrates and inhibitors [Ekins et al. 2000a; 
Doniger et al. 2002]. Significantly fewer activities have been devoted to the development 
of tools for identifying PXR activators. Experimentally, high throughput screening assays 
have been developed for detecting PXR binding ligands [Jones et al. 2000]. 
Computationally, pharmacophore [Ekins et al. 2002; Schuster et al. 2005] and 
quantitative structure and activity relationship (QSAR) [Jacobs 2004] models were 
explored for predicting PXR activators. Because of the importance of PXR in drug 
metabolism and drug-drug interactions, more efforts are needed to explore additional 
methods for predicting a broader spectrum of PXR activators than those covered by 
existing studies. 
 
We explored SLMs for predicting PXR and human PXR (hPXR) activators which 
are more relavent to drug discovery [Ung et al. 2007]. PXRs show high amount of 
sequence diversity in its ligand-binding domain [Moore et al. 2002], resulting in marked 
differences in ligand selectivity of PXRs across species which is likely to have 
evolutionary significance in cross-species differences in adaptation to toxic compounds 
CHAPTER 3 PHARMACOKINETIC PREDICTION MODELS 64
[Krasowski et al. 2005]. Some compounds are known to activate mouse but not human 
PXR and vice versa. Therefore, it is more relevant to develop prediction systems for 
hPXR activators. Nonetheless, prediction systems for PXR as well as hPXR activators 
were developed in this work for facilitating the search of broader spectrum of activators 
particularly those of species frequently used in drug toxicity tests. 
 
SLMs have been used for predicting compounds of different pharmacological 
properties [Doniger et al. 2002; Xue et al. 2004c; Yap et al. 2005]. The most widely used 
SLMs in these studies are SVM, PNN and k-NN. These methods have consistently 
exhibited good prediction performance for compounds of diverse structures. Moreover, a 
feature selection method can be incorporated into these methods for selecting molecular 
descriptors most relevant to the prediction of compounds with specific pharmacological 
property [Xue et al. 2004b; Xue et al. 2004c; Li et al. 2005a; Li et al. 2005b]. 
 
PXR activators are structurally diverse partly because PXR ligand binding domain 
is highly flexible [Watkins et al. 2001]. None-the-less, certain common physicochemical 
characteristics can be found at the binding site. For instance, the binding site is largely 
hydrophobic but contains a few polar residues capable of both donating and accepting 
hydrogen bonds [Watkins et al. 2001]. These and other distinguished binding-site 
features likely define the common structural and physicochemical properties of the 
compounds that can bind and activate PXR, which can be exploited by using SLMs to 
distinguish PXR activators and non-activators. Several molecular descriptors of PXR 
activators have been used for deriving QSAR [Jacobs 2004] and pharmacophore models 
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[Ekins et al. 2002; Schuster et al. 2005]. It is likely that not all of the molecular 
descriptors related to PXR activation have been included in previous studies due to the 
limited coverage of compounds and the number of other relevant descriptors. Therefore, 
feature selection methods [Xue et al. 2004b; Xue et al. 2004c; Li et al. 2005a; Li et al. 
2005b] may be applied for finding additional molecular descriptors relevant to PXR 
activation. The use of a higher number of relevant molecular descriptors also serves to 
improve the performance of SLMs.  
 
In this work, PXR and hPXR activator prediction systems were developed by 
using SVM, PNN, and k-NN, which were trained and tested by using a significantly 
higher number of compounds than those used in the previous studies [Ung et al. 2007]. A 
comprehensive literature search was conducted to collect a diverse set of literature-
reported PXR activators and non-activators. A popular feature selection method, 
recursive feature elimination (RFE) [Guyon et al. 2002; Xue et al. 2004b; Xue et al. 
2004c; Li et al. 2005a; Li et al. 2005b], was used to extract molecular descriptors 
associated with PXR activation. The performance of these systems were tested by using 
10-fold cross validation and an independent set of 15 newly published experimental PXR 
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3.1.2 Methods 
 
3.1.2.1 Collection of PXR activators and non-activators 
 
Figure 3.1 illustrates the procedure for searching and selecting PXR activators, 
human PXR (hPXR) activators, and the corresponding non-activators. PXR activators 
were selected based on the criterion that they have been reported to show potent 
activation to at least one PXR ortholog regardless of its effect on other PXR orthologs. A 
total of 128 PXR activators were collected from literature, which were used as the 
activator dataset for predicting PXR activators irrespective of host species. There are 98 
PXR activators reported to activate hPXR, which were used as the activator dataset for 
predicting hPXR activators. The first dataset is of higher statistical significance because 
of the higher number of compounds included. Compared to the largest dataset of 53 
compounds used in the previous studies [Ekins et al. 2002; Jacobs 2004; Schuster et al. 
2005], the datasets for the current study contain a significantly higher number of 
compounds and are more diverse in structures as shown by the computed structural 
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Figure 3.1 A flowchart of the procedure for searching and selecting PXR activators, 





















PXR non-activators include known PXR antagonists and PXR non-binders 
reported in the literature. Moreover, compounds explicitly reported not to activate PXR-
regulated gene expression of CYP3A4 were further considered as implicated PXR non-
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activators if they would satisfy the subsequent criterion that they would not have been 
reported to induce the expression of other PXR-regulated drug-metabolizing enzyme 
genes such as CYP2B6 and CYP2C8/9. These PXR non-activators and implicated PXR 
non-activators were used as the non-activator dataset for predicting PXR activators 
irrespective of host species. The hPXR non-activator dataset include all compounds in the 
PXR non-activator dataset plus known non-human PXR activators.  
 
The 2D and 3D structures of each compound were generated by using ChemDraw 
[CambridgeSoft Corporation 2002] and DS ViewerPro 5.0 [Accelrys], respectively, and 
geometrical optimization was conducted subsequently. The optimized 3D structure of 
each compound was manually inspected to ensure that the chirality of each chiral agent is 
properly generated and is consistent with that described in the literature. For those 
compounds with transactivation activities but without a reported active enantiomer, the 
default enantiomer structure in the chemical database such as PubChem 
(http://pubchem.ncbi.nlm.nih.gov/) and ChemFinder (http://www.chemfinder.com/) was 
straightforwardly used directly. Under this definition, a total of 128 PXR activators, 77 
PXR non-activators and 98 hPXR activators and 77 hPXR non-activators are collected 
and used in this study. 
 
3.1.2.2 Construction of training and testing sets 
 
 
            PXR and hPXR activators and non-activators were divided into training and 
testing sets in a manner suitable for conducting 10-fold cross validation study. For 
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instance, the 128 PXR activators and 77 PXR non-activators were each randomly divided 
into ten subsets of approximately equal size. Nine of the subsets were used as the training 
set, and the remaining subset was used as the testing set for PXR activators and non-
activators respectively. This process was repeated ten times such that every subset is used 
as the test set once. The same procedure was applied to the 98 hPXR activators and 77 
hPXR non-activators for constructing the training and testing sets of the hPXR activator 
prediction systems. An additional set of 15 experimentally determined PXR activators 
(14 of which are structurally dissimilar to our dataset compounds by visual inspection) 
obtained from a recent publication [Lemaire et al. 2006] was used as the independent set 
for further evaluation of the performance of our prediction systems.   
3.1.2.3 Molecular descriptors  
 
 
This study used the same 199 molecular descriptors set as mentioned in Chapter 2 
(section 2.2). Redundant and un-related descriptors are further reduced by using the RFE 
method, which has been described in Chapter 2 (section 2.3) 
3.1.2.4 Computational parameters and performance evaluation 
 
 
There is only one parameter to be optimized in training each of the SVM (hard 
margin SVM, for soft margin SVM one more parameter is needed to be optimized), k-NN 
and PNN classification systems. The classification speed of these SLM-based prediction 
systems is in the order of a few thousands to hundreds of thousands of compounds per 
second [Li et al. 2005a]. The classification speed of SVM is usually 25-55% faster than 
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that of k-NN and PNN due to the fact that SVM typically uses 45-75% of the training set 
as support vectors for classification, whereas k-NN and PNN use the whole training set.  
 
SLMs generally require a sufficient number of samples to develop a classification 
system. Irrelevant molecular descriptors may reduce the performance of these 
classification systems [Kohavi et al. 1997b; Xue et al. 2004b; Xue et al. 2004c; Li et al. 
2005a]. SVM has been found to be the least sensitive to data over-fitting, even in the 
cases when a large number of redundant and overlapping molecular descriptors are used 
[Vapnik 1995]. This is because SVM is based on the structural risk minimization 
principle, which minimizes both training error and generalization error simultaneously.  
 
 SVM, k-NN and PNN do not explicitly provide information about the importance 
of each molecular descriptor. For SVM, this problem is further compounded when kernel 
function is used as there is no simple method to inversely map the solution back into the 
input space. Incorporation of feature selection methods [Li et al. 2005b; Yap et al. 2005] 
and regression methods[Yap et al. 2004b] have been frequently used for extracting 
important molecular descriptors from these statistical learning-based prediction systems. 
 
3.1.3 Results and Discussion 
 
3.1.3.1Promiscuity nature of PXR activator structures and the selected molecular 
descriptors for classifying PXR activators 
 
          Table 3.1 gives the computed DI value of PXR activators and those of several 
groups of compounds possessing various different activities or properties. PXR activators 
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are structurally more diverse not only than some of the well known promiscuous binder 
groups such as ER agonists and P-glycoprotein substrates, but also than some of the 
compound groups involved in multiple mechanisms such as human intestine absorbing 
agents. Figure 3.2 shows the structures of selected PXR activators, which are indicative 
of the extent of structural diversity of PXR activators. The DI value of our dataset is 
0.535, which is smaller than that of 0.605 of the largest dataset of other PXR activators 
studies [Schuster et al. 2005]. Therefore, our dataset is structurally more diverse than 
those of other studies of PXR activators. 
 
Table 3.1 Diversity index (DI) for the compounds in several chemical groups and the 
number of molecular descriptors selected by RFE for predicting each group of 
compounds by using a SLM classification system. These chemical groups are arranged in 
descending order of structural diversity. 
Chemical Group No. of 
Compounds





Blood-brain barrier penetrating agents [Li et al. 
2005b] 
276 0.430 37 
Genotoxic agents [Li et al. 2005a] 229 0.441 39 
FDA approved drugs 1121 0.495 -- 
CYP 3A4 inhibitors 233 0.505 -- 
PXR activators (this work) 128 0.535 83 
CYP 2C9 inhibitors  167 0.541 -- 
NCI diversity set 1804 0.544 -- 
CYP 3A4 substrates 362 0.547 -- 
CYP 2C9 substrates 144 0.552 -- 
P-glycoprotein substrates [Xue et al. 2004c] 116 0.555 22 
CYP D6 inhibitors 180 0.575 -- 
CYP 2D6 substrates 198 0.588 -- 
Human intestine absorbing agents [Xue et al. 
2004b] 
131 0.596 27 
PXR activators in Schuster and Langer’s 
pharmacophore model [Schuster et al. 2005] 
53 0.605 -- 
ER agonists [Li et al. 2006a] 243 0.618 31 
 
CHAPTER 3 PHARMACOKINETIC PREDICTION MODELS 72
Figure 3.2 Structure of selected PXR activators of different structural features. The CAS 
































































PCB 196 (42740-50-1) 
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A total of 83 molecular descriptors, listed in Table 3.2, were selected by the RFE 
method from a set of 199 molecular descriptors. These descriptors include simple 
molecular description such as count of atom types (nhyd, nhal, nhet, ncocl, nnitro), ring 
(nring) and rotatable bonds (nrot), molecular connectivity and geometry (3χC, 4χPC, 
5χCH, 6χCH, 1χv, 2χv, 3χvP, 3χvC, 4χvPC, 6χvCH, dis1, dis2, dis3, etc), molecular 
flexibility (phi), electrotopological states or Estates (S car, S het, S hal, S(1), S(5), S(12), 
S(13), S(16), S(18), Tcent, Tradi, Tdiam, Tiwie, etc), molecular surface area (PSA, Sapc, 
Sanc, Sapcw, Sancw, Svpc, etc), molecular shape (Rugty, Gloty), hydrophobicity (Shpl, 
Shpb, Hiwpl, Hiwpb, Hiwpa) and quantum chemical descriptors (εa, εb, µ, η, SN, IP, A, 
µ cp, χ en, ω, etc).  
 
Table 3.2 RFE selected 83 molecular descriptors for SLMs classification of PXR 
activators. The selected descriptors are from the 199 molecular descriptor set used in this 




nhyd Count of hydrogen atoms 
nhal Count of halogen atoms 
nhet Count of hetero atoms 
ncocl Count of Cl atoms 
nnitro Count of N atoms 
nring Numbers of rings 





ndonr Number of H-bond donors 
3χC Simple molecular connectivity Chi indices for cluster 
4χPC Simple molecular connectivity Chi indices for 
path/cluster 
5χCH Simple molecular connectivity Chi indices for cycles 
of 5 atoms 
6χCH Simple molecular connectivity Chi indices for cycles 
of 6 atoms 
Connectivity 
(15) 
1χv Valence molecular connectivity Chi indices for path 
order 1 
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2χv Valence molecular connectivity Chi indices for path 
order 2 
3χvP Valence molecular connectivity Chi indices for path 
order 3 
3χvC Valence molecular connectivity Chi indices for cluster 
4χvPC Valence molecular connectivity Chi indices for 
path/cluster 
6χvCH valence molecular connectivity Chi indices for cycles 
of  6 atoms 
2κ a Kappa alpha indices for two bonded framents 
phi Kier molecular flexibility index 
S car Sum of Estate indices of carbon atoms 
S het Sum of Estate indices of hetero atoms 
S hal Sum of Estate indices of halogen atoms 
S(1) Atom-type H Estate sum for -OH 
S(2) Atom-type H Estate sum for =NH 
S(5) Atom-type H Estate sum for > NH  
S(12) Atom-type H Estate sum for CH n (Saturated) 
S(13) Atom-type H Estate sum for CH n (unsaturated) 
S(16) Atom-type Estate sum for -CH 3 
S(18) Atom-type Estate sum for >CH 2 
S(21) Atom-type Estate sum for : CH : (aromatic) 
S(25) Atom-type Estate sum for =C< 
S(26) Atom-type Estate sum for : C:- 
S(34) Atom-type Estate sum for =N- 
S(36) Atom-type Estate sum for >N- 
S(37) Atom-type Estate sum for -N<< (NO2) 
S(39) Atom-type Estate sum for -OH 
S(40) Atom-type Estate sum for =O 
S(41) Atom-type Estate sum for -O- 
S(42) Atom-type Estate sum for :O: 
S(60) Atom-type Estate sum for -Cl 
Tcent Centric Index 
Tradi PetitJohn R2 Index 




Tiwie Information Weiner 
εa Hydrogen bond donor acidity (covalent HBDA) 
εb Hydrogen bond acceptor basicity (covalent HBAB) 
µ Molecular dipole moment 
η Absolute hardness 
SN Softness 
IP Ionization potential 
A Electron affinity 





χ en Electronegativity index 
Table 3.2 Continued
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ω Electrophilicity index 
Q H, Max Most positive charge on H atoms 
Q C, Max Most positive charge on C atoms 
Q N, Max Most positive charge on N atoms 
Q O, Max Most positive charge on O atoms 
Q H, Min Most negative charge on H atoms 
Q C, Min Most negative charge on C atoms 
Q N, Min Most negative charge on N atoms 
Q H, SS Sum of squares of charges on H atoms 
Q N, SS Sum of squares of charges on N atoms 
Rnc Relative negative charge 
dis1 Length vectors (longest distance, longest third atom, 
4th atom) 
dis2 Length vectors (longest distance, longest third atom, 
4th atom) 
dis3 Length vectors (longest distance, longest third atom, 
4th atom) 
PSA Polar molecular surface area 
Sapc Sum of solvent accessible surface areas of positively 
charged atoms 
Sanc Sum of solvent accessible surface areas of negatively 
charged atoms 
Sapcw Sum of charge weighted solvent accessible surface 
areas of positively charged atoms 
Sancw Sum of charge weighted solvent accessible surface 
areas of negatively charged atoms 
Svpc Sum of van der Waals surface areas of positively 
charged atoms 
Svpcw Sum of charge weighted van der Waals surface areas 
of positively charged atoms 
Svncw Sum of charge weighted van der Waals surface areas 
of negatively charged atoms 
Rugty Molecular rugosity 
Gloty Molecular globularity 
Shpb Hydrophobic region 
Capty Capacity factor 
Hiwpl Hydrophilic Integy Moment 




Hiwpa Amphiphilic Moment 
 
            
Table 3.2 Continued
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Some of these RFE selected descriptors such as hydrophobicity, hydrogen bond 
acceptors, molecular globularity and some Volsurf descriptors are also consistent with the 
structural features or descriptors described or used in the previous pharmacophore and 
QSAR studies of PXR activators. Pharmacophore models have shown that hydrophobic 
and hydrogen bond acceptors (HBAs) are important features for PXR activators [Ekins et 
al. 2002; Schuster et al. 2005]. In a QSAR study  [Jacobs 2004], hydrogen bond 
acceptors, dispersion forces, molecular globularity and some VolSurf descriptors were 
found to be the key positive correlated variables for constructing the PXR QSAR model 
for predicting PXR activators.  
 
The number of selected descriptors in this study is substantially larger than the 
22~39 molecular descriptors selected in the prediction of compounds of various other 
drug activities or properties [Xue et al. 2004b; Xue et al. 2004c; Li et al. 2005a; Li et al. 
2005b]. An examination of the selected descriptors showed that most of the “extra” set of 
descriptors is from the electro-topological, connectivity and quantum chemical classes. 
As shown in Figure 3.2, apart from the usual chemical structures, a substantial number of 
PXR activators contained highly complex multi-aromatic rings, or highly-flexible chain-
like structures, or halogen-rich structures. These structural features coupled with highly 
diverse structural frameworks are likely to be the primary reasons for the need for the 
“extra” set of electro-topological, connectivity and quantum mechanical descriptors in 
distinguishing PXR activators. 
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3.1.3.2 Performance of SLMs for predicting PXR activators 
 
 
Table 3.3 gives the prediction performance of the three SLMs, with and without 
the use of the RFE feature selection method, for predicting PXR and hPXR activators and 
non-activators based on a 10-fold cross validation study. The parameters of the PXR 
SVM, k-NN and PNN systems are δ=1, k=1, and δ=0.3 respectively. Those of the hPXR 
systems are δ=1, k=3, and δ=0.2, respectively. The use of the RFE feature selection 
method helps to improve the overall prediction performance of the PXR SLM systems 
from an accuracy level of 72.6~74.0% to that of 75.4~77.4%, and that of the hPXR 
systems from an accuracy level of 72.5%~74.9% to that of 75.0%~79.6%. All of the 
SLM systems appear to show good performance. When considering overall prediction 
accuracy, PNN and SVM perform better than k-NN.  
Table 3.3 Performance of three statistical learning methods (k-NN, PNN and SVM) for 
predicting PXR and hPXR activators and non-activators determined by a 10-fold cross 











Q (%) C 
k-NN 81.7 57.5 72.6 0.410 
PNN 81.9 60.9 74.0 0.446 
All 
Descriptors 
SVM 81.0 62.2 73.9 0.441 
k-NN 84.0 61.2 75.4 0.473 





Descriptors SVM 81.2 70.3 77.1 0.528 
k-NN 80.6 62.4 72.5 0.448 
PNN 80.7 63.8 73.2 0.461 
All 
Descriptors 
SVM 77.8 71.4 74.9 0.504 
k-NN 80.8 67.7 75.0 0.499 




Descriptors SVM 84.4 73.6 79.6 0.598 
The results are expressed in SE (sensitivity or prediction accuracy for PXR activators), 
SP (specificity or prediction accuracy for PXR non-activators), Q (overall accuracy) and 
C (Matthews correlation coefficient). 
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Our classification systems were further evaluated by using 15 newly published 
hPXR activators [Lemaire et al. 2006] which are shown in Figure 3.3. These include 5 
herbicides (pretilachlor, metolachlor, oxadiazon, alachlor and isoproturon), 6 fungicides 
(bupirimate, fenarimol, propiconazole, fenbuconazole, prochloraz and imazalil), and 4 
insecticides (toxaphene, permethrin, fipronil and diflubenzuron). As shown in Table 3.4, 
86.7%, 73.3% and 73.3% of these activators were correctly predicted by the SVM, PNN 
and k-NN PXR prediction systems, 66.7%, 66.7%, and 53.3% were correctly predicted 
by the corresponding hPXR prediction systems respectively. One possible reason for the 
lower accuracy of the hPXR systems could be that they were trained by using compounds 
structurally more different from the newly published hPXR activators than some PXR 
activators in the training set of PXR prediction systems. As shown in Table 3.5, the 
Euclidean distance between the 15 newly published hPXR activators and the 28 PXR 
activators outside the hPXR dataset is closer than that of the 98 hPXR activators. One 
activator, the fenbuconazole, was incorrectly predicted by all of our PXR and hPXR 
systems. One possible reason for misclassifying this compound could be that it contained 
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Figure 3.3 Structure of 14 novel PXR activators from a recent publication [Lemaire et al. 







































CHAPTER 3 PHARMACOKINETIC PREDICTION MODELS 80
 
Table 3.4 Performance of the PXR and hPXR activator prediction systems for predicting 
the 15 recently published hPXR activators. A: predicted PXR activator and N: predicted 

















1  Pretilachlor    51218-49-6  129.5 A A A N A N 
2  Toxaphene  8001-35-2 114.2 A A A A A A 
3  Metolachlor    51218-45-2  107.2 A A A N A A 
4  Oxadiazon    19666-30-9  94.2 A A A A A N 
5 Bupirimate  41483-43-6  93.5 A A A A A A 
6  Fenarimol    60168-88-9  89.6 A A N A N A 
7 Permethrin  52645-53-1  88.4 A A A A N A 
8  Propiconazole  60207-90-1  85.1 A N N A A A 
9 Alachlor  15972-60-8 71.3 A A A N A A 
10 Fipronil  120068-37-3  58.7 A A A A A N 
11 Fenbuconazole    114369-43-6  56.1 N N N N N N 
12  Prochloraz    67747-09-5  50.5 A A A A A N 
13 Isoproturon  34123-59-6  50.1 A A A A N A 
14  Imazalil    35554-44-0  46.5 N N A N N N 
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Table 3.5 The Euclidean distance of the 15 PXR activators in the independent set to the 
28 ambiguous PXR activators and the 98 human PXR activators. 
 













51218-49-6 153559-76-3 57.6 153559-49-0 64.1 
8001-35-2 5566-34-7 86.3 789-02-6 68.5 
51218-45-2 15972-60-8 20.3 51169-17-6 75.8 
19666-30-9 5300-03-8 65.5 57-83-0 81.4 
41483-43-6 50-23-7 129.2 97240-79-4 82.4 
60168-88-9 72-43-5 72.7 2528-16-7 69.9 
52645-53-1 3862-25-7 113.5 52315-07-8 75.7 
60207-90-1 53-43-0 68.9 63-05-8 73.9 
15972-60-8 15972-60-8 4.6 51169-17-6 73.5 
120068-37-3 1582-09-8 99.0 71145-03-4 113.3 
114369-43-6 72-43-5 91.9 51169-17-6 143.9 
67747-09-5 53-43-0 92.7 23930-19-0 77.2 
34123-59-6 80-05-7 102.7 86-35-1 63.4 
35554-44-0 15972-60-8 49.0 51169-17-6 63.1 
35367-38-5 72-43-5 77.6 57-41-0 107.1 
 
 
3.1.3.3 Relevance of molecular descriptors to the activity of PXR activators 
 
 
Our selected descriptors are consistent with the molecular binding features 
derived from the study of the binding site of the ligand-free and drug-bound PXR 
receptor structures [Watkins et al. 2001]. It has been reported [Watkins et al. 2001] that 
molecular flexibility, surface area, geometry, and connectivity are important for 
characterizing molecular recognition between PXR ligand-binding site and activators. 
The solved crystal structure of human PXR ligand-binding domain shows high mobility 
and flexibility in largely hydrophobic site that incorporates a few polar residues capable 
of forming hydrogen bonds with a binding ligand [Watkins et al. 2001; Watkins et al. 
2003a; Chrencik et al. 2005]. Hydrogen bonds are found to be important in determining 
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the specificity of molecular recognition. Upon binding to PXR ligand-binding site, PXR 
activator would orient in a specific orientation stabilize by hydrogen bonds and cause 
conformational change of PXR ligand binding domain to recruit the binding of 
coactivators. On the other hand, connectivity is important not only for discriminating 
between active from non-active analogs but also for representing important molecular 
topological features involved in PXR activation. Moreover, electrotopological states, 
hydrophobicity, and quantum chemical descriptors describe polarity and charge of 
molecules that contribute to hydrogen bonding, polar, and salt-bridge interactions 
between PXR activators with the amino acid residues in the ligand-binding cavity of PXR.  
 
PXR activators generally show higher content of halogen atoms especially 
chlorine atoms than non-activators as can be seen from higher mean values of halogen 
atom count (nhal) (1.16 vs. 0.80), chlorine atom count (ncocl) (1.02 vs. 0.27), and atom-
type estate sum for chlorine S(60) (6.33 vs.1.63). Moreover, PXR activators contain less 
nitrogen atoms (nnitro) than non-activators (0.80 vs.1.79), and have lower values of 
several descriptors including the mean values of atom-type electrotopological state (estate) 
sum for >NH, S(5) (0 vs.0.45); atom-type estate sum for =N-, S(34) (0.31 vs.1.15); atom-
type estate sum for >N-, S(36) (0.15 vs. 0.94); and atom-type estate sum for –N<<, S(37) 
(0.05 vs. 0.41). In addition, polar and salt bridges between PXR ligand binding domain 
(LBD) residues and п-п stacking between aromatic rings of activators and LBD are also 
important for PXR activation. The descriptors for sums of solvent accessible surface 
areas of positively charged atoms (Sapc, Sapcw, Svpc), negatively charged atoms (Sanc, 
Sancw), and ionization potential (IP) are associated with salt-bridge interactions. Those 
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atom-type sum for CHn unsaturated, S(13); and atom-type sum for :CH: aromatic, S(21) 
are relevant to п-п stacking.  
 
Although PXR activators generally are found to contain lower number of 
hydrogen bond donors (εa) and acceptors (εb) than those of non-activators, nonetheless 
hydrogen bonding could play a role in the binding of the activator to PXR. It was found 
that on average PXR activators have higher number of hydrogen bond acceptors (HBAs) 
(εb) than hydrogen bond donors (HBDs) (εa), which are consistent with the results from 
QSAR and pharmacophore studies [Ekins et al. 2002; Jacobs 2004; Schuster et al. 2005]. 
A higher number of HBAs for PXR activators might result from the existence of the 
HBDs containing residues His-327, His-407, and Arg-410 residues in the interior region 
of PXR ligand-binding site. These features are captured by the RFE-selected descriptors 
Svpcw and Svncw for the sum of weighted van der Waals surface areas of positive and 
negative atoms, respectively. The mean values of Svncw (36.25 vs. 21.84) are higher than 
those of Svpcw for PXR activators showing complementary charge for activators to the 
PXR ligand-binding site may contribute to the entry of binding site and stable binding.   
 
The computed mean values for the number of rotatable bonds (nrot) (4.45 vs.5.99), 
Kier molecular flexibility index (phi) (5.84 vs.6.24), polar molecular surface area (PSA) 
(61.90 vs.69.53)  of PXR activators are smaller than those of non-activators, which is 
consistent with the view that PXR activators are generally smaller in size [Handschin et 
al. 2005]. The smaller size and lower number of rotatable bonds enable a better access to 
the ligand-binding site. While how a ligand gains access to the PXR ligand-binding 
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cavity remains unclear, it has been hypothesized that the flexible α2 (residues 192-205) 
that is unique to the PXR might be a critical component for ligand entry and exit the site 
[Watkins et al. 2003a]. The flexible region might operate like a trapping-door allowing 
ligands to enter the center of the ligand-binding site. In addition, Leu209 located near the 
C terminus of α2 shifted in position by up to 7.7Å when bound by different ligands 
[Watkins et al. 2003b]. Binding by co-activators further stabilizes the bound orientations 
of ligands. Taken together, the large and flexible ligand-binding pocket of PXR explains 
the promiscuous nature of PXR to bind to a variety of endogenous and xenobiotic 
compounds. 
 
While some aspects of activator binding to PXR can be exhibited by analyzing the 
selected descriptors, these descriptors are quantitative representations of structural and 
physicochemical features. Therefore, analysis of these descriptors without consideration 
of the receptor site structure is insufficient for providing molecular level picture about the 
connection between a descriptor and the predicted activity. In the protein 3D structure 
database PDB (http://www.rcsb.org/pdb/Welcome.do), there are four entries of ligand-
bound PXR structures. Analysis of some of these structures provides useful information 
about the atomic-level interactions represented by some of our selected descriptors. 
Figure 3.4 and Figure 3.5 show the binding site structure of PXR bound by activator 
SR12813 [Watkins et al. 2001; Watkins et al. 2003a; Chrencik et al. 2005] and 
hyperforin [Watkins et al. 2003b] respectively. Both activators form hydrophobic 
contacts with two hydrophobic residues and they form hydrogen bonds with two polar 
residues. These provide clear molecular picture about the connection between our 
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selected descriptors, hydrophobic and hydrogen bond descriptors, and activator-binding 
to PXR. 
 
Figure 3.4 Binding of PXR activator SR12813 (in ball and stick) at PXR (in wire frame) 
ligand-binding site. The activator forms hydrogen bonds with Ser247 and His407, and 
hydrophobic contact with Met243 and Met246. 
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Figure 3.5 Binding of PXR activator hyperforin (in ball and stick) at PXR (in wire frame) 
ligand-binding site. The activator forms hydrogen bonds with Ser247 and His407, and 



















   
           
 
          
         From the chemistry point of view, one can state that the molecular structure of a 
compound is the key in understanding its physicochemical properties and ultimately its 
biological activity and physiological effect [Johnson et al. 1990]. Although hydrophobic 
interactions and hydrogen bondings are known to play important roles in molecular 
recognition from ligand-protein, protein-protein, up to macromolecular assemblies, there 
are many ways to describe these interactions from chemistry point of views as can be 
expressed by various molecular descriptors. However, which descriptions are more 
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relevant to a given activity has to be further characterized by various means such as using 
feature selection methods in the machine learning methods.  
 
         Current representations of molecular physicochemical properties by molecular 
descriptors are still far from complete. Further refinement to develop a more 
sophisticated set of molecular descriptors is definitely an important task. Moreover, it is 
essential to include more PXR activators and non-activators from future experimental 
studies. Currently we used a set of 199 molecular descriptors. However, when the dataset 
grows in the future we believe more a complete set of molecular descriptors is required. 
Furthermore, the biological activity of a compound is an induced response that is 
influenced by numerous factors dictated by many levels of biological complexity. The 
relationship between structure and activity is thus more implicit and thereby requires a 
more thorough investigation and rigorous validation [Tong et al. 2004a]. Hence, the 





           Identification of novel PXR activators from structurally diverse compounds is 
important for the discovery of drugs with desired metabolic and toxicological profiles. 
This study shows that SLMs, especially SVM, are useful for in silico prediction of the 
activators of highly promiscuous proteins such as PXR and for characterizing the 
molecular features of PXR activation. By incorporating feature selection methods such as 
RFE into SLMs, molecular descriptors relevant to PXR activators can be identified. Most 
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of these selected molecular descriptors are consistent to those used in previous 
pharmacophore and QSAR studies and with the findings from X-ray crystallography 
studies. Further works on the improvement and refinement of feature selection methods 
as well as molecular descriptors are needed in order to improve the capability of SLMs 
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One important pharmacokinetic property of a drug is its ability or inability to 
penetrate the blood brain barrier (BBB) [Norinder et al. 2002]. BBB-penetration is 
important for drugs that target receptors in the brain. Examples of these drugs are 
antipsychotics, antiepileptics and antidepressants [Hardman et al. 2002]. For drugs not 
directed at targets in the brain, prevention of BBB-penetration is desirable so as to avoid 
unwanted central nervous system (CNS) related side effects.  
 
A variety of experimental techniques have been employed for BBB-penetration 
study and screening [Li 2002]. Moreover, computational methods have been introduced 
as potential prescreening tools with the aim to reduce the cost and enhance the speed of 
BBB-penetration analysis [Norinder et al. 2002]. The most widely explored 
computational methods are regression methods [Young et al. 1988; Abraham et al. 1994; 
Lombardo et al. 1996; Norinder et al. 1998; Clark 1999; Kelder et al. 1999; Luco 1999; 
Feher et al. 2000; Keserü et al. 2001; Liu et al. 2001a; Liu et al. 2001b; Platts et al. 2001; 
Hou TJ et al. 2003; Liu X et al. 2004] and statistical learning prediction methods [Ajay et 
al. 1999; Baldi et al. 2000; Crivori et al. 2000; Cruciani et al. 2000; Trotter et al. 2001; 
Doniger et al. 2002]. As shown in Table 3.6, previous statistical learning methods 
achieve a high prediction accuracy of 75%~92% for BBB-penetrating (BBB+) and 
60%~80% for BBB non-penetrating (BBB-) agents. The corresponding overall accuracy 
is in the range of 71%~81%, which is substantially lower than that of the BBB+ accuracy 
due to the lower BBB- accuracy. A more balanced prediction with an improved BBB- 
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accuracy is needed for facilitating the prediction of BBB- agents as well as for reducing 
the false positive rate of the prediction of BBB+ agents. 
 
Table 3.6 Prediction accuracies of BBB penetrating (BBB+) and non-penetrating agents 
(BBB-) from different studies reported in the literatures.  
Study 
(Reference) 
Methods No. of 
Agents 
BBB+ 








Ajay et al. 1999    BNN 275 92.0 71.0 81.8 
Crivori et al. 
2000         
PCA 120 90.0 65.0 71.7 
Cruciani et al. 
2000        
PCA 35 >75.0 >75.0 >75% 
Trotter et al. 
2001    
SVM 304 78.9 60.4 76.0 
Doniger et al. 
2002        
NN 324 81.5 69.9 75.7 
Doniger et al. 
2002       


































It is cautioned that direct comparison of these results may not be appropriate because of 
the use of different sets of agents, molecular descriptors, classification methods and 
parameters, and method for generating testing sets. BNN (Bayesian neural network), 
PCA (principal component analysis), NN (neural network), LR (linear regression), LDA 
(linear discriminate analysis), C4.5 DT (C4.5 decision tree), PNN (probabilistic neural 
network), k-NN (k-nearest neighbors), SVM (support vector machine). 
 
In earlier studies of the prediction of agents of different pharmacokinetic, 
pharmacodynamic and toxicological properties by using SLMs, it has been found that 
selection of appropriate molecular descriptors can give a substantially more balanced 
prediction accuracy and enhance the overall accuracy [Xue et al. 2004b; Xue et al. 
2004c]. For instance, the prediction accuracies for human intestine absorption and non-
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absorption agents are improved from 83.4% and 63.2% to 90.0% and 80.7%, and those 
for torsades de pointes causing agents and non-causing agents are improved from 54.5% 
and 90.6% to 66.8% and 89.3% respectively. It is therefore of interest to examine 
whether proper selection of molecular descriptors can also improve the BBB- accuracy 
and the overall BBB+/BBB- accuracy by using SLMs.  
 
Several SLMs such as LR, LDA, k-NN, DT, PNN, and SVM were evaluated in 
this study. A total of 415 BBB+ and BBB- agents reported from the literature were 
collected and used to test these methods. A widely-used feature selection method, 
recursive feature elimination (RFE), was used for selecting molecular descriptors relevant 
to the prediction of BBB+ and BBB- agents. 5-fold cross validation and independent 





3.2.2.1 Selection of BBB+ and BBB- agents 
 
 
               In this work, a total of 415 agents with known BB ratio (the ratio of the steady 
state concentration of a drug in the brain and blood) were selected from Micromedex 
[MICROMEDEX 2003], American Hospital Formulary Service (AHFS) [Bethesda 2001] 
and a number of publications [Luco 1999; Crivori et al. 2000; Feher et al. 2000; Platts et 
al. 2001; Iyer et al. 2002; Ooms et al. 2002; Lobell et al. 2003a].  The 2D structure of 
each of the compounds studied was generated by using ChemDraw [CambridgeSoft 
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Corporation 2002] and DS ViewerPro 5.0 [Accelrys 2005], which was subsequently 
converted into 3D structure by using CONCORD [Pearlman] and optimized by using the 
semiempirical AM1 method [Dewar et al. 1985]. All the geometries had been fully 
optimized without symmetry restrictions. The 3D structure of each compound was 
manually inspected to ensure that the chirality of each chiral agent is properly represented.  
 
3.2.2.2 Construction of training and testing sets 
 
 
Agents were divided into BBB+ and BBB- groups according to whether the BB 
ratio is ≥ 0.1 or < 0.1 respectively [Luco 1999; Hou et al. 2002]. Under this definition, 
there are a total of 276 BBB+ and 139 BBB- agents in the dataset. These 415 agents were 
randomly divided into five subsets of approximately equal size for conducting 5-fold 
cross validation test of the prediction accuracy of each of the SLMs. To evaluate the 
models, representative training and validation sets were constructed from the datasets 
according to the Remove-until-done algorithm.  
 
3.2.2.3 Molecular descriptors  
 
 
This study used the same 199 molecular descriptors set as mentioned in Chapter 2 
(section 2.2). Redundant and un-related descriptors are further reduced by using the RFE 
method as described in Chapter 2 (section 2.3). 
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3.2.3 Results and discussion 
 
3.2.3.1 Molecular descriptors selected for BBB penetration prediction 
 
 Table 3.7 lists the descriptors selected for the prediction of BBB+ and BBB- 
agents from the feature selection method RFE. Six of the selected descriptors are VolSurf 
descriptors [Cruciani et al. 2000]. In VolSurf, information from 3D molecular field maps 
are extracted into one dimensional descriptors specially designed for pharmacokinetic 
applications [Crivori et al. 2000; Cruciani et al. 2000]. Thus it is not surprising that 
VolSurf descriptors are selected for the prediction of BBB penetration and BBB-non-
penetration properties of agents. The six selected VolSurf descriptors are molecular 
rugosity, capacity factor, hydrophilic and hydrophobic region, hydrophobic and 
amphiphilic moment. Those from the class of electrotopological state constitute the 
largest percentage of the descriptors selected. A large variety of descriptors in this class, 
such as those of different functional groups, hydrophilic, and hydrophobic properties, are 
important in characterization of pharmacokinetic properties. There are also a substantial 
number of descriptors from the quantum chemical, connectivity, and geometric classes. 
The selected quantum chemical descriptors determine molecular dipole moment, 
chemical potential, electronegativity, hydrogen bond donor acidity, and the atomic charge 
on H and O atoms in a molecule. The selected molecular connectivity descriptors are the 
valence molecular connectivity Chi indices for cycles of 5 and 6 atoms. The rest of 
geometrical descriptors, except for VolSurf descriptors, describe the molecular size and 
the sum of solvent accessible surface areas of negatively charged atoms. These 
descriptors are also important in describing electrostatic, topological and geometric 
properties of chemical compounds.  
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Table 3.7 Thirty-seven molecular descriptors selected from the RFE feature selection 
method for classification of blood-brain barrier penetrating and non-penetrating agents 
Descriptors Description Class 
Rugty Molecular rugosity geometrical properties 
Shpl Hydrophilic region geometrical properties 
Shpb Hydrophobic region geometrical properties 
Capty Capacity factor geometrical properties 
Hiwpb Hydrophobic Intery Moment geometrical properties 




Length vectors (longest distance, longest third 
atom, 4th atom) 
geometrical properties 
Sanc Sum of solvent accessible surface areas of 
negatively charged atoms 
geometrical properties 
5χvCH valence molecular connectivity Chi index for 
cycle of 5 atoms 
connectivity and shape 
6χvCH valence molecular connectivity Chi index for 
cycle of 6 atoms 
connectivity and shape 




µ Molecular dipole moment quantum chemical 
properties 
µ cp Chemical potential quantum chemical 
properties 
χ en Electronegativity index quantum chemical 
properties 
Q H, Max Most positive charge on H atoms quantum chemical 
properties 
Q O, Max Most positive charge on O atoms quantum chemical 
properties 
Q H, Min Most negative charge on H atoms quantum chemical 
properties 
S hal Sum of Estate indices of halogen atoms electro-topological state 
S(1) Atom-type H Estate sum for -OH electro-topological state 
S(4) Atom-type H Estate sum for -NH 2 electro-topological state 
S(8) Atom-type H Estate sum for =CH 2 (sp2) electro-topological state 
S(10) Atom-type H Estate sum for :CH: (sp2, 
aromatic) 
electro-topological state 
S(13) Atom-type H Estate sum for CH n (unsaturated) electro-topological state 
S(16) Atom-type Estate sum for -CH 3 electro-topological state 
S(17) Atom-type Estate sum for =CH 2 electro-topological state 
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S(25) Atom-type Estate sum for =C< electro-topological state 
S(26) Atom-type Estate sum for : C:- electro-topological state 
S(27) Atom-type Estate sum for : C :: electro-topological state 
S(30) Atom-type Estate sum for =NH electro-topological state 
S(34) Atom-type Estate sum for =N- electro-topological state 
S(35) Atom-type Estate sum for :N: electro-topological state 
S(36) Atom-type Estate sum for >N- electro-topological state 
S(37) Atom-type Estate sum for -N<< (NO2) electro-topological state 
S(39) Atom-type Estate sum for -OH electro-topological state 
S(41) Atom-type Estate sum for -O- electro-topological state 
 
These selected descriptors are also overlapped with those used in QSAR studies 
of BBB penetrating and non-penetrating agents. Iyer and coworkers [Iyer et al. 2002] 
showed that both hydrogen bonding and ClogP (which measures overall hydrophobicity) 
are the primary descriptors for the BBB classification in their dataset. Pan and coworkers 
[Pan et al. 2004] found that ClogP, polar surface areas, the number of hydrogen bond 
donors, and molecular flexibility such as the number of rotatable bonds are the most 
important descriptors in their model. Ooms and coworkers [Ooms et al. 2002] showed 
that polarity inversely correlated with the BBB permeability while hydrophobicity 
directly correlated to BBB permeability. Similarly, Rose and coworkers [Rose et al. 2002] 
showed that decressing skeletal branching of carbon chain and hydrogen bond donors 
enhance BBB permeability.  
 
Hydrophobicity is collectively described by the two geometrical (Shpb, Hiwpb) 
and eight electrotopological state (S(8), S(10), S(13), S(16), S(17), S(25), S(26), S(27)) 
descriptors selected by RFE. The selected descriptors related to hydrogen bonds are four 
quantum chemical (Q H, Max,  Q O, Max ,     Q H, Min, εa) and nine electrotopological states (S(1), 
Table 3.7 Continued
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S(4), S(30), S(34), S(35), S(36), S(37), S(39), S(41)) descriptors, which collectively 
describe hydrogen bond donor acidicity and hydrogen bond acceptor basicity properties. 
Polarity is collectively described by the three geometrical (Shp1, Hiwpa, Sanc) and two 
quantum chemical (µ, χ en) descriptors selected by RFE. Molecular flexibility and skeletal 
branching of carbon chain are collectively described by the two RFE-selected molecular 
connectivity and shape descriptors (5χvCH, 6χvCH).  
 
              Because composite descriptors encode multiple physicochemical and structural 
aspects of a molecule, it is difficult to extract from these descriptors information about 
which specific molecular characteristics are important for the BBB+ and BBB- prediction. 
Nonetheless, it is possible to infer some information from non-composite descriptors. As 
many descriptors are overlapping and some of them are redundant, it is more appropriate 
to group them into classes of descriptors of similar properties and discuss their 
contribution to the BBB penetration predictions at the class level. Table 3.8 gives the 
classes of non-composite descriptors selected by our computations. It is found that 
hydrophobicity is a dominant factor involved in BBB penetration. This is not surprising 
because hydrophobicity is a primary descriptor in the BBB penetration model. In addition 
to the shape, and size descriptors, electrostatic descriptor and hydrogen bonding are 
found to be other dominant forces involved in BBB penetration. They are consistent with 
the findings that the electrostatic interaction between the solute molecule and the 
membrane and the ability of a molecule to form hydrogen bonds are important factors 
involved in BBB penetration [Pan et al. 2004]. 
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Table 3.8 Important descriptor classes selected for the prediction of blood-brain barrier 












BBB+/BBB- 18.9 27.1 35.1 8.1 10.8 
 
               It is also possible to roughly distinguish between BBB+ and BBB- from the 
values of five selected descriptors, µ, εa, Shpb, Rugty, and dis1. These descriptors are 
representative of the four dominant interaction forces, electrostatic, hydrogen bond 
acceptor, hydrogen bond donor and hydrophobicity, and size and shape of the compounds, 
respectively. µ is the molecular diplole moment, εa  is the hydrogen bond donor acidity, 
Shpb is the hydrophobic region, Rugty is the molecular wrinkled surface, and dis1 is the 
length vector of the longest distance. The average values of these five descriptors for 
BBB+ and BBB- compounds of all of the various datasets are given in Table 3.9. In 
general, BBB penetration agents are generally smaller in size, lower in molecular 
wrinkled surface shape, more hydrophobic, lower in the molecular dipole moment, and 
more hydrogen bonding sites than BBB non-penetration agents. This conclusion is 
consistent with the findings that less polar, more lipophilic compounds partition more 
readily into the brain and the greater binding of the solute to the membrane, the higher 
the BBB partitioning [Iyer et al. 2002]. 
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Table 3.9 Differences in the values of descriptors important for distinguishing between 
blood-brain barrier penetrating (BBB+) agents and non-penetrating (BBB-) agents 
Descriptors Average value a 
BBB+ 
Average value a 
BBB- 
µ 1.89 (1.90) 2.92 (3.48) 
εa 0.01 (0.87) -0.34 (1.36) 
Shpb 2.44 (2.85) 2.17 (3.96) 
Rugty 1.18 (2.31) 1.54 (2.84) 
dis1 -4.52 (0.68) -4.37 (1.01) 
a Values in parentheses are the standard deviations.  
 
3.2.3.2 Prediction accuracy for BBB+ and BBB- agents 
 
 
The BBB+ and BBB- prediction accuracy of the different SLMs by using both the 
full molecular descriptor set and the RFE-selected descriptor set are given in Table 3.10. 
The listed accuracy is the average accuracy from the 5-fold cross validation study by 
using each SLM. The detailed 5-fold cross validation results of one of the methods, SVM 
with and without the use of RFE, are given in Table 3.11. It is found that the use of RFE 
substantially improves the BBB- accuracy and overall accuracy of all of the methods 
studied in this work. The BBB- accuracy is improved from 42.8~64.3% to 46.4%~75.0%, 
while the overall accuracy Q is improved from 46.8%~79.1% to 71.0%~83.7% and the 
Matthews correlation coefficient C is improved from -0.067~0.524 to 0.321~0.645 by 
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Table 3.10 Comparison of the prediction accuracy of the BBB penetrating (BBB+) and 
non-penetrating agents (BBB-) agents by different statistical learning methods. The 
accuracy of each method is taken from the average accuracy of a 5-fold cross validation 
by using 276 BBB+ and 139 BBB- agents. 





























LR 63.6 83.9 42.8 46.4 57.1 71.0 0.063 0.321 
LDA 40.0 78.2 58.4 58.3 46.8 71.2 0.067 0.360 
C4.5 
DT 
83.7 80.3 54.9 62.8 73.8 74.3 0.398 0.433 
k-NN 77.0 85.5 58.0 61.4 70.8 77.1 0.348 0.477 
PNN 76.2 84.3 57.8 62.1 70.3 76.5 0.357 0.481 
SVM 89.9 88.6 64.3 75.0 79.1 83.7 0.524 0.645 
LR (logistic regression), LDA (linear discriminate analysis), C4.5 DT (C4.5 decision 
tree),k-NN (k nearest neighbor), PNN (probabilistic neural network), SVM (support 
vector machine),RFE (recursive feature elimination), Matthews correlation coefficient 
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Table 3.11 Support vector machine (SVM) and support vector machine with recursive 
feature elimination (SVM+RFE) prediction accuracy of the BBB penetrating agents 
(BBB+) and non-penetrating agents (BBB-) by using 5-fold cross validation. 





 TP FN SE 
(%) 
TN FP SP 
(%) 
 




SVM 1 45 7 86.5 18 6 75 82.9 0.609 
 2 45 10 81.8 15 14 51.7 71.4 0.349 
 3 54 8 87.1 22 4 84.6 83.4 0.690 
 4 50 6 89.3 14 11 56 79.0 0.485 
 5 46 5 90.2 19 16 54.3 75.6 0.487 
 average   89.9   64.3 79.1 0.524 
 SD   ±3.16   ±13.07 ±4.53 ±0.117
 SE   ±1.29   ±5.34 ±1.85 ±0.048
SVM+RFE 1 39 13 75.0 22 2 91.7 80.3 0.622 
 2 49 6 89.1 24 5 82.8 86.9 0.713 
 3 58 4 93.5 21 5 80.8 89.8 0.752 
 4 51 5 91.1 15 10 60.0 81.5 0.547 
 5 48 3 94.1 21 14 60.0 80.2 0.593 
 average   88.6   75.0 83.7 0.645 
 SD   ±7.01   ±12.83 ±3.90 ±0.08 
 SE   ±2.86   ±5.24 ±1.59 ±0.03 
Predicted results are given in TP (true positive), FN (false negative), TN (true negative), 
FP (false positive), SE (sensitivity) which is the prediction accuracy for BBB+, SP 
(specificity) which is the prediction accuracy for BBB-, Q (overall prediction accuracy ), 
and C (Matthews correlation coefficient ). Statistical significance is indicated by SD 
(standard deviation), and SE (standard error) respectively. 
 
Of the SLMs studied, SVM gives the highest BBB+, BBB-, Q and C values of 
88.6%, 75.0%, 83.7% and 0.645 by using RFE selected descriptors and of 89.9%, 64.3%, 
79.1% and 0.524 by using the full set of descriptors. The overall accuracy of SVM with 
RFE selected descriptors is found to be slightly higher than those from previous studies 
listed in Table 3.6. For the other five methods tested in this work, their prediction 
accuracies for BBB+ agents are in the range of 78.2%~85.5% by using RFE selected 
descriptors and of 40.0%~83.7% by using the full set of descriptors, and those for BBB- 
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agents are in the range of 46.4%~62.8% by using RFE selected descriptors and of 
42.8%~58.4% by using the full set of descriptors respectively. Thus SVM appears to give 
somewhat better prediction accuracy than the other SLMs, which is consistent with the 
results from an earlier study of BBB+ and BBB- agents [Doniger et al. 2002] and other 
studies of different chemical and protein systems [Furey et al. 2000; Bock et al. 2001; 
Trotter et al. 2003].  This suggests that SVM is capable of prediction of BBB+ and BBB- 
agents at a comparable or perhaps better accuracy with respect to that from other 
classification methods without requiring either the knowledge of mechanism or the 
intrinsic structure activity relationships. 
 
To compare with previous binary classification models, prediction accuracies of 
BBB+ and BBB- agents from different studies reported in the literatures are provided in 
Table 3.6. However, it should be cautioned that direct comparison of these results might 
not be appropriate because of the use of different sets of agents, molecular descriptors, 
classification methods and parameters, and method for generating testing sets. A 
meaningful comparison could be achieved if all the classification models are tested by 
using the same set of BBB+ and BBB- agents not used in training any of these models. 
Such a testing set should ideally include some of the newly discovered BBB+ agents, 
particularly the novel ones. Examples of such agents are AD4 (thiol antioxidant and the 
N-acytel cysteine (NAC) related compound) [Bahat-Stroomza et al. 2005], 2,5-Bis(4-
amidinophenyl)furan (DB75) and 2,5-bis(4-amidinophenyl)furan-bis-O-
methylamidoxime (DB289) [Sturk et al. 2004], glucosamine-kynurenic acid[Robotka H 
et al. 2005], (R)-3'-(5-chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-
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[1',3']oxazolidin-2'-one [Tatsumi et al. 2005], GPI 15427 [Tentori et al. 2005] and 
(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-
2,6-dicarboxylic acid (-)-11be (MGS0039) [Nakazato et al. 2004].  
 
On the other hand, the binary classification models developed in this and other 
studies could not be directly compared with the continuous BBB value QSAR models 
without incorporating algorithms that provide quantitative activity values. Binary 
classification models have primarily been explored with the intention of analyzing agents 
of diverse structures, in many cases more diverse than those of QSAR models which are 
required to provide accurate activity values. SVM regression model has been introduced 
to provide activity values for some drug classification problems including the prediction 
of COX-2 selective inhibitors [Liu et al. 2004], the prediction of binding affinities to 
human serum albumin [Xue et al. 2004a] and the case studies of drug-likeness, 
agrochemical-likeness, and enzyme inhibition predictions [Zernov et al. 2003]. Such a 
regression model can be developed for the prediction of BBB+ and BBB- agents, which 
can be directly compared to the continuous BBB value QSAR models. 
 
It has been shown that chance correlations might have occurred during descriptor 
selection especially if the number of descriptors available for selection is large [Topliss et 
al. 1979; Jouan-Rimbaud et al. 1996]. Y-randomization has been frequently used to 
determine the probability of chance correlation during descriptor selection processes 
[Manly 1997; Leardia et al. 1998]. In this study, the process of scrambling the data set 
and descriptor selection process was repeated for 30 times. This y-randomization analysis 
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was conducted on the SVM model that consistently gives better classification accuracies 
in this and other studies [Burbidge et al. 2001; Czerminski et al. 2001; Meyer et al. 2003]. 
Unless over-fitting is found in the SVM model, no further analysis on other models is to 
be conducted. The average Matthews correlation coefficient of these scrambled SVM 
classification systems derived by using the 5-fold cross validation sets were found to be 
0.118, which is significantly lower than that of the original SVM classification system, 
which is 0.645. This suggests that the original SVM classification system is relevant and 
unlikely to be a result of chance correlation. 
 
A frequently used method for checking whether a prediction system would be 
over-fitted is to compare the prediction accuracies determined by using cross validation 
methods with those determined by using independent validation sets [Hawkins 2004]. 
Since descriptor selection was performed by using the cross validation method as the 
modeling testing sets, an over-fitted classification system is expected to have much 
higher prediction accuracy for the cross validation sets than that for the independent 
validation sets. As shown in Table 3.12, the prediction accuracy of the SVM systems 
based on the cross validation method and those based on independent validation sets are 
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Table 3.12 Comparison of accuracy of blood-brain barrier penetrating (BBB+) and non-
penetrating agents (BBB-) by using cross validation with independent validation set. 









TP FN SE 
(%) 
TN FP SP 
(%) 
Q (%) C 
88.6 75.0 83.7 0.645 57 7 89.1 25 7 78.1 85.4 0.672
Predicted results are given in TP (true positive), FN (false negative), TN (true negative), 
FP (false positive), SE (sensitivity) which is the prediction accuracy for BBB+, SP 
(specificity) which is the prediction accuracy for BBB-, Q (overall prediction accuracy ), 
and C (Matthews correlation coefficient ).  
 
 
Prediction of BBB+ and BBB- agents might need to be correlated to 
pharmacodynamic properties in order to determine their clinical significance. This is 
because a drug with high BB ratio may not have effects in the brain either because of the 
absence of target receptors or insufficient potencies towards the target receptors in the 
brain. Conversely, a drug with a relatively low BB ratio might still have effects in the 
brain because of its high potency towards specific receptors. An example of such a drug 
would be diazepam, which is an antidepressant that exerts its effects in the brain even 





Feature selection method such as RFE appears to be helpful in improving the 
performance of SLMs for the prediction of BBB penetration potential of chemical agents. 
Of the six SLMs tested, SVM appears to give slightly higher prediction accuracy than 
other methods for both BBB+ and BBB- agents. Recent efforts are directed at the 
improvement of the efficiency and speed of feature selection methods [Furlanello et al. 
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2003], which could further help to optimally select molecular descriptors and enable the 
development of more accurate and efficient prediction tools. Prediction accuracy of 
SLMs might be further improved by consideration of factors such as hydrogen bonding, 
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Chapter 4 Prediction of pharmacodynamics properties of 
pharmaceutical agents  
 
 There is a wide ranges of pharmacodynamic models such as the anti-cancer 
model, anti-viral model, hematological model, and neurological model. The aim of this 
chapter is to investigate the applicability of SLMs in predicting and characterizing 
pharmacodynamic property using agonists of estrogen receptor (ER) as an example. ER 
is not only important in tissue and organ development, its malfunction may contribute to 
diseases such as breast cancer. In this study, SLMs are used to study the 






Estrogen receptors (ERs) belong to members of the nuclear receptor family and 
they play important roles in cell growth, development, and homeostasis processes in 
various tissues. There are two ER isoforms. ERα is primarily expressed in the uterus, 
vagina, liver, and pituitary. ERβ is mainly expressed in ovary, prostate, epididymis, lung, 
hypothalamus, and bladder. Both ERα and ERβ share modest overall sequence identity (~ 
47%) with highly conserved regions in the DNA-binding and ligand-binding domains and 
low homology at the N-terminal transactivation domain [Tsai et al. 1994]. The C-
terminal of the ligand-binding domain contains regions for ER dimerization and for 
recruiting transcriptional coactivators [Danielian et al. 1992]. 
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 ER ligands are of three types: agonists, antagonists and selective ER modulators 
[MacGregor et al. 1998]. ER modulators can act as either agonists or antagonists 
depending on the cellular and promoter context as well as the ER isoforms [Paech et al. 
1997]. In particular, ER agonists have been used as drugs for hormone replacement 
therapy, contraception, prevention of osteoporosis [Coelingh 2004], and for the treatment 
of metastatic prostate cancer [Oh 2002]. ER agonists also show neuroprotective actions 
both dependent and independent of ER activity [Behl 2002] and are reported to have 
beneficial cardiovascular effects [Lissin et al. 2000]. Apart from these beneficial 
therapeutic applications, a number of environmental ER agonists and partial-agonists, 
produced as industrial compounds and pesticides, are known to disrupt human endocrine 
functions by mimicking endogenous estrogens [Safe et al. 2001]. Exposure to 
environmental ER agonists and partial agonists has been proposed to be a risk factor for 
the disruption of reproductive system development and tumorigenesis in humans 
[Hileman 1997].  
 
As part of the effort for developing fast and low-cost tools for facilitating drug 
design and chemical safety evaluations, a few SLMs have been used for computer 
prediction of ER binders [Fang et al. 2001; Hu et al. 2003; Asikainen et al. 2004; Tong et 
al. 2004b]. These methods use specific structural and physicochemical properties of the 
known ER binders and non-binders to statistically derive structure-activity relationships 
(SAR) [Fang et al. 2001; Tong et al. 2004b], quantitative structure-activity relationships 
(QSAR) [Hu et al. 2003; Asikainen et al. 2004], and the rule-based decision forest 
models [Hong et al. 2002] for predicting ER binding potential of a molecule. The 
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prediction accuracy of these methods are in the range of 87.1%~97.6% for ER binders 
and 80.2%~96.0% for ER non-binders, which are at a useful level for facilitating the 
prediction of ER binders and non-binders.  
 
However, prediction of ER binders does not automatically enable the 
identification of ER agonists. Moreover, the published ER binder prediction models were 
primarily developed by using compounds that are significantly lower in number and 
narrower in structural diversity than the currently known ER binders and non-binders. 
For instance, the largest number of ER binders used in previous study is 130 with a 
structure DI value of 0.645, which is compared to the 243 known ER agonists with a DI 
value of 0.598. Therefore, it is desirable to develop methods for predicting ER agonists 
from a more diverse set of ER agonists and ER non-agonists.  
 
Several SLMs have been explored for the prediction of various 
pharmacodynamic, pharmacokinetic and toxicological classes of chemical agents 
including drug-like molecules [Byvatov et al. 2003; Zernov et al. 2003], p-glycoprotein 
substrates [Xue et al. 2004c], CNS drugs [Doniger et al. 2002], genotoxic agents [Snyder 
et al. 2001; He et al. 2003], torsade-causing drugs [Yap et al. 2004a], and agents of other 
specific pharmacokinetic properties [Yap et al. 2004b]. The most widely used SLMs are 
SVM, k-NN, PNN and C4.5 DT. These methods have been shown to be particularly 
useful for predicting compounds of diverse structures, and some of them consistently 
show better prediction performance than those of other SLMs. Moreover, they can be 
used to determine molecular descriptors. 
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This study evaluated the capability of the most widely used SLMs for predicting 
ER agonists by using a significantly higher number and more diverse range of ER 
agonists and non-agonists than in previous studies [Li et al. 2006a]. A comprehensive 
literature search was conducted to collect a diverse set of literature-reported ER agonists 
and non-agonists. A feature selection method, recursive feature elimination (RFE), which 
has been used for extracting molecular descriptors relevant to specific types of 
pharmaceutical agents [Guyon et al. 2002; Yu et al. 2003; Xue et al. 2004b], was used 
for selecting molecular descriptors relevant to the prediction of ER agonists. Two 
evaluation methods were used to objectively assess the performance of these methods. 
One is 5-fold cross validation and the other one is validation by the use of an independent 
validation set of known ER agonists and non-agonists. 
 
            This study is focused on the classification of ER agonist vs. non-agonist 
regardless of ER isoforms. ER agonists refer to compounds that show estrogenic activity 
to at least one of the ER isoforms regardless of whether it has antagonist activity to 
another isoform. ER agonists can be found from several sources including endogenous 
estrogens such as estradiol from human body, phytoestrogens such as genistein [Branham 
et al. 2002]  from plants, mycoestrogens such as α-zearalenol [Branham et al. 2002] from 
fungi, xenoestrogens such as chlorothalonil and o,p´-DDT [Kojima et al. 2004] from 
pesticides and environmental pollutants, and drug leads or candidates such as diphenolic 
azoles. ER non-agonists include all ER non-binders and ER antagonists. 
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X-ray crystallography studies have shown that agonist and pure antagonist has 
different binding modes in the ligand-binding domain [Brzozowski et al. 1997]. 
Antagonist can be divided into “active” type that induces conformational change of the 
ligand-binding domain and “passive” type that lacks some bulky side chain [Shiau et al. 
2002]. These distinguishing features are determined by the structural and 
physicochemical properties of the compounds, which can be exploited by SLMs for 
separating ER agonists from ER non-agonists. Moreover, molecular descriptors 
associated with these features, which are responsible for separating ER agonists from 
non-agonists, can be extracted by means of feature selection methods [Li et al. 2005b; 
Yap et al. 2005]. Some relevent molecular descriptors were identified before extensively 
used for deriving SAR [Fang et al. 2001; Tong et al. 2004b], QSAR [Hu et al. 2003; 
Asikainen et al. 2004] and the rule-based decision forest models [Hong et al. 2002]. It is 
likely that not all relevent molecular descriptors have been identified in previous studies 
due to the limited number of compounds. Therefore, in addition to the improvement of 
the performance of SLMs, our feature selection method can be used to identify additional 




4.2.1 Data collection of ER agonists and ER non-agonists 
 
            Data for ER agonists and non-agonists were collected from several sources 
including National Center for Toxicological Research Estrogen Receptor Binding 
Database (NCTRER) (http://www.epa.gov/nheerl/dsstox/sdf_nctrer.html), Endocrine 
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Disruptor Knowledge Base (EDKB) (http://edkb.fda.gov/databasedoor.html), and other 
publications [Blair et al. 2000; Nishihara et al. 2000; Fang et al. 2001]. Many of the 
compounds in the NCTR ER database and EDKB are given as ER binders without 
specific description whether or not they are ER agonists. Thus, additional literature 
search was conducted to confirm their ER agonistic status. Those ER binders reported to 
be as ER antagonists and non-binders are classified as ER non-agonists. Under this 
definition, a total of 243 ER agonists and 463 ER non-agonists were collected and used in 
this study. 
 
The 2D structure of each compound was generated by using ChemDraw 
[CambridgeSoft Corporation 2002] and DS ViewerPro 5.0 [Accelrys 2005], and was 
subsequently converted into 3D structure by using CONCORD[Pearlman] followed by 
optimization using the semi-empirical AM1 method [Dewar et al. 1985]. All the 
generated geometries had been fully optimized without symmetry restrictions. The 3D 
structure of each compound was manually inspected to ensure that the chirality of each 
chiral agent is properly generated.  
 
            There are 130 compounds with chiral centers in the collected dataset. The active 
enantiomer of each of these compounds was selected on the basis of literature reports 
[Fang et al. 2001; Mueller et al. 2004]. In some cases, an enantiomer is a full agonist of 
both ER isoforms, while another enantiomer is a full agonist of one isoform and weaker 
or non-agonist of the other isoform. For instance, S-indenestrol is a full ERα/β agonist 
but R-indenestrol only shows full agonism to ERβ [Mueller et al. 2004]. In this study, the 
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transactivation criteria of agonists were used rather than their binding activities. For those 
compounds where the transactivation activities were determined by using racemaic 
mixtures without enantiomer activity information, the default enantiomer structure in the 
chemical database such as PubChem [PubChem 2004] and ChemFinder [ChemFinder 
1995] was used directly.  
4.2.2 Structural diversity 
 
            DI values for the current study with a larger dataset and from previous ER binder 
studies [Fang et al. 2001; Tong et al. 2004b] are 0.598 and 0.645, respectively. In 
addition, the DI values of three other ER-binder classes (flavanones, steroids with a 
phenolic ring, and flavones) [Fang et al. 2001] are 0.740, 0.771, 0.816, respectively, 
showing low structural diversity. The DI values suggest that the dataset of ER agonists 
used in this work is more diverse than those used in earlier studies for ER binders. 
 
4.2.3 Construction of training and testing sets 
 
 
            ER agonists and non-agonists were further divided into training and testing sets 
by two different methods, 5-fold cross validation and validation by an independent 
evaluation set. For 5-fold cross-validation, a group of 243 ER agonists and that of 463 ER 
non-agonists was randomly divided into five subsets of approximately equal size 
respectively. For the independent evaluation set study, these compounds were divided 
into training and independent validation set by the Remove-until-done algorithm. Based 
on this algorithm the training and independent evaluation set contains 626 compounds 
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(216 ER agonists, 410 ER non-agonists), and 80 compounds (27 ER agonists, 53 ER non-
agonists) respectively. An additional set of 11 ER agonists and 16 ER non-binders, 
obtained from additional search of literatures such as newly published papers, were used 
as independent validation set to further evaluate the performance of SLMs. 
 
4.2.4 Molecular descriptors  
 
 
This study used the same 199 molecular descriptors set as mentioned in Chapter 2 
(section 2.2). Redundant and irrelevent descriptors are further removed by using the RFE 
method, which was described in Chapter 2 (section 2.3). 
 
4.3 Results and discussion 
 
4.3.1 Overall prediction accuracies and merit of the statistical learning methods 
 
The effect of feature selection method on the performance of SLMs for the 
prediction of ER agonists can be shown by comparing the computed accuracies of SVM 
with and without the use of RFE, which are shown in Table 4.1. The accuracy of SVM 
with RFE are found to be 86.2% for ER agonists and 91.1% for ER non-agonists, these 
results are substantially better than those of 78.8% for ER agonists and 85.7% for ER 
non-agonists derived from SVM without RFE. Similar prediction accuracy are found in 
two additional 5-fold cross validation studies conducted by using training-testing sets 
separately generated from different random number seed parameters. This suggests that 
RFE is useful in selecting the proper set of molecular descriptors for the prediction of ER 
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agonists as well as other classes of pharmaceutical agents [Guyon et al. 2002; Yu et al. 
2003; Xue et al. 2004b]. The results show that selection of appropriate molecular 
descriptors is not only important for the improvement of prediction accuracy but more 
importantly to provide insight into physicochemical nature as well as the molecular 
mechanism of the action of ER agonists. 
 
Table 4.1 The accuracy of ER agonists and ER non-agonists derived from SVM without 
the use of a feature selection method (SVM) and from SVM with the use of the feature 
selection method RFE (SVM+RFE) by using 5-fold cross validation.  
ER agonists ER non-agonists Method Cross 
validation 




1 39 13 75.0 78 13 85.7 80.1 0.607 
2 35 13 72.9 89 14 86.4 78.9 0.590 
3 36 7 83.7 79 11 87.8 86.5 0.700 
4 43 12 78.2 71 15 82.6 80.9 0.602 
5 38 7 84.4 80 13 86.0 85.5 0.684 
Average  78.8  85.7 82.4 0.637 
SVM 
SE  ±2.29  ±0.85 ±1.52 ±0.02 
1 42 10 80.8 82 9 90.1 86.7 0.712 
2 40 8 83.3 93 10 90.3 88.1 0.728 
3 38 5 88.4 83 7 92.2 91.0 0.797 
4 48 7 87.3 77 9 89.5 88.7 0.763 
5 41 4 91.1 87 6 93.5 92.8 0.837 
Average  86.2  91.1 89.5 0.767 
SVM 
+RFE 
SE  ±1.84  ±0.75 ±1.09 ±0.02 
The results are given in TP (true positive), FN (false negative), TN (true negative), FP 
(false positive), Q (overall accuracy), C (Matthews correlation coefficient), SE 
(sensitivity or prediction accuracy for ER agonists) and SP (specificity or prediction 
accuracy for ER non-agonists). Statistical significance is indicated by SE (standard error). 
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Table 4.2 Comparison of the prediction accuracy of ER agonists and ER non-agonists 
derived from different statistical learning methods by using 5 fold cross validation in this 
work.  
Method ER agonists SE (%) ER non-agonists SP (%) Q (%) 
C4.5 DT 66.3 83.8 77.8 
PNN 83.6 76.0 78.7 
k-NN 72.7 85.9 81.5 
SVM+RFE 86.2 91.1 89.5 
The methods include C4.5 DT (C4.5 decision Tree), PNN (probabilistic neural network), 
k-NN (k nearest neighbor), SVM+RFE (support vector machine & recursive feature 
elimination). 
 
Table 4.2 gives the prediction accuracy of ER agonists and ER non-agonists 
derived from other three SLMs, namely k-NN, PNN and C4.5 DT by using the RFE 
selected descriptors and five-fold cross validation method. For comparison, prediction 
from SVM is also included in Table 4.2. The prediction accuracy from the other three 
methods is comparable to each other. For ER agonists, the accuracy of these methods is 
in the range of 66.3%~86.2% with SVM giving the best accuracy at 86.2%. For ER non-
agonists, the accuracy from these methods is in the range of 76.0%~91.1% with SVM 
giving the best accuracy at 91.1%.  
            A frequently used method for checking whether a prediction system is over-fitting 
would be to compare the prediction accuracy determined by using cross validation 
methods with those determined by using independent validation sets [Hawkins 2004]. 
Since descriptor selection was performed by using the cross validation method as the 
modeling testing sets, an over-fitted classification system is expected to have much 
higher prediction accuracy for the cross validation sets than that for the independent 
validation sets. As shown in Table 4.3, the prediction accuracies of the SVM systems 
based on the 5 fold cross validation method and those based on independent validation 
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sets are similar. This shows that the SVM classification systems in this work are unlikely 
to be over-fitted.  
Table 4.3 Comparison of the ER agonists and ER non-agonists prediction accuracies by 
using SVM with two different validation method, 5-fold cross validation and independent 
validation set. 
SVM with  
5-fold cross validation 
SVM with Independent Validation Set 
SE (%) SP (%) Q (%) TP FN SE 
(%) 
TN FP SP (%) Q (%) 
86.2 91.1 89.5 24 3 88.9 52 1 98.1 95.0 
The results are given in TP (true positive), FN (false negative), TN (true negative), FP 
(false positive), Q (overall accuracy), SE (sensitivity) which is the prediction accuracy for 
ER agonists and SP (specificity) which is the prediction accuracy for ER non-agonists. 
The number of ER agonists or ER non-agonists is TP+FN or TN+FP. 
 
It had been shown that chance correlation may occur during descriptor selection 
especially if the number of descriptors available for selection is large [Topliss et al. 1979; 
Jouan-Rimbaud et al. 1996]. Y-randomization has been frequently used to determine the 
probability of chance correlation during descriptor selection processes [Manly 1997; 
Leardia et al. 1998]. In y-randomization, a portion of ER agonists in the data set were 
randomly selected and converted to ER non-agonists. A portion of ER non-agonists 
compounds were also randomly selected and converted to ER agonists. The ratios of ER 
agonists to ER non-agonists were kept unchanged during y-randomization. The 
“scrambled” data set was then used for the descriptor selection process. The process of 
scrambling of the data set and descriptor selection process was repeated for 20 times. 
This y-randomization analysis was conducted on the SVM model that consistently gives 
the better classification accuracies in this and other studies [Burbidge et al. 2001; 
Czerminski et al. 2001; Meyer et al. 2003]. Unless over fitting is found in the SVM 
model, no further analysis on other models is to be conducted. The average Matthews 
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correlation coefficient of these scrambled SVM classification systems derived by using 
the 5-fold cross validation sets were found to be 0.331, which is significantly lower than 
that of the original SVM classification system, which turns out to be 0.767. This suggests 
that the original SVM classification system is relevant and unlikely to arise as a result of 
chance correlation. 
 
The performance of SVM classification system was further evaluated by two 
additional tests. One is the comparison of the ER binder and non-binder prediction 
accuracy of SVM with those of the tree-based model developed by Fang and coworkers 
[Fang et al. 2001] in a cited study in which all of the compounds have been provided 
[Fang et al. 2001]. The training set consists of 129 ER binders and 101 ER non-binders 
used by Fang et al [Fang et al. 2001] and the testing set includes 56 ER binders and 354 
ER non-binders used by Nishihara et al [Nishihara et al. 2000]. The ER binder accuracy 
of SVM is found to be 83.3% which is comparable to that of 87.1% derived from the 
tree-based model [Fang et al. 2001]. The ER non-binder and the overall prediction 
accuracy of SVM are detemrmined ad 94.7% and 93.1% respectively, which are 
significant higher than those of 81.8% and 82.5% derived from the tree based model 
[Fang et al. 2001].  
 
The second test was conducted by using newly identified ER agonists and non-
binders extracted from sources such as the most recent publications. They were carefully 
checked to ensure that they have not been included in our dataset. Table 4.4 contains 11 
ER agonists and 16 ER non-binders reported in the literatures after a comprehensive 
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Medline search. These compounds were used to test the two SVM systems that we 
developed, one developed by using our ER agonists/non-agonists dataset and the other by 
using the ER binder/non-binder dataset of Fang et al [Fang et al. 2001]. It has found that 
the accuracy of the first SVM system are 90.9% for ER agonists and 100% for ER non-
agonists, and those of the second SVM system are 72.7% for ER binders and 87.5% for 
ER non-binders. This evidence suggests that SVM trained from a structurally more 
diverse set of compounds could produce a significantly better prediction performance.  
Table 4.4 Recently published ER agonists (+) and ER non-binders (-) searched from 
literatures.  Some of the references are given by their PubMed IDs. DIH: drug 
information handbood [Lacy et al. 2004]. 
No. Compound Name CAS No. Class Ref 
1 prochloraz  67747-09-5    + 16219411 
2 propamocarb  24579-73-5    + 16219411 
3 PCB 74  32690-93-0    + 16203234 
4 2-Methoxyestradiol  362-07-2      + 15755993 
5 PPT  263717-53-9   + 15722404 
6 4-ethoxymethyl phenol  57726-26-8    + 12732288 
7 CHF 4056  437756-52-0   + 11861784 
8 NNC 45-0781  207277-66-5   + 11738615 
9 indole-3-carbinol  700-06-1      + 16192472 
10 dichlofenthion  97-17-6       + 15064155 
11 chlorpyrifos  2921-88-2     + 15064155 
12 PCB 138  35065-28-2   - 16203234 
13 PCB 153  35065-27-1   - 16203234 
14 PCB 170  35065-30-6   - 16203234 
15 PCB 180  35065-29-3   - 16203234 
16 PCB 187  52663-68-0   - 16203234 
17 PCB 194  35694-08-7   - 16203234 
18 PCB 199  52663-75-9   - 16203234 
19 PCB 203  52663-76-0   - 16203234 
20 citalopram  59729-33-8   - DIH 
21 mefloquine  53230-10-7   - DIH 
22 zonisamide  68291-97-4   - DIH 
23 escitalopram  128196-01-0  - DIH 
24  mirtazapine  85650-52-8   - DIH 
25  nitisinone  104206-65-7  - DIH 
26 enterolactone  78473-71-9   - 15276617 
27 enterodiol  80226-00-2   - 15276617 
 
CHAPTER 4 PHARMACODYNAMIC PREDICTION MODELS 119
Some environmental estrogen, such as kepone (chlordecone), has been found to 
remain estrogenic long after it is released into the environment and its molecular structure 
is very different from estradiol [Kupfer 1975; Guzelian 1982]. This makes it difficult to 
deduce estrogenic activity of these chemicals solely based on their molecular structures 
[Soto et al. 1994]. There are two such environmental estrogens in our independent 
validation set, kepone (chlordecone) and o, p’-DDT, which were correctly predicted by 
our SVM system (trained from our ER agonists/non-agonists dataset) as ER agonists, 
demonstrating its strength in identification of environmental estrogens, which are 
classically hard to characterize at least for kepone and o p’-DDT, and its ability to deduce 
the estrogenic activity of chemicals based on the selected molecular descriptors. 
Overall, our study suggests that SLMs, particularly SVM, are useful for 
facilitating the prediction of novel ER agonists from compounds with diverse structures. 
The prediction accuracy of these methods is at a comparable level as that determined 
from previous studies for ER binders in which a substantially less diverse set of 
compounds were used. Another advantage of the SLMs studied in this work is that they 
do not require knowledge about the molecular mechanism or structure-activity 
relationship of a particular drug property.  
4.3.2 Molecular descriptors associated with ER agonism 
 
A total of 31 molecular descriptors were selected by RFE to be associated with 
the properties of the ER agonists and non-agonists. These descriptors, given in Table 4.5, 
represent the structural and physicochemical properties associated with ER agonism, 
some of which are consistent with those used in earlier studies. For instance,  earlier 
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studies on the SAR for ER binders have indicated that aromatic ring structures or ring 
structures containing at least one hydrogen-bonding heteroatom are important features of 
estrogenic property [Fang et al. 2001]. The QSAR model of ER binders has been given as 
a linear function of molecular bulk, polarity, and hydrogen-bonding effects [Hu et al. 
2003].  Eight of the selected molecular descriptors are related to the features described in 
the literature. These include properties such as molecular globularity (Gloty) and 
hydrophobic region (Shpb) that describe the bulk, S(10) that describes electro-topological 
state of the sp2 atoms in an aromatic ring, 3χC and 4χvPC that describe simple and valence 
molecular connectivity for a cluster and path of atoms, electrophilicity index (Ω) and 
electronegativity index (χen) that describe quantum mechanical properties related to 
polarity, and hydrogen bond acceptor basicity (εb) that describes quantum chemical 
properties associated with hydrogen bonding. 
Table 4.5 Molecular descriptors selected from the RFE feature selection method for the 
classification of ER agonists and ER non-agonists. 
Descriptors Description Class 
Nhet Count of hetero atoms simple molecular 
property 
3χC Simple molecular connectivity Chi indices 
for cluster  
connectivity 
4χvPC Valence molecular connectivity Chi indices 
for path/cluster 
connectivity 




S(16) Atom-type Estate sum for -CH 3 electrotopological 
state 
Tcent Centric Index electrotopological 
state 
Tpeti PetitJohn I2 Index electrotopological 
state 
Tiwie Information Weiner electrotopological 
state 
εb Hydrogen bond acceptor basicity (covalent quantum chemical 
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HBAB) properties 
Μ Molecular dipole moment quantum chemical 
properties 
Η Absolute hardness quantum chemical 
properties 
IP Ionization potential quantum chemical 
properties 
µ cp Chemical potential quantum chemical 
properties 
χ en Electronegativity index quantum chemical 
properties 
Ω Electrophilicity index quantum chemical 
properties 
Q H, Max Most positive charge on H atom quantum chemical 
properties 
Q H, Min Most negative charge on H atom quantum chemical 
properties 
Q C, Min Most negative charge on C atom quantum chemical 
properties 




Mpc Mean of positive charges quantum chemical 
properties 
dis2 Length vectors (longest third atom) geometrical 
properties 
dis3 Length vectors (4th atom) geometrical 
properties 
Sapc Sum of solvent accessible surface areas of 
positively charged atoms 
geometrical 
properties 
Sanc Sum of solvent accessible surface areas of 
negatively charged atoms 
geometrical 
properties 
Sapcw Sum of charge weighted solvent accessible 
surface areas of positively charged atoms 
geometrical 
properties 
Svpc Sum of van der Waals surface areas of 
negatively charged atoms 
geometrical 
properties 
Rugty Molecular rugosity geometrical 
properties 
Gloty Molecular globularity geometrical 
properties 
Shpb Hydrophobic region geometrical 
properties 
Hiwpl Hydrophilic Integy Moment geometrical 
properties 
Hiwpa Amphiphilic Moment geometrical 
properties 
Table 4.5 Continued
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           Structural studies from X-ray crystallography appear to lend further support to our 
selected molecular descriptors. Table 4.6 gives the characteristics of several known 
structures of ligand-ER complexes. The major types of molecular interactions in these 
structures are hydrophobic, non-polar, aromatic, polar, and hydrogen bond, which are 
consistent with our selected molecular descriptors.  




ER Isoform Ligand Contacting 
Residues 
Mode of Interactions 
1ERE ERα 
[Brzozowski 
















Hydrogen bond to A-ring 
of E2 
 
Hydrogen bond between 
guanidinium group of 
Arg394 with E2 A-ring 
 
Hydrogen bond to D-ring 
of E2 
 
Hydrophobic contacts on 
planar A/B-ring interface 
 
Non-polar contacts on D-
ring of E2 
1ERR ERα 
[Brzozowski 
















Hydrogen bond to D-ring 
of RAL but the phenolic 
hydroxyl group of His524 
is displaced 5.1 Angstrom 
relative to agonist E2 
 
Hydrogen bond to A-ring 
of E2 
 
Hydrogen bond to the 
bulky side chain of E2 
 
Non-polar contact to D-
ring of E2 
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1QKM ERβ [Pike 














Htdrogen bonding to the 
phenolic hydroxyl (O14) 
of genistein 
 
Hydrogen bond to the O2 





Polar contacts with keto 
group of genistein 
1QKN ERβ [Pike 














Hydrogen bonding to the 
phenolic hydroxyl of 








Hydrogen bond to D-ring 
phenolic group of RAL 
2ERD ERα [Shiau 
et al. 1998] 










Hydrophobic contacts to 
the A-ring of DES 
 
Hydrogen bond to A-ring 
phenolic hydroxyl of DES 
 
Van der Waals contacts 
with A’-ring of DES 
 
Hydrogen bond to A’-ring 
of DES 
2ERT ERα [Shiau 









Van der Waals contacts 
with C ring of OHT 
 
 
Hydrogen bond to A ring 
of OHT 
1L2I ERα [Shiau 








Hydrogen bond with 
phenolic oxygen of A’-
ring 
 
Hydrogen bond with 
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phenolic oxygen of A-
ring 
 





ER antagonists bind to the same binding site as agonists but induce slightly 
different molecular conformations. For instance, the antagonist raloxifene (RAL) binds to 
the same site as an agonist estradiol (E2) in the ligand binding domain of ERα. However, 
the binding of RAL causes the imidazole ring of His524 rotates and displaces 5.1 
angstrom from the position occupied by E2 in order to form a favorable hydrogen-
bonding position [Brzozowski et al. 1997], as shown in Figure 4.1A and Figure 4.1B. 
This shows that atomic connectivity is important for ER agonism. Molecular descriptors 
associated with connectivity, such as our selected 3χC and 4χvPC, can be important for 
selecting ER agonists from ER binders. Hence, knowing certain molecular descriptors 
associated with ER binding may not always be sufficient for identifying ER agonists 
because both ER agonists and antagonists display similar binding modes to ER. Specific 
molecular descriptors such as connectivity and spatial charge distribution appear to be 
important for distinguishing agonists from antagonists. The use of these molecular 
descriptors in this study is likely to be one of the reasons for the good performance of 
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Figure 4.1A  and Figure 4.1B respectively show binding of agonist E2 and 
antagonist RAL to ERα from X-ray crystallography by Brzozowski and 
coworkers[Brzozowski et al. 1997]. Only 3 residues (Glu353, Arg394 and His524) in the 
ligand binding domain (LBD) are shown for clarity. From the figure, both E2 and RAL 
bind to LBD with similar types of interactions (hydrophobic, polar, hydrogen bonds), 
His524 is rotated 5.1 angstrom away from the position occupied by E2 in order to form a 
favorable hydrogen bond with RAL although both E2 and RAL form hydrogen bonds 
with Glu353 and Arg394 in similar molecular conformation. This shows that slight 
variation in rotamer orientation of residues in LBD can cause dramatic effect as agonist 
or antagonist activities. The variation of these activities cannot be determine from ER 
binding affinity since both ER agonists and ER antagonists exhibit similar interaction 
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types. Hence, SLMs together with feature selection method are used to characterize 
Estrogen Receptor associated molecular descriptors. 
 
X-ray crystallography studies have indicated that ER antagonists such as OHT, 
RAL, ICI possess bulky side chains that protrude out of the opening lips of the ligand 
binding site and thus preventing helix12 from adopting the agonist-bound conformation 
[Brzozowski et al. 1997; Shiau et al. 1998; Pike et al. 1999; Pike et al. 2001]. The 
protruded side chains cause helix12 adopt an alternative conformation that occludes the 
binding of transcriptional coactivators. Our selected molecular descriptors in this study 
such as Gloty for molecular globularity, Shpb for hydrophobic region, and S(10) 
corresponding to the electro-topological state of sp2 atoms in the aromatic ring correlate 
well with the bulky property of ER antagonists. Moreover, RAL and OHT are antagonists 
of ERα that contain basic amine side chains forming hydrogen bonds with Asp351 in the 
crystal structures. These basic side chains of the antagonists displace the AF2 helix from 
a conformation that favor the recruitment  of transcriptional coactivators to that 
unfavorable to such recruitment [Shiau et al. 1998]. Our selected molecular descriptor εb 
for hydrogen bond acceptor basicity is also consistent with the fact that some ER 
antagonists such as RAL and OHT (which belong to one class of ER non-agonists) 
contain basic amine side chains of ER antagonists.  
 
Note that our study is focused on the prediction of ER agonists and non-agonists 
without further classification of ER antagonists and ER non-binders [Li et al. 2006a]. 
Therefore, our prediction systems are not intended for identification of ER antagonists. 
CHAPTER 4 PHARMACODYNAMIC PREDICTION MODELS 127
Nonetheless, as ER antagonists form an important group of ER non-agonists in our 
dataset, some of the molecular characteristics specific to ER antagonism are likely to be 
included in our selected molecular descriptors. Shiau and coworkers have shown that, 
while it is an agonist of ERα, THC also acts as a “passive” ERβ antagonist due to the lack 
of a bulky side chain [Shiau et al. 2002]. Upon binding to ERβ, THC destabilizes helix 
12 of ERβ from recruiting transcriptional coactivators [Shiau et al. 2002]. Based on our 
definition of ER agonists, THC was included in the ER agonist group. Because of the 
lack of “passive” ER antagonists in our dataset, it is unlikely that “passive” antagonism is 
adequately covered in our selected molecular descriptors. Further studies for extending 
our models for predicting ER antagonism and for distinguishing between “active” and 
“passive” antagonism are needed for better understanding of different types of ER 
binding and for the design of ER antagonist-based drugs. 
 
To provide further insight into the correlation between our selected molecular 
descriptors and ER agonism, these molecular descriptors are classified into five major 
classes of interaction type, such as electrostatic interactions, hydrogen bonding, 
hydrophobicity, size and shape. The computed average values of the most relevant 
descriptor in each of the five classes over all ER agonists and those over all ER non-
agonists are given in Table 4.7. It is found that the molecular properties for ER agonists 
are generally larger in size, higher in molecular globularity, more hydrophilic, lower in 
the electrophilicity index, and exhibiting higher hydrogen bonding potential than non-
agonists. These properties are consistent with the observation that the ligand binding site 
of ER is generally “plastic” to various structurally distinct compounds with relatively 
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large molecular volume [Shiau et al. 1998], and to the finding that the basic side chains 
of antagonists displace the AF2 helix thereby disfavouring the recruitment of 
transcriptional coactivators [Shiau et al. 1998]. 
Table 4.7 Average values of the descriptors most relevant to distinguishing ER agonists 
from ER non-agonists. The averages are taken over all of the ER agonists and ER non-
agonists respectively. 
Average Value a Descriptor Descriptor Class 
ER agonists ER non-
agonists 
Ω (electrophilicity index) Electrostatic 48.16 (±0.64) 53.04 (±0.73) 
Nhet (count of hetero atoms) Hydrogen bonding 3.89 (±0.17) 3.77 (±0.14) 
Hiwpl (hydrophilic integy 
moment) 
Hydrophobicity 14.23 (±0.27) 12.29 (±0.29) 
dis2 (length vectors of the 
longest third atom) 
Size 15.44 (±0.25) 13.61 (±0.25) 
Gloty (molecular globularity) Shape 2.13 (±0.02) 1.98 (±0.02) 
a Values in parentheses are the standard error.  
 
4.3.3 Misclassified ER agonists and non-agonists from independent test sets 
 
 
            Figure 4.2 and Figure 4.3 show the four misclassified ER agonists and one 
misclassified ER non-agonist in our independent evaluation set and the set of recently 
discovered ER agonists/non-binders. The misclassified ER agonists are d-BHC (CAS No. 
319-86-8), ethyhexyl salicylate (CAS No. 118-60-5), α-endosulfan (CAS No. 959-98-8), 
and prochloraz (CAS No. 67747-09-5). The only misclassified ER non-agonist is 4-
hydroxybenzaldehyde (CAS No. 123-08-0). From Figure 4.2 and 4.3, the misclassified 
compounds are mainly polychlorinated pesticides with multiple chlorine atoms attached 
to same ring structure. This seems to suggest that our currently used molecular 
descriptors may not be sufficient to properly represent these types of structure, and 
further improvement and refinement of our molecular descriptors would be needed. 
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Figure 4.2 Structures of misclassified ER agonists in the independent validation set.          
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In Figure 4.2 and Figure 4.3 the chemical names, relevant chemical abstracts service 
(CAS) number of compound and structure type are shown in. Hetero atoms (oxygen) are 
marked. 
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SLMs are subjected to some degree of error due to such factors as dataset quality 
and the inherent limitation in predicting biological activities solely based on structure-
derived molecular descriptors. From the chemistry point of view, one can state that the 
molecular structure of a compound is the key in understanding its physicochemical 
properties and ultimately its biological activity and physiological effect [Johnson et al. 
1990]. However, biological activity of a compound is an induced response that is 
influenced by numerous factors dictated by the many levels of biological complexity. The 
relationship between structure and activity is thus more implicit and thereby requires a 
more thorough investigation and rigorous validation [Tong et al. 2004a]. Hence, the 




ER agonists are important in regulating a wide range of biological processes such 
as tissue development and oncogenesis. Some environmental compounds disrupt normal 
functions of endocrine system due to their ER agonism. Thus, identification of novel ER 
agonists from structurally diverse compounds is important for drug discovery and 
environmental safety evaluation. Works on QSAR for ER binders have identified some 
types of molecular interactions important for ER binding. However, knowledge of ER 
binding is insufficient for determining ER agonism, which is more relevant to drug 
discovery and safety evaluation. Hence, SLMs were explored as tools for predicting ER 
agonists and for characterizing molecular descriptors associated with ER agonism. This 
study shows that SLMs such as SVM, k-NN and PNN are useful for performing these 
tasks. Among the SLMs, SVM shows the highest classification accuracy. By 
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incorporating feature selection methods such as RFE into SLMs, molecular descriptors 
relevant to ER agonistic activities can be identified. Some of these selected molecular 
descriptors are consistent with those used in previous studies and with the findings from 
X-ray crystallography studies. Further studies on the improvement and refinement of 
feature selection methods as well as molecular descriptors would be needed in order to 
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A variety of compounds are toxic to humans. Harmful effects on the human body 
can be produced by some chemical byproducts released to the environment, pesticides, 
house-hold products and other chemical materials. ADRs are responsible for the failure 
of a substantial percentage of investigational drugs and the withdrawal of marketed 
drugs. Investigational drugs need to be screened to eliminate un-safe candidates in the 
early stage of drug discovery. A variety of toxicological tests and clinical safety 
evaluations need to be conducted and evaluated by the drug regulatory authorities for 
drug safety assessment. Because of the high cost of conducting toxicity tests and clinical 
trials, efforts have been directed at developing low-cost and efficient computational tools 
for predicting ADRs so as to eliminate unsafe drug candidates in the early stages of drug 
development. In this work, SLMs are used to construct the prediction systems for the 
toxicity properties of genotoxicants (section 5.1) and toxicants of Tetrahymena pyriformis 
(section 5.2) respectively. 
 
 





Genotoxicity is a form of ADRs that are evaluated in the drug discovery and 
approval processes. The molecular mechanisms of genotoxicity are numerous and they 
include DNA intercalation by aromatic ring of a drug, DNA methylation, DNA adduct 
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formation and strand break, and unscheduled DNA synthesis [Bolzan et al. 2002]. Some 
genotoxic compounds require metabolic activation and their genotoxic effects are 
mediated via N-dialkylation [Snyder et al. 2004]. These events subsequently result in 
chromosomal aberrations, micronuclei, sister chromatid exchanges, and cell death, which 
constitue to drug ADRs  [Bolzan et al. 2002].  
 
Tools for fast and efficient prediction of drug genotoxic potential, particularly 
those based on computational methods, are being developed [Kramer 1998; Schwetz et al. 
1998]. For instance, expert systems that use structural alert for predicting genotoxicity as 
well as other toxicological profiles are now commercially available. These include 
Deductive Estimation on Risk from Existing Knowledge (DEREK), Multiple Computer 
Automated Structure Evaluation (MCASE) and Toxicity Prediction by Komputer 
Assisted Technology (TOPKAT). Specific details about these computational databases 
can be found in the review by Greene [Greene 2002]. QSARs have been developed for 
predicting genotoxic potential of several groups of related chemicals [Marchant 1996; 
Cash 2001]. However the QSARs of a majority of chemical groups are yet to be 
determined which hinders the practical application of this method. 
 
SLMs have recently been explored as a new approach for genotoxicity prediction 
without the restriction on the features of structures or types of molecules  [He et al. 2003; 
Mattioni et al. 2003; Mosier et al. 2003]. Instead of focusing on specific structural feature 
or a particular group of related molecules, these methods classify molecules into 
genotoxic (GT+) and non-genotoxic (GT-) agents based on their general structural and 
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physicochemical properties regardless of their structural and chemical types. Therefore, 
in principle, these methods are expected to be applicable to a diverse set of molecules. 
However, the performance of these methods can be practically limited by the quality of 
molecular descriptors, diversity of training and testing data, and the efficiency of 
statistical learning algorithm. 
 
So far, three statistical learning methods, LDA, k-NN, and PNN, have been used 
and they have achieved prediction accuracy of up to 73.8% for GT+ and 92.8% for GT- 
agents respectively  [He et al. 2003; Mattioni et al. 2003; Mosier et al. 2003]. However, 
these methods have been developed and tested by using no more than 394 GT+ and GT- 
agents [Snyder et al. 2004], which is significantly smaller in number and diversity than 
the 860 known GT+ and GT- agents found from our recent literature search. Therefore, 
there is a need to examine if a similar level of accuracy can be achieved for the more 
diverse set of molecules. It is also of interest to determine if the GT+ accuracy can be 
further improved by a training set composed of a more diverse set of GT+ agents. 
Moreover, other SLMs such as SVM [Burges 1998; Cristianini et al. 2000] and C4.5 DT 
[Quinlan 1993] have shown promising potential, and it is useful to evaluate these 
methods.  
 
This work is intended to evaluate several SLMs by using 860 GT+ and GT- 
agents [Li et al. 2005a]. These methods include SVM, PNN, k-NN and C4.5 DT. In 
particular, SVM is studied because of its good performance in a number of classification 
problems [Furey et al. 2000; Bock et al. 2001; Trotter et al. 2001; Doniger et al. 2002]. 
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SVM has been applied to the prediction of chromosome aberrations [Serra et al. 2003], 
torsade-causing potential of drugs [Yap et al. 2004a], blood-brain barrier (BBB)-
penetrating agents [Trotter et al. 2001; Doniger et al. 2002], P-glycoprotein substrates 
[Xue et al. 2004c], SAR of enzyme inhibition [Burbidge et al. 2001], and QSARs of 
antihistamines and antibacterials [Czerminski et al. 2001].  Most of these studies have 
consistently demonstrated that SVM, to various degrees, gives better prediction accuracy 
than other supervised SLMs [Furey et al. 2000; Bock et al. 2001; Trotter et al. 2001; 
Doniger et al. 2002].  
 
A widely-used feature selection method, Recursive Feature Elimination (RFE), is 
used in this work for selecting the molecular descriptors relevant to the classification of 
GT+ and GT- agents. This method has recently gained popularity due to its effectiveness 
in discovering informative features or attributes in drug activity analysis [Guyon et al. 
2002; Yu et al. 2003], toxicological, pharmacokinetic and pharmacodynamic properties 
[Xue et al. 2004b; Xue et al. 2004c]. To adequately assess the prediction accuracy of the 
methods used in this work, two different evaluation methods are used. One is 5-fold cross 
validation which is a popular method for evaluating drug prediction systems [Furey et al. 
2000; Trotter et al. 2003], and the other is the use of an external independent validation 
set which has been found to be equally useful for assessing drug prediction systems [Xue 
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5.1.2 Methods 
 
5.1.2.1 Selection of GT+ and GT- agents 
 
 
 A total of 860 GT+ and GT- agents with known genotoxicity test results are 
selected from several sources including the 1999-2002 Physician’s Desk Reference, 
National Toxicology Program, and a number of publications [Snyder et al. 2001; He et al. 
2003; Mattioni et al. 2003; Mosier et al. 2003; Snyder et al. 2004].  Genotoxicity tests for 
generating these data include the pre-ICH four standard batteries (Ames test, in vitro 
cytogenetics, in vivo cytogenetics, mouse lymphoma assay) and the Salt-Overly-Sensitive 
(SOS) chromotest (which is a rapid alternative genotoxicity test based on the detection of 
the DNA damage through the SOS pathway) [Quillardet et al. 1993; Vasilieva 2002].  
 
5.1.2.2 Construction of training and testing sets 
 
 
Agents with genotoxicity test results are divided into GT+ and GT- groups 
according to whether or not these genotoxicity test results showed at least one positive 
finding. Under this definition, a total of 229 GT+ agents and 631 GT- agents are collected 
and used in this study. The 860 agents were randomly divided into five subsets of 
approximately equal size for conducting 5-fold cross validation test of the prediction 
accuracy of each of the statistical learning methods. To evaluate the models, 
representative training and validation sets were constructed from the datasets according 
to the Remove-until-done algorithm. The generated training, testing and independent 
evaluation set contains 577 (166 GT+, 411 GT-), 160 (36 GT+, 124 GT-) and 123 (27 
GT+, 96 GT-) compounds respectively.  
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5.1.2.3 Molecular descriptors  
 
 
This study used the same 199 molecular descriptors set as mentioned in Chapter 2 
(section 2.2). Redundant and irrelevant descriptors are further reduced by using the RFE 
method, which were described in Chapter 2 (section 2.3). 
 
5.1.2.3 Parameter for feature selection  
 
  The choice of the feature selection parameter m affects the performance of SVM 
as well as the speed of feature selection. Although it is desirable to remove one feature at 
a time (m = 1), this is often difficult due to high CPU cost. It has been found that, in some 
cases, removal of several features at a time (m > 1) significantly improves computational 
efficiency without losing too much accuracy [Xue et al. 2004b; Xue et al. 2004c]. Our 
studies on a subset of randomly selected GT+ and GT- agents in this work and 
compounds of different pharmacokinetic properties  suggested that the accuracy of a 
SVM system with m = 5 is only a few percentage lower than that with m = 1, which is 
consistent with the findings from other studies [Furlanello et al. 2003; Yu et al. 2003]. 
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5.1.3 Results and discussion 
 
5.1.3.1 Overall prediction accuracies 
 
 
SVM, PNN and k-NN are conducted by using our own software, and C4.5 DT 
was performed by using the code from Quinlan [Brown et al. 2000; Huang et al. 2002]. 
Prediction results of SVM without RFE and SVM with RFE (SVM+RFE) by using 5-fold 
cross validation are presented in Table 5.1. The accuracy of SVM+RFE is 75.5% for 
GT+ agents and 90.6% for GT- agents, which are slightly better than the values of 69.4% 
for GT+ agents and 88.2% for GT- agents derived from SVM without RFE. The GT+ 
prediction accuracy is noticeably improved, which indicates the usefulness of RFE in 
selecting the proper set of features for the prediction of GT+ and GT- agents. The use of 
these RFE-selected descriptors also slightly improves the prediction accuracy of the other 
three statistical methods. The GT+ accuracy is improved from 70.4% to 74.1% for PNN 
and from 44.4% to 55.6% for DT respectively, and that of k-NN remains roughly 
unchanged. The GT- accuracy of k-NN is improved from 82.2% to 86.5%, and those of 
PNN and DT are roughly unchanged. These results showed that feature selection by using 
RFE plays an important role in improving the prediction capability for the above methods 
in general. Similar prediction accuracy is also found from two additional 5-fold cross 
validation studies conducted by  using training-testing sets separately generated from 
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Table 5.1 Support vector machine (SVM) and support vector machine with recursive 
feature elimination (SVM+RFE) prediction accuracy of the genotoxic (GT+) and non-
genotoxic (GT-) agents by using 5-fold cross validation. 











1 32 17 65.3 109 11 90.8 83.4 0.59 
2 30 10 75.0 115 14 89.1 85.8 0.62 
3 32 13 71.1 119 21 85.0 81.6 0.53 
4 32 19 62.7 106 11 90.6 82.1 0.56 
5 32 12 72.7 107 18 85.6 82.2 0.56 
average   69.4   88.2 83.0 0.57 
SD   4.6   2.5 1.5 0.03 
 
SVM 
SE   1.9   1.0 0.6 0.01 
1 35 14 71.4 111 9 92.5 86.4 0.66 
2 32 8 80.0 118 11 91.5 88.8 0.69 
3 35 10 77.8 123 17 87.9 85.4 0.62 
4 35 16 68.6 109 8 93.2 85.7 0.65 
5 35 9 79.5 110 15 88.0 85.8 0.65 
average   75.5   90.6 86.4 0.66 




SE   1.9   0.9 0.5 0.01 
Predicted results are given in TP (true positive), FN (false negative), TN (true negative), 
FP (false positive), SE (sensitivity) which is the prediction accuracy for GT+, SP 
(specificity) which is the prediction accuracy for GT-, Q (overall prediction accuracy ), 
and C (Matthews correlation coefficient ). Statistical significance is indicated by SD 
(standard deviation), and SE (standard error) respectively. 
 
Table 5.2 gives the GT+ and GT- prediction accuracy derived from the four 
methods SVM, PNN, k-NN and DT by using the independent validation set and the RFE-
selected molecular descriptors. The GT+ accuracy is found to span over the range of 
55.6%-77.8% and the GT- accuracy is in the range of 75.0%-92.7%. Similar levels of 
accuracy is obtained for SVM, PNN and k-NN, with SVM giving the highest value of 
77.8% and 92.7% for GT+ and GT- agents respectively. DT appears to give substantially 
lower accuracy, which is in concordante with other reported experimental results [Weston 
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et al. 2001; Saeys et al. 2004]. A possible reason for this lower accuracy could be that DT 
uses information gain to determine the optimum set of descriptors, which might not be 
the most effective approach for every problem. It has been pointed out that filter methods, 
such as information gain, may not be as efficient as wrapper methods, such as RFE, for 
determining the subset of descriptors relevant to a particular problem  [He et al. 2003]. 
Table 5.2 Comparison of the prediction accuracy of genotoxic (GT+) and non-genotoxic 
(GT-) agents derived from different machine learning methods by using the independent 
validation set in this work. 





SP   (%) 
Q  
(%) 
C4.5 DT  15 12 72 24 55.6 75.0 70.7 
PNN σ=0.2 20 7 77 19 74.1 80.2 78.9 
k-NN k=3 19 8 83 13 70.4 86.5 82.9 
SVM σ=3 21 6 89 7 77.8 92.7 89.4 
C4.5 DT (C4.5 decision tree), PNN (probabilistic neural network), k-NN (k-nearest 
neighbors), SVM (support vector machine), parameters σ is the width of Gaussian kernel 
function. Predicted results are given in TP (true positive), FN (false negative), TN (true 
negative), FP (false positive), SE (sensitivity) which is the prediction accuracy for GT+, 
SP (specificity) which is the prediction accuracy for GT-, Q (overall prediction accuracy ).  
 
5.1.3.2 Relevance of selected features to genotoxicty study 
 
 
Apart from the quality of datasets used, selection of descriptors relevant to 
genotoxicity study is important for optimizing the prediction system by reducing, noise in 
a statistical learning process. A total of 39 molecular descriptors are selected by the RFE 
method, as shown in Table 5.3. Most of these are found to be relevant to the assessment 
of genotoxicity. For instance, an important characteristics of some GT+ agents is their 
ability to intercalate DNA [He et al. 2003]. The selected electro-topological state 
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descriptors S(10) and S(14) describe atom-type H estate sum for :CH: sp2 aromatic 
structures and atom-type H estate sum for CHn aromatic structures respectively.  
Table 5.3 Molecular descriptors selected from the recursive feature elimination (RFE) 
method for support vector machine (SVM) classification of genotoxic (GT+) and non-
genotoxic (GT-) agents. 
Descriptors Description Class 
Nrot Number of rotatable bonds Simple molecular 
properties 
ndonr Number of H-bond donors Simple molecular 
properties 
















S(2) Atom-type H Estate sum for =NH Electro-topological 
state 
S(4) Atom-type H Estate sum for -NH 2 Electro-topological 
state 
S(10) Atom-type H Estate sum for :CH: (sp2, aromatic) Electro-topological 
state 
S(13) Atom-type H Estate sum for CH n (unsaturated) Electro-topological 
state 
S(14) Atom-type H Estate sum for CH n (aromatic) Electro-topological 
state 
S(16) Atom-type Estate sum for -CH 3 Electro-topological 
state 
S(25) Atom-type Estate sum for =C< Electro-topological 
state 
S(26) Atom-type Estate sum for : C:- Electro-topological 
state 
S(27) Atom-type Estate sum for : C :: Electro-topological 
state 
S(30) Atom-type Estate sum for =NH Electro-topological 
state 
S(34) Atom-type Estate sum for =N- Electro-topological 
state 
S(35) Atom-type Estate sum for :N: Electro-topological 
state 
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S(41) Atom-type Estate sum for -O- Electro-topological 
state 





Tpeti PetitJohn I2 Index Electro-topological 
state 
Μ Molecular dipole moment Quantum chemical 
properties 
µ cp Chemical potential Quantum chemical 
properties 
χ en Electronegativity index Quantum chemical 
properties 
ω Electrophilicity index Quantum chemical 
properties 
Q H, Max, 
Q N, Max, 
Q O, Max 
Most positive charge on H, N, O atoms Quantum chemical 
properties 
Q H, Min, Most negative charge on H atoms Quantum chemical 
properties 
Rpc Relative positive charge Quantum chemical 
properties 
Rnc Relative negative charge Quantum chemical 
properties 
Rugty Molecular rugosity Geometrical 
properties 
Gloty Molecular globularity Geometrical 
properties 
Shpl Hydrophilic region Geometrical 
properties 
Shpb Hydrophobic region Geometrical 
properties 
Capty Capacity factor Geometrical 
properties 
Hiwpl Hydrophilic Integy Moment Geometrical 
properties 
Hiwpb Hydrophobic Integy Moment Geometrical 
properties 
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Many GT+ agents are known to structurally modify or form covalent bond with 
DNA via chemical reactions. A substantial portion of the RFE selected descriptors are 
from the class of electro-topological state that describe characteristics of specific types of 
functional groups involved in DNA modification. There are also a substantial number of 
descriptors from the quantum chemical class that determine molecular dipole moment, 
chemical potential, electronegativity, electrophilicity, relative positive and negative 
charge, and the atomic charge on H, N and O atoms in a molecule. These properties are 
important for describing features of chemical reactions involved in the modification of 
DNA. 
The size, shape, and polar property of a molecule have also been found to play a 
role in genetic damages caused by GT+ agents [Cruciani et al. 2000].  Eight of the 
selected descriptors are VolSurf descriptors [Crivori et al. 2000; Cruciani et al. 2000]. 
These are molecular rugosity, molecular globularity, capacity factor, hydrophilic and 
hydrophobic region, hydrophilic integy moment, hydrophobic moment and amphiphilic 
moment. These descriptors primarily describe the size, shape, and polar property of a 
molecule. In general VolSurf descriptors, which are 1D descriptors extracted from the 
computed 3D molecular field maps, were developed specifically for pharmacokinetics 
and pharmacodynamics applications [Chung et al. 1997].  It is thus not surprising that the 
VolSurf descriptors related to the molecular size, shape, and polar property are selected.  
Molecular connectivity is another feature known to be important for 
discriminating between some GT+ compounds from their GT- analogs. For instance, 4-
amino-3-nitro-2,5-dimethylaniline is a GT+ agent, while its analog 4-amino-3-nitro-2,6-
dimethylaniline is GT- [Mattioni et al. 2003; Mosier et al. 2003] . Four molecular 
CHAPTER 5 TOXICITY PREDICTION MODELS 144
connectivity descriptors, 3χC, 4χPC, 3χvC, and 4χvPC, are selected by RFE in this work. These 
descriptors are simple molecular connectivity chi indices for cluster, simple molecular 
connectivity chi indices for path/cluster, valence molecular connectivity chi indices for 
cluster, and valence molecular connectivity Chi indices for path/cluster respectively.  
 
5.1.3.3 Performance evaluation 
 
 
To assess the performance of the statistical learning methods for genotoxicity 
prediction of the more diverse set of molecules, it would be useful to examine whether 
the accuracy from these methods is at a similar level as those derived by the use of a 
significantly smaller set of molecules. Note that, a direct comparison with results from 
previous studies would be inappropriate because of the differences in the dataset and 
molecular descriptors used. Although desirable, it is impossible to conduct a separate 
comparison using results directly from other studies without detailed information about 
the algorithms of molecular descriptors and classification methods used in each study. 
Nonetheless, a tentative comparison may provide some crude estimate regarding the 
approximate level of accuracy of the genotoxicity prediction systems derived in this work.  
 
Table 5.4 gives the prediction results of the four statistical methods from this 
work along with those derived from previous studies. The GT+ accuracy of these four 
methods are  found to be comparable and in some cases slightly better than those of 
earlier studies derived from k-NN  and the consensus model developed with k-NN, LDA, 
and PNN [He et al. 2003]. The GT- accuracy of these four methods is also comparable to 
those of earlier studies [Snyder et al. 2001; He et al. 2003; Mattioni et al. 2003; Mosier et 
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al. 2003; Snyder et al. 2004]. . The results from all of these statistical learning methods 
are significantly better than those obtained by DEREK, TOPKAT, MCASE programs 
[Snyder et al. 2004]. This is likely due to the capability of statistical learning methods for 
classification of a more diverse range of molecules than that of structural-alert based 
approaches. 
Table 5.4 Overview of the prediction accuracies of genotoxic (GT+) and non-genotoxic 
(GT-) agents from this work as with those from other studies. Prediction accuracies of 
this work listed here are based on independent evaluation sets, which are similar to those 
based on 5-fold cross validation.  
Study 
(Reference) 














[Philip D. Mosier 
















Philip D. Mosier 
[Linnan He et al. 
2003] 
k-NN 140 66.7 92.9 85.0 
Linnan He 










73.8 84.3 81.2 
Brian E. Mattioni 
[Snyder RD et 
al. 2004] 
k-NN 334 69.3 74.1 72.2 




















Since different groups used different sets of descriptors, the accuracies given in this table 
only reflect the relative efficiency of each method. * Best performance characteristics of 
the three programs were selected. 
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Overall, the current study suggests that statistical learning methods, particularly 
SVM, k-NN and PNN, are shown to be useful for genotoxicity assessment of a broad 
range of molecule [Li et al. 2005a]. The prediction accuracy of these methods is found to 
be similar to those results of earlier studies which were analysed by using a much smaller 
number of molecules. Another advantage of the methods utilized in this study is that they 
do not require knowledge about the molecular mechanism or structure-activity 
relationship of a particular drug property. Moreover, the classification speed of these 
methods is generally fast. For instance, the number of compounds classified per second 
on a P4 3.6Ghz machine using the SVM, k-NN, PNN and DT method is approximately 
4000, 3000, 2000 and 62000 respectively. SVM would typically use a portion of the 
training set as support vectors for classification. In contrast, k-NN and PNN would use 
the whole training set for classification. The number of support vectors of SVM is in the 
range of 45-75% of the training set. Thus the classification speed of SVM is usually 25-
55% faster than that of k-NN and PNN. On the other hand, the classification speed of 
SVM is slower than that of the decision tree methods which use a set of rules to reach a 
decision leaf. 
 
5.1.3.4 Misclassified GT+ and GT- agents from independent test sets 
 
The results revealed six GT+ and seven GT- agents in the independent evaluation 
set that were misclassified by SVM. As depicted in Figure 5.1 and Figure 5.2 
respectively. The six misclassified GT+ compounds are mebendazole, clomiphene, 
lansoprazole, clarithromycin, imipramine and ampicillin. From the study of Snyder and 
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coworkers [Snyder et al. 2004], ampicillin, imipramine and lansoprazole were also 
misclassified by MCASE, DEREK and TOPKAT. Clomiphene was misclassified by 
MCASE and TOPKAT, but was classified correctly by DEREK which alerts the 
halogenated alkene structure [Snyder et al. 2004]. Mebendazole was misclassified by 
DEREK but predicted to exhibit equivocal genotoxicity by TOPKAT and MCASE as 
genotoxic with 57% probability [Snyder et al. 2001]. To the best of our knowledge, there 
is no computational study on clarithromycin, which has been found to be genotoxic in in 
vitro cytogenetics tests [Greene 2002] but non-genotoxic in other assays such as bacterial 
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Figure 5.1 Six structures of misclassified genotoxic (GT+) agents in the independent 
validation set. Chemical name and relevant chemical abstracts service (CAS) number of 
these compounds are shown in the figure. Hetero atoms (oxygen, nitrogen, fluorine, 
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Figure 5.2 Seven structures of misclassified non-genotoxic (GT-) agents in the 
independent validation set. Chemical name and relevant chemical abstracts service (CAS) 
number of these compounds are shown in the figure. Hetero atoms (oxygen, nitrogen, 
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   DEREK is a knowledge-based expert system of qualitative estimation model 
[Greene 2002]. MCASE performs a quantitative prediction by cleaving each test 
molecule into 2-10 atom fragments and consideration of their physicochemical properties 
[Greene 2002]. TOPKAT uses electrotopological states as well as shape, symmetry, 
molecular weight and ClogP as descriptors in a QSAR model for prediction [Snyder et al. 
2004]. Although each of these methods is able to correctly predict one of the 6 GT+ 
compounds misclassified by our method, there are also GT+ compounds, such as 
naloxone and pentobarbital [Snyder et al. 2004], correctly predicted by our method but 
misclassified by each of these methods. While all of the methods misclassified some of 
the GT+ compounds due to the general inadequacy for fully representing all of the 
properties of these molecules, each method appears to be more useful to specific types of 
compounds than other methods. For instance, clomiphene is correctly predicted by 
DEREK because of the use of knowledge-based alert for halogenated alkene structure, 
while it is misclassified by our method because of the lack of a descriptor to properly 
represent halogen atoms. Thus the use of multiple methods may be useful to cover a more 
diverse set of compounds. 
 
The seven misclassified GT- compounds are dansyltryptamine, ketotifin, 2-
chloro-4-(4-methoxyphenyl)-3-phenylquinoline, ceftibuten, 5-chloro-1,3-dihydro-1,3,3 
trimethylspiro, candesartan, and indinavir. Both candesartan and indinavir were classified 
correctly by MCASE, DEREK and TOPKAT [Snyder et al. 2004]. Ketotifin was 
correctly classified by MCASE and DEREK, but misclassified by TOPKAT [Snyder et al. 
2004]. Ceftibuten was correctly classified by MCASE and TOPKAT, but misclassified 
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by DEREK [Ashby 1985]. The first two compounds contain aromatic amines, the third 
contains an α,β-unsaturated ketone group, the fourth is composed of an α,β-unsaturated 
amide group, These chemical groups can be easily distinguished from the structural alerts 
of genotoxicity [He et al. 2003] used in MCASE, DEREK and TOPKAT, but they are not 
properly described by the commonly used molecular descriptors. This could perhaps be 
the reason for the observed failure of our method to correctly classify these four 
compounds. Dansyltryptamine, 2-chloro-4-(4-methoxyphenyl)-3-phenylquinoline and 5-
chloro-1,3-dihydro-1,3,3 trimethylspiro were correctly predicted by using LDA, k-NN, 
PNN and their consensus model in an earlier study [He et al. 2003]. These are polycyclic 
aromatic compounds that contain either chlorine atom or aromatic amine and N-dimethyl 
group. One possible reason for the correct prediction of these compounds in that study 
[He et al. 2003] is that it focused on polycyclic aromatic compounds only and thus was 
easier to select all of the relevant features without the concern of introducing noises for 
other types of chemical groups. In contrast, our study includes a diverse set of 
compounds, and our feature selection method could only pick up those descriptors that 
are both relevant to the polycyclic aromatic compounds and without significant noise to 
other types of compounds. It is also noted that there are polycyclic aromatic compounds, 
such as 9-aminophenanthrene and ethyl 5-hydroxy-2-methylindole-3-carb-oxylate that 
were correctly predicted by our method and misclassified in the earlier study [Basak et al. 
1999; Luco 1999; Serra et al. 2003; Wegner et al. 2004]. This seems to suggest that the 
currently available descriptors might not be fully representative of the polycyclic 
aromatic compounds.  
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In general, the main reason for the SVM misclassification of these GT+ and GT- 
compounds is that none of the currently-used descriptors adequately represents the 
compounds containing multi-rings with various hetero atoms such as nitrogen, oxygen, 
sulphur, fluorine and chlorine. Currently-used topological descriptors are capable of 
representing molecular shape, connectivity, and some level of molecular flexibility 
[Furlanello et al. 2003]. However, due to the limited coverage of the number of bond 
linkage in a hetero-atom loop, these descriptors are not yet capable of describing the 
special features of a complex multi-ring structure that contains multiple hetero atoms. 
Another reason for the misclassification of some of these compounds cold be due to the 
fact that none of the currently-used descriptors could be used to fully represent molecules 
containing a long flexible chain. Therefore, there is a need to explore different 
combination of descriptors and to select more optimum set of descriptors by using more 
refined feature selection algorithms and parameters. However, indiscriminate use of 
many existing topological descriptors, which are overlapping and redundant to each other, 
may introduce noise as well as extending the coverage of some the aspects of these 
special features. Thus, it may be necessary to introduce more appropriate descriptors for 
representing these and other special features. 
 
5.1.4 Conclusion                
 
Our study demonstrates that SLMs, particularly SVM, k-NN and PNN, are useful 
for facilitating the prediction of genotoxic potential of a diverse set of molecules without 
requiring the intrinsic mechanism knowledge of the compounds [Li et al. 2005a]. 
Prediction accuracy of these methods may be further improved by introducing molecular 
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descriptors that can better represent complex ring structures and flexible long chains, and 
by selection of descriptors most relevant to genotoxicity prediction by means of more 
refined feature selection methods and parameters. Current efforts are directed at the 
improvement of the efficiency and speed of feature selection methods [Furlanello et al. 
2003], which could further help to optimally select molecular descriptors and enable the 
development of more accurate and efficient computational tools for genotoxicity 
prediction. Moreover, recent works on the introduction of weighting function into SVM 
descriptors [Chapelle et al. 2002] might also be helpful in developing SVM into a 
practical tool for the prediction of toxicological properties of chemical agents.  
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A variety of compounds are toxic to humans. Investigational drugs need to be 
screened to eliminate un-safe candidates, and adverse drug reactions have led to 
withdrawal of some marketed drugs [Johnson et al. 2000; van de Waterbeemd et al. 
2003]. Harmful effects can be produced by some chemical byproducts released to the 
environment [Safe 1990], pesticides [McDuffie 2005], house-hold products [Kaufman et 
al. 2005] and other chemical materials [Needham et al. 2005]. Toxicological tests and 
safety evaluations are needed and have been used for assessing the toxic potential of 
compounds and investigational drugs, many of which have been tested with Tetrahymena 
pyriformis [Sauvant et al. 1995; Wu et al. 1997; Sauvant et al. 1999; Darcy et al. 2002; 
Bonnet et al. 2003]. Computational methods have been developed as potential tools for 
facilitating fast and efficient prediction of Tetrahymena pyriformis toxicity (TPT) 
[Schultz 1999; Niculescu et al. 2000; Serra et al. 2001; Ren 2003b; Schuurmann et al. 
2003; Devillers 2004; Gini et al. 2004; Aptula et al. 2005; Roy et al. 2005; Spycher et al. 
2005].  
 
Structure-toxicity relationship (STR) [Schultz 1999; Cottrell et al. 2003; Netzeva 
et al. 2003a; Gonzalez et al. 2004; Schultz et al. 2005] and QSARs [Cronin et al. 2001; 
Cronin et al. 2002; Devillers 2004; Aptula et al. 2005; Netzeva et al. 2005; Roy et al. 
2005] models have been developed for predicting TPT of several groups of structurally-
related compounds including benzenes, phenols, aromatic compounds, aliphatic 
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compounds, and cyanoacetic acids. However, STR or QSAR models for majority of 
chemical classes are yet to be developed. In an effort to access computational methods 
applicable to diverse sets of compounds, SLMs were explored for developing TPT 
prediction systems for both individual chemical groups [Serra et al. 2001; Netzeva et al. 
2003b; Ren 2003b; Schuurmann et al. 2003; Melagraki et al. 2005; Spycher et al. 2005] 
and multiple chemical groups [Niculescu et al. 2000; Gini et al. 2004]. These methods 
achieve impressive predictive performance, but their practical application potential may 
not be fully realized because of the limited diversity of training data, quality of molecular 
descriptors, and the efficiency of statistical learning algorithm. 
 
So far, three classes of SLMs have been employed for predicting TPT agents. 
These include LDA [Schuurmann et al. 2003], various regression methods [Serra et al. 
2001; Netzeva et al. 2003b; Ren 2003b; Schuurmann et al. 2003; Spycher et al. 2005], 
and neural networks [Niculescu et al. 2000; Serra et al. 2001; Gini et al. 2004; Melagraki 
et al. 2005; Spycher et al. 2005]. Because of the diversity of compounds and mechanisms 
of toxic actions, it is desirable to explore additional SLM such as SVM, k-NN and C4.5 
DT that have shown promising potential in predicting toxicological and pharmacological 
properties of diverse groups of compounds [Xue et al. 2004b; Xue et al. 2004c; Li et al. 
2005a; Li et al. 2005b; Yap et al. 2005; Li et al. 2006b]. Instead of focusing on specific 
structural features or a particular group of related molecules, SLMs generally classify 
diverse sets of compounds into TPT and non-TPT agents based on their general structural 
and physicochemical properties irrespective of their structural and chemical affiliation. 
The published studies are based on 200~270 [Ren 2003b; Schuurmann et al. 2003; 
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Melagraki et al. 2005; Spycher et al. 2005], 450~480 [Serra et al. 2001; Netzeva et al. 
2003b], and 730~830 [Niculescu et al. 2000; Gini et al. 2004] TPT and non-TPT agents 
respectively. The agents used in these studies are substantially smaller in number and 
diversity than the 1,129 known TPT and non-TPT agents found from our comprehensive 
search of the literature. Therefore, the performance of both the already-explored and yet-
to-be-explored SLMs needs to be tested by using the more diverse set of compounds.  
 
In this study, several SLMs were tested using all of the 1129 known TPT and non-
TPT agents that were collected. The methods were LR, C4.5 DT, k-NN, PNN and SVM. 
In particular, SVM was explored because of its good performance in the prediction of 
genotoxicity [Li et al. 2005a], chromosome aberrations [Serra et al. 2003], torsade-
causing potential of drugs [Yap et al. 2004a], blood-brain barrier-penetrating agents 
[Trotter et al. 2001], P-glycoprotein substrates [Xue et al. 2004c], structure-activity 
relationship of enzyme inhibition [Burbidge et al. 2001], and QSAR of antihistamines 
and antibacterials [Czerminski et al. 2001].  Most of these studies have consistently 
demonstrated that SVM, to various degrees, gives better prediction accuracy than other 
supervised statistical learning methods.  
 
A feature selection method, recursive feature elimination (RFE), was used in this 
work for improving the prediction performance of SLMs and for selecting the molecular 
descriptors relevant to the classification of TPT and non-TPT agents. RFE has recently 
gained popularity due to its effectiveness for discovering informative molecular 
descriptors responsible for distinguishing activities [Guyon et al. 2002], toxicological [Li 
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et al. 2005a], and pharmacological properties [Xue et al. 2004b] of various compounds. 
To adequately assess the prediction accuracy of the methods used in this work, 5-fold 
cross validation method which is a popular method for evaluating drug prediction 




5.2.2.1 Selection of TPT and non-TPT- agents 
 
A total number of 1129 TPT and non-TPT agents with known IGC50 (mol/L) 
values (the 50% growth inhibition concentration in 2-day Tetrahymena pyriformis assay)  
are selected from a number of publications [Schultz 1999; Cronin et al. 2001; Serra et al. 
2001; Cronin et al. 2002; Cottrell et al. 2003; Netzeva et al. 2003a; Ren 2003b; 
Schuurmann et al. 2003; Devillers 2004; Gini et al. 2004; Gonzalez et al. 2004; Aptula et 
al. 2005; Netzeva et al. 2005; Roy et al. 2005; Schultz et al. 2005]. The 2D structure of 
each compound was constructed by using ChemDraw [CambridgeSoft Corporation 2002] 
and DS ViewerPro 5.0 [Accelrys 2005], and was subsequently converted into 3D 
structure by using CONCORD [Pearlman] followed by geometrical optimization using 
the clean structure module of DS Viewer Pro. All the structures were fully optimized 
without symmetry restrictions. The 3D structure of each compound was manually 
inspected to ensure that the chirality of each chiral agent is properly assigned. 
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Schultz [Schultz 1997] proposed a short-term, static protocol to calculate the 
chemical toxicity values from a population growth impairment test using the common 
freshwater ciliate Tetrahymena pyriformis (strain GL-C). The 50% impairment growth 
concentration (IGC50) is the recorded endpoint. The acute toxicity toward Tetrahymena 
pyriformis is defined as log(1/ IGC50) (mm/L), where the logarithm is taken to convert 
the data set to a computationally efficient range (-1.64 to 3.36 log units)[Serra et al. 
2001]. Toxicity level generally increases with increasing value of log (1/IGC50). 
Compounds with positive values are generally considered to be toxic or weakly toxic. 
However, because of the differences of experimental conditions and other factors, some 
levels of variations are expected for the measured log (1/IGC50) values. Careful study of 
the available TPT and non-TPT agents is needed to derive a statistically more meaningful 
cut-off value. After careful analysis of the toxic characteristics of the TPT and non-TPT 
compounds in our dataset, a more conservative cut-off value of log (1/ IGC50) = -0.5 was 
chosen for separating TPT and non-TPT agents. Some toxic compounds such as phenol 
were found to have a log (1/IGC50) value as low as -0.21, hence the log (1/IGC50) cut-off 
value needs to be lower than -0.21. On the other hand, some safe compounds such as 
salicylic acid, which is used as a food preservative and in toothpaste, has a log (1/IGC50) 
value as high as -0.51.  Therefore the log (1/IGC50) cut-off value was tentatively set at the 
lowest possible value of -0.5 that optimally excludes the known toxic agents in the non-
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5.2.2.2 Construction of training and testing sets 
 
Under this definition, a total of 841 TPT and 288 non-TPT agents are collected 
and used in this study. To evaluate the models, representative training and validation sets 
were constructed from the datasets according to the Kennard and Stone algorithm. This 
provide a training set of 560 TPT and 192 non-TPT agents, and a validation set of 281 
TPT and 96 non-TPT agents respectively. These compounds were further separated into 
training and testing sets by 5-fold cross-validation which was widely used for model 
validation. For 5-fold cross-validation, these compounds are randomly divided into five 
subsets of approximately equal size. Four subsets are selected as the training set and the 
fifth as the testing set. This process is repeated five times so that every subset is selected 
as a testing set once.  
 
5.2.2.3 Molecular descriptors  
 
 
This study used the same 199 molecular descriptors set as mentioned in Chapter 2 
(section 2.2). Redundant and irrelevant descriptors are further reduced by using the RFE 
method, which has been described in Chapter 2 (section 2.3). 
 
5.2.3 Results and Discussions 
 
5.2.3.1 Overall prediction accuracy 
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SVM, PNN, k-NN and LR computations were conducted by using our own 
software. C4.5 DT computation was performed by using the code from Quinlan [Quinlan 
1993].  Table 5.5 gives the TPT and non-TPT prediction accuracies of each of these 
methods by using the full set of molecular descriptors and the RFE-selected descriptors. 
The prediction accuracy was estimated based on 5-fold cross-validation studies. The TPT 
accuracy was determined to be in the range of 73.7%-94.4% when the full set of 
descriptors was used, and in the range of 86.9%~94.2% when the set of RFE-selected 
descriptors was used. The non-TPT accuracy is in the range of 59.5%~82.0% when the 
full set of descriptors was used, and in the range of 71.2%~87.5% when the set of RFE-
selected descriptors was used. The use of RFE-selected descriptors significantly 
improved the performance of LR, PNN and SVM from the non-TPT accuracy level of 
59.5%~82.0% to that of 71.2%~87.5%. The use of RFE-selected descriptors significantly 
improved the performance of LR from an overall accuracy level of 70.1% to that of 
87.1%. The overall accuracy of the other methods is already at a high level of 
85.8%~88.9% when the full set of descriptors was used, and the use of RFE-selected 
descriptors only slightly improved the overall accuracy of SVM. These results showed 
that feature selection by using RFE is useful in improving the SLMs’ prediction 
capability for TPT agents, especially for improving the prediction accuracy of non-TPT 
agents. Due to the random splitting of the agents, the estimates might vary with different 
random number seed parameters; therefore, the whole 5-fold cross-validation procedure 
was repeated five more times. Similar prediction accuracies are also found from the five 
additional 5-fold cross-validation studies conducted by  using training-testing sets 
separately generated from different random number seed parameters. 
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Table 5.5 Comparison of the prediction accuracy of Tetrahymena pyriformis toxic (TPT) 
and non-toxic (non-TPT) agents by different statistical learning methods. The accuracy of 
each method was estimated from a 5-fold cross validation by using 841 TTP and 288 







Accuracy Q (%) 
Matthews 
correlation 






















LR 73.7 92.5 59.5 71.2 70.1 87.1 0.346 0.654 
C4.5 
DT 
91.2 89.5 70.1 72.9 85.8 85.3 0.623 0.618 
k-NN 93.2 94.2 76.4 71.5 88.9 88.4 0.706 0.690 
PNN 89.2 86.9 82.0 87.5 87.3 87.1 0.684 0.696 
SVM 94.4 93.5 72.9 82.0 88.9 90.4 0.701 0.751 
The methods used are logistic regression (LR), C4.5 decision tree (C4.5 DT), k nearest 
neighbor (k-NN), probabilistic neural network (PNN), and support vector machines 
(SVM).  Two sets of molecular descriptors were used, one is a full set of molecular 
descriptors and the other is a subset of 49 molecular descriptors selected by using the 
recursive feature elimination (RFE) method, Des: descriptors. 
 
Based on the computed overall accuracy and Matthews correlation coefficients, 
the performance of SVM appears to be slightly better than the other methods. Detailed 
prediction results of SVM without RFE and SVM with RFE (SVM+RFE) by using 5-fold 
cross validation are presented in Table 5.6. The accuracy of SVM+RFE are 93.5% for 
TPT agents and 82.0% for non-TPT agents, the former is slightly lower and the latter is 
substantially better than the values of 94.4% for TPT agents and 72.9% for non-TPT 
agents derived from SVM without RFE. The overall prediction accuracy is slightly 
improved, which indicates the usefulness of RFE in selecting the proper set of features 
for the prediction of TPT and especially for non-TPT agents.  
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Table 5.6  Performance of support vector machines (SVM) and support vector machines 
with recursive feature elimination (SVM+RFE) for predicting Tetrahymena pyriformis 
toxic (TPT) and non-toxic (non-TPT) agents as evaluated by 5-fold cross validation. 





 TP FN SE 
(%) 
TN FP SP 
(%) 
 




1 155 12 92.8 41 14 74.6 88.3 0.682 
2 168 10 94.4 44 18 71.0 88.3 0.685 
3 156 6 96.3 40 20 66.7 88.3 0.690 
4 162 5 97.0 36 10 78. 93.0 0.786 
5 153 14 91.6 48 17 73.9 86.7 0.664 
average   94.4   72.9 88.9 0.701 
SD   ±2.27   ±4.33 ±2.38 ±0.05 
SVM 
SE   ±1.02   ±1.94 ±1.06 ±0.02 
1 155 12 92.8 44 11 80.0 89.6 0.724 
2 167 11 93.8 46 16 74.2 88.8 0.700 
3 154 8 95.1 45 15 75.0 89.6 0.730 
4 158 9 94.6 45 1 97.8 95.3 0.874 
5 152 15 91.0 54 11 83.1 88.8 0.728 
average   93.5   82.0 90.4 0.751 
SD   ±1.61   ±9.56 ±2.76 ±0.07 
SVM 
+RFE 
SE   ±0.72   ±4.28 ±1.24 ±0.03 
Predicted results are given in TP (true positive), FN (false negative), TN (true negative), FP (false 
positive), SE (sensitivity) which is the prediction accuracy for TPT, SP (specificity) which is the 
prediction accuracy for non-TPT, Q (overall prediction accuracy ), and C (Matthews correlation 
coefficient ). Statistical significance is indicated by SD (standard deviation), and SE (standard 
error) respectively. 
 
The performance of LR method appears to be more significantly improved than 
that of other methods when the 49 RFE selected descriptors were used instead of the full 
199 descriptor set. LR generally requires a sufficient number of samples and appropriate 
number of descriptors to develop an accurate classification system. Given a fixed number 
of samples, excessive number of descriptors may cause the model to be over-fitted [Sutter 
et al. 1993; Kohavi et al. 1997a; Xue et al. 2004b] . Moreover, the introduction of 
irrelevant molecular descriptor may also affect the performance of LR model to some 
extent. It likely that the use of the 49 RFE selected descriptors helps improving the 
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performance of LR model by reducing the level of over-fitting and that of the noise 
generated by irrelevant descriptors. 
 
It has been reported that chance correlation might occur during descriptor 
selection, especially when the number of descriptors available for selection is large 
[Jouan-Rimbaud et al. 1996]. Therefore Y-randomization has been frequently used to 
determine the probability of chance correlation during descriptor selection processes 
[Manly 1997]. In y-randomization, a portion of TPT agents in the data set was randomly 
selected and converted to non-TPT agents. Another portion of non-TPT agents was also 
randomly selected and converted to TPT agents. The ratios of TPT agents to non-TPT 
agents were kept unchanged during y-randomization. The “scrambled” data set was then 
used for the descriptor selection process. The process of scrambling of the data set and 
descriptor selection process was repeated for 10 times. This y-randomization analysis was 
conducted on the SVM model that consistently gives the better classification accuracies 
in this and other studies [Burbidge et al. 2001; Czerminski et al. 2001]. Unless over 
fitting is found in the SVM model, no further analysis on other models is to be conducted. 
The average Matthews correlation coefficient of these scrambled SVM classification 
systems derived by using the 5-fold cross validation sets were found to be 0.430, which is 
significantly lower than that of the original SVM classification system, which is 0.751. 
This suggests that the original SVM classification system is relevant and unlikely a result 
of chance correlation. 
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Apart from the use of randomized cross validation method, an external 
independent validation test set is frequently been used for testing the robustness of a 
model. We were not able to find new Terrahymena Pyriformis toxic compounds in the 
recent publications. Hence, representative training and validation sets were constructed 
from our existing datasets according to the Kennard and Stone algorithm, with the 
training set used for model construction and validation set for independent testing.  
 
The prediction results by each of the SLM prediction system with the selected 
descriptors for using the Kennard and Stone algorithm the validation set selected can be 
found in Table 5.7. A frequently used method for checking whether a prediction system 
is over-fit is to compare the prediction accuracy for cross validation sets with those for 
independent validation sets [Hawkins 2004]. Since descriptor selection was performed 
with the cross validation method using the modeling testing sets, an over-fitted 
classification system is expected to have much higher prediction accuracy for the cross 
validation sets than that for the independent validation set. As shown in Table 5.6 and 
Table 5.7, the prediction accuracy of the SLM systems based on the 5 fold cross 
validation method and those based on the independent validation set are found to be 
similar. This shows that the SLM classification systems developed in this study are 
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Table 5.7 Comparison of the prediction accuracy of Tetrahymena pyriformis toxic (TPT) 
and non-toxic (non-TPT) agents by different statistical learning methods. The accuracy of 
each method was estimated from an independent validation set by using 281 TTP and 96 
non-TTP agents. 














LR -- 277 4 67 29 91.2 98.6 69.8 0.762 
C4.5 DT -- 266 15 75 21 90.5 94.7 78.1 0.744 
k-NN 3 280 1 70 26 92.8 99.6 72.9 0.859 
PNN 0.2 273 8 89 7 96.0 97.2 92.7 0.896 
SVM 0.4 280 1 85 11 96.8 99.6 88.5 0.916 
Predicted results are given in TP (true positive), FN (false negative), TN (true negative), 
FP (false positive), SE (sensitivity) which is the prediction accuracy for TPT, SP 
(specificity) which is the prediction accuracy for non-TPT, Q (overall prediction 
accuracy ), and C (Matthews correlation coefficient ).LR (logistic regression), LDA 
(linear discriminate analysis), C4.5 DT (C4.5 decision tree), k-NN (k nearest neighbor), 
PNN (probabilistic neural network), SVM (support vector machine). 
 




Apart from the quality of dataset used, selection of molecular descriptors most 
relevant to the prediction of TPT agents is important for optimizing the prediction models 
and for elucidating the molecular factors contributing to TPT. A total umber of 49 
molecular descriptors were selected by the RFE method in this work, all of them were 
found to match or partially match those descriptors used in the published TPT QSAR 
models and other statistical learning models. Table 5.8 is the list of molecular descriptors 
selected by the RFE method for classification of TPT and non-TPT agents. The first, 
second and third column gives the RFE selected descriptors, their description, and the list 
of the matched or partially-matched molecular descriptors used in previously published 
TPT models respectively. 
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Table 5.8 Molecular descriptors selected from the recursive feature elimination (RFE) 
method for support vector machine (SVM) classification of Tetrahymena pyriformis toxic 
(TPT) and non-toxic (non-TPT) agents. 
Molecular 
Descriptor 
Description Matched or Partially-
Matched Molecular 
Descriptors Used in 
Published TPT Models  
noxy Count of O atoms Total number of oxygen atoms 
[Cronin et al. 2002] 
3χP Simple molecular connectivity Chi 
indices for path order 3 
Total number of paths, χ value 
of path chains of length 7, no. 
of path chains of length 6, 
eccentric connectivity index 
[Serra et al. 2001] 
Kier simple and valence 
molecular connectivity indices 
[Cronin et al. 2002] 
3χC Simple molecular connectivity Chi 
indices for cluster 
Total number of paths, χ value 
of path chains of length 7, no. 
of path chains of length 6, 
eccentric connectivity index 
[Serra et al. 2001]; Kier simple 
and valence molecular 
connectivity indices [Cronin et 
al. 2002] 
4χPC Simple molecular connectivity Chi 
indices for path/cluster 
Total number of paths, χ value 
of path chains of length 7, no. 
of path chains of length 6, 
eccentric connectivity index 
[Serra et al. 2001]; Kier simple 
and valence molecular 
connectivity indices [Cronin et 
al. 2002]  
1χv Valence molecular connectivity Chi 
indices for path order 1 
Total number of paths, χ value 
of path chains of length 7, no. 
of path chains of length 6, 
eccentric connectivity index 
[Serra et al. 2001]; Kier simple 
and valence molecular 
connectivity indices [Cronin et 
al. 2002] 
S(9) Atom-type H Estate sum for =CH- 
(sp2) 
No. of sp2 hybridized carbons 
bonded to 3 other carbons 
[Cronin et al. 2002], Sum of 
Estate indices [Serra et al. 
2001] 
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S(12) Atom-type H Estate sum for CH n 
(Saturated) 
Sum of Estate indices [Cronin 
et al. 2002] 
S(13) Atom-type H Estate sum for CH n 
(unsaturated) 
No. of sp2 hybridized carbons 
bonded to 3 other carbons 
[Cronin et al. 2002], Sum of 
Estate indices [Serra et al. 
2001] 
S(16) Atom-type Estate sum for -CH 3 Sum of Estate indices [Cronin 
et al. 2002] 
S(17) Atom-type Estate sum for =CH 2 No. of sp2 hybridized carbons 
bonded to 3 other carbons 
[Cronin et al. 2002], Sum of 
Estate indices [Serra et al. 
2001] 
S(18) Atom-type Estate sum for >CH 2 Sum of Estate indices [Cronin 
et al. 2002] 
S(20) Atom-type Estate sum for =CH- No. of sp2 hybridized carbons 
bonded to 3 other carbons 
[Cronin et al. 2002], Sum of 
Estate indices [Cronin et al. 
2002] 
S(22) Atom-type Estate sum for >CH- Sum of Estate indices [Ren 
2003a] 
S(25) Atom-type Estate sum for ≡C- Sum of Estate indices [Serra et 
al. 2001] 
S(41) Atom-type Estate sum for -O- Estate index for the Hydroxy 
group [Cronin et al. 2002] 
Tcent Centric Index Eccentric connectivity index 
[Cronin et al. 2002] 
Tbala Balaban Index Balaban, Weiner topological 
indices [Cronin et al. 2002] 
Tradi PetitJohn R2 Index Balaban, Weiner topological 
indices [Cronin et al. 2002] 
Tpeti PetitJohn I2 Index Balaban, Weiner topological 
indices [Cronin et al. 2001] 
Tiwie Information Weiner Balaban, Weiner topological 
indices [Cronin et al. 2001; 
Gonzalez et al. 2004] 
εb Hydrogen bond acceptor basicity 
(covalent HBAB) 
Total number of hydrogen 
bond acceptors [Netzeva et al. 
2003a; Schultz et al. 2005] 
µ Molecular dipole moment Dipole moment [Cronin et al. 
2002; Roy et al. 2005]  
η Absolute hardness Absolute hardness [Aptula et 
al. 2005] 
IP Ionization potential (IP) Ionization potential [Ren et al. 
Table 5.8 Continued
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2002]; Corrected for ionization 
[Roy et al. 2005], Energy value 
of HOMO [Schuurmann et al. 
2003] 
µ cp  Chemical potential Chemical potential [Spycher et 
al. 2005] 
χ en Electronegativity index  HOMO energy [Ren et al. 
2002], σ and π 
electronegativity [Devillers 
2004; Schultz et al. 2005] 
ω Electrophilicity index Soft electrophilicity index 
[Melagraki et al. 2005];  
Q H, Max Most positive charge on H atoms The largest positive charge on 
a hydrogen atom [Schultz et al. 
2005], Acidity constant 
[Schultz et al. 2005] 
Q C, Max Most positive charge on C atoms Partial charge of C [Schultz et 
al. 2005] 
Q H, Min Most negative charge on H atoms Maximum partial charge of H 
atoms [Cronin et al. 2002] 
Q C, Min Most negative charge on C atoms Partial charge of C [Schultz et 
al. 2005] 
A Q, min Most negative charge in a molecule Largest negative charge value 
[Schuurmann et al. 2003] 
Q C, SS Sum of squares of charges on C and 
all atoms 
Partial charge of C [Ren 
2003a] 
Mnc Mean of negative charges Average atomic negative 
charges [Schuurmann et al. 
2003] 
Mac Mean absolute charge Sum of absolute charge on N 
and O atoms [Schuurmann et 
al. 2003] 
dis1 Length vectors longest distance Molecular surface areas (SA) 
[Schuurmann et al. 2003] 
dis2 Length vectors  longest third atom Molecular surface areas (SA) 
[Cronin et al. 2001; Cronin et 
al. 2002] 
dis3 Length vectors longest 4th atom) Molecular surface areas (SA) 
[Devillers 2004]  
Sapc Sum of solvent accessible surface 
areas of positively charged atoms 
Molecular surface area 
[Devillers 2004] 
Sanc Sum of solvent accessible surface 
areas of negatively charged atoms 
The negatively charged 
molecular surface 
area[Devillers 2004]  
Sancw Sum of charge weighted solvent 
accessible surface areas of negatively 
The negatively charged 
molecular surface area 
Table 5.8 Continued
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charged atoms [Schuurmann et al. 2003] 
Svncw Sum of charge weighted van der 
Waals surface areas of negatively 
charged atoms 
The negatively charged 
molecular surface area 
[Schuurmann et al. 2003] 
Rugty Molecular rugosity Charged partial surface area 
[Serra et al. 2001] 
Gloty Molecular globularity Charged partial surface area 
[Schultz 1999; Ren 2003b; 
Gonzalez et al. 2004; Aptula et 
al. 2005], Normalized 
molecular area projected onto 
xz-plane [Cronin et al. 2001; 
Cronin et al. 2002; Melagraki 
et al. 2005; Netzeva et al. 
2005; Schultz et al. 2005] 
Shpb Hydrophobic region Hydrophobicity values 
[Schuurmann et al. 2003]; 
octanol/water partition 
coeeficient [Ren 2003b; Roy et 
al. 2005] 
Capty Capacity factor Charged partial surface area 
[Cronin et al. 2001] 
Hiwpl Hydrophilic Integy Moment Electrophilicity [Schultz 1999; 
Ren 2003b; Gonzalez et al. 
2004; Aptula et al. 2005], 
dipole moment [Cronin et al. 
2001; Cronin et al. 2002; 
Melagraki et al. 2005; Netzeva 
et al. 2005; Schultz et al. 2005] 
Hiwpb Hydrophobic Integy Moment Hydrophobicity values [Ren 
2003b; Roy et al. 2005], 
octanol/water partition 
coeeficient [Schultz 1999; 
Netzeva et al. 2005] 
Hiwpa Amphiphilic Moment Electrophilicity [Gunatilleka et 
al. 2000], Super-
delocalizability [Cronin et al. 
2001; Cronin et al. 2002; 
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Terrahymena pyriformis toxicity involves multiple mechanisms and chemical 
features which may not be fully described by a few descriptors, particularly for a larger 
number of compounds than those covered in previous studies. Gunatilleka and Poole 
reported, based on their study of compounds that are believed to interact only through a 
narcosis type mechanism, that the main factors contributing to non-specific toxicity are 
solute size and lone-pair electron interactions, with the solute size and hydrogen bond 
basicity being the most important factors for toxicity [Gunatilleka et al. 2000]. They have 
found that small compounds of high hydrogen-bond basicity tend to show higher toxicity. 
The descriptor for hydrogen bond acceptor basicity (εb) is selected by RFE in this study. 
Rugty (molecular rugosity), Gloty (molecular globularity), dis1 (length vector longest 
ditance), dis2 (length vector longest 3rd atom), and dis3 (Length vector longest 4th atom) 
are the RFE selected VolSurf and other descriptors related to the size and shape of a 
compound. Thus our study is consistent with the conclusion from Gunatilleka and Poole. 
Apart from these descriptors, several studies have found that polar surface area 
descriptors to be significant for toxicity predictions [Cronin et al. 2001; Cronin et al. 
2002; Schuurmann et al. 2003; Devillers 2004]. The RFE selected descriptors that cover 
polar surface property are Sapc (sum of solvent accessible surface areas of positively 
charged atoms) and Sanc (sum of solvent accessible surface areas of negatively charged 
atoms). 
 
Narcosis is often associated with hydrophobicity. Uptake, transport and 
distribution of organic toxicants via passive diffusion is best modeled by hydrophobicity 
that usually represented by 1-octanol/water partition coefficient (logKow) [Cronin et al. 
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2001; Cronin et al. 2002; Melagraki et al. 2005; Netzeva et al. 2005; Schultz et al. 2005]. 
Shpb (hydrophobic region) and Hiwpb (hydrophobic integy moment) are the RFE 
selected descriptors correlated to those hydrophobic descriptors used in previous QSAR 
studies [Cronin et al. 2001; Cronin et al. 2002; Netzeva et al. 2005; Schultz et al. 2005]. 
Reactive toxicants are known to be electrophiles associated with irreversible interactions 
with biomolecules[Aptula et al. 2005]. It has been reported that both global and local 
electrophilicity can capture the toxicity properties of a large variety of aliphatic 
compounds [Roy et al. 2005]. Electrophilicity is related to the flow of electrons between 
a donor and a receptor and is associated to the electronic chemical potential and the 
chemical hardness of the ground state of atoms or molecules [Roy et al. 2005]. Both 
chemical potential (µ cp) and absolute hardness (η) are selected by RFE method in this 
study. In addition, both absolute hardness (η) and the chemical potential (µ cp) have high 
correlation with hydrogen bond donor acidity as reported by Mignon and coworkers 
[Mignon et al. 2005]. 
 
Steric properties of a compound can affect membrane transport and specific 
interactions at reactive sites with implications to its toxicological profiles. For instance, 
the isobutyl and isoamyl acrylates are less toxic than the linear analogues [Schultz et al. 
2005]. The steric properties of a molecule can be described by topological descriptors 
such as topological shape index [Netzeva et al. 2003b]. The RFE selected topological 
descriptors in this study are four simple molecular connectivity descriptors, 3χP (simple 
molecular connectivity Chi indices for path order 3), 3χC (simple molecular connectivity 
Chi indices for cluster), 4χPC (simple molecular connectivity Chi indices for path/cluster), 
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and 1χv (valence molecular connectivity Chi indices for path order 1). Moreover, other 
topological descriptors such as Tcent (Centric Index), Tbala (Balaban Index), Tradi 
(PetitJohn R2 Index), Tpeti (PetitJohn I2 Index), and Tiwie (Information Weiner) are also 
selected by RFE. 
 
Weak acid respiratory uncouplers, which are generally bulky and electronegative 
compounds, produce their toxic effect by disrupting ATP synthesis. They induce 
disruption of the hydrogen ion gradient in the inner mitochondrial membrane [Schultz 
1999]. Increased acidity of phenols promotes their ability to uncouple the respiratory 
chain from oxidative phosphorylation [Schuurmann et al. 2003]. Moreover, toxicity of 
α,β-unsaturated aldehydes such as cinnamaldehyde have been attributed to Schiff-base 
formation [Netzeva et al. 2005; Schultz et al. 2005]. These two toxic events are related to 
the ionization ability and unequal charge distribution profile of a compound. Both acidity 
and the Schiff-base formation are represented by the three REF selected descriptors Q C, 
Max (most positive charge on C atoms), Q H, Max (most positive charge on hydrogen atoms) 
and IP (ionization potential). 
 
Genotoxicity is one of the causes of the observed Terrahymena pyriformis 
toxicity, which  involves either oxidative damage to DNA by free radicals formed by 
one-electron oxidation [Netzeva et al. 2003a] or DNA methylation via intercalation. The 
three RFE-selected descriptors, absolute hardness (η), chemical potential (µ cp), 
electronegativity index (χ en) and electrophilicity index (ω) are correlated to the formation 
of free radicals. DNA intercalation is primarily mediated by aromatic ring via п-п 
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interactions with DNA base-pairs. The RFE selected electro-topological state descriptors 
S(9) and S(13), which describe atom-type H estate sum for  =CH- (sp2) and CH n 
(unsaturated) represent the ability of a compound to form п-п interactions with DNA 
base-pairs. The other REF selected descriptor S(16), which describes atom-type Estate 
sum of -CH3, can be used to represent the potential of DNA methylation.  
 
5.2.3.3 Performance evaluation 
 
To assess the performance of SLMs for TPT agents’ prediction on the more 
diverse set of molecules, it is useful to examine whether the accuracy from these methods 
is at a similar level as those derived from the use of a significantly smaller number of 
compounds. A direct comparison with results from previous studies is inappropriate 
because of the differences in the dataset and molecular descriptors used. Although 
desirable, it is impossible to conduct a separate comparison using results directly from 
other studies without detailed information about the algorithms of molecular descriptors 
and classification methods used in each study. Nonetheless, a tentative comparison may 
provide some crude estimate regarding the approximate level of accuracy of the TPT 
prediction systems derived in this study.  From Table 5.5, the overall accuracies of all of 
our tested SLMs are in the range of 85.3%~90.4% with SVM, k-NN and PNN giving 
better performance. These accuracy is comparable to the accuracies of 90%~92% of the 
linear regression and neural network models derived from 220~448 compounds [Serra et 
al. 2001; Spycher et al. 2005], but somehow lower than the accuracy of 97%~99% 
derived from the linear discriminant analysis and binary logistic regression models of 220 
compounds [Schuurmann et al. 2003]. 
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Overall, our study suggests that statistical learning methods, particularly SVM, k-
NN and PNN, are found to be useful for toxicity prediction of a broad range of molecule 
[Xue et al. 2006]. The prediction accuracy of these methods is at a level similar to some 
of the earlier studies that were tested by using a much smaller number of molecules. 
Another advantage of these methods is that they do not require knowledge about the 
molecular mechanism or structure-activity relationship of a particular drug property 
before a prediction model can be developed. However, these methods are limited in 
providing detailed information about the mechanism of the predicted properties, even-
though some levels of knowledge may be extracted from the molecular descriptors 
selected by feature selection methods. Development of regression-based SLM models 
might enable more quantitative description about the mechanism of predicted properties 




This section shows that SLMs, particularly SVM, k-NN and PNN, are useful for 
facilitating the prediction of toxic potential to Tetrahymena pyriformis from a diverse set 
of molecules without requiring the knowledge of mechanisms and choice of specific 
molecular descriptors. The current SLMs are limited in their ability for facilitating the 
study of the mechanism of predicted properties. Such a weakness might be partially 
overcome by the development of regression-based SLM models for quantitative 
description about the mechanism of predicted properties. Prediction accuracy of some 
toxic agents is known to be affected by the inadequate coverage of the currently available 
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molecular descriptors [Li et al. 2005a]. The introduction of additional molecular 
descriptors is useful for further improving the prediction accuracy of SLMs and 
developing these methods into practical tools for the prediction of toxicological 
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Chapter 6 Concluding remarks 
 
 
This last chapter summarizes the major findings (section 6.1) and discusses major 
contributions of this work to the progress of using SLMs for pharmacological properties 
predictions (section 6.2). Limitations of the present work and suggestions of possible 
areas for future studies are discussed in section 6.3 and section 6.4, respectively. 
 
6.1 Major findings 
 
6.1.1 Merits of SLMs in the studies of pharmacological properties 
 
 
In Chapter 3, Chapter 4 and Chapter 5, our studies show that SLMs, particularly 
SVM, are useful for facilitating the prediction of pharmacological properties of a diverse 
set of molecules, such as the PXR activators, the BBB agents, the ER agonists, the 
genotoxic agents and the TPT agents, without requiring the intrinsic mechanism 
knowledge of chemical compounds. Instead of focusing on specific structural features or 
a particular group of related molecules, SLMs generally classify diverse sets of 
compounds into positive (active) and negative (inactive) agents based on their general 
structural and physicochemical properties irrespective of their structural and chemical 
affiliation. SLMs consistently show promising capability for predicting chemical agents 
of diverse range of structures and of a wide variety of pharmacodynamic, 
pharmacokinetic, and toxicological properties. Thus, it is likely that SLMs, especially 
SVM, are efficient computational tools for the prediction of pharmacological properties 
of pharmaceutical agents. 
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6.1.2 Merits of RFE in the studies of pharmacological properties 
 
 
From the chemistry point of view, one can state that the molecular structure of a 
compound is the key in understanding its physicochemical properties and ultimately its 
biological activity and physiological effect [Johnson et al. 1990]. In Chapter 3, Chapter 4 
and Chapter 5, a feature selection method, RFE, is incorporated into SVM to select 
appropriate descriptors that are relevant to the pharmacological property prediction 
models. RFE was found to be capable of automatic selection of molecular descriptors and 
reduction of the noise generated by the use of overlapping and redundant molecular 
descriptors. It was also found that selection of appropriate molecular descriptors by RFE 
give substantially more balanced prediction accuracy and enhance the overall accuracy. 
In addition, the analysis of selected features by RFE provides useful clues to the 
structural and physicochemical features contributing to a specific pharmacological 
property from structurally diverse compounds. Moreover, the RFE selected descriptors 
capture the relevant pharmacological properties and are consistent with QSAR, 
pharmacophore, and X-ray crystallographic studies. 
 
6.1.3 The pharmacokinetic models: PXR activators and BBB agents  
 
 
             In Chapter 3 we explored three SLMs for predicting PXR activators, which were 
trained and tested by using significantly higher number of compounds, 128 PXR 
activators (98 human) and 77 PXR non-activators, than those of previous studies. RFE 
feature selection method was used to select molecular descriptors relevant to PXR 
activator prediction, which are consistent with conclusions from other computational and 
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structural studies. In a 10-fold cross-validation test, our SLMs systems correctly 
predicted 81.2%~84.0% of PXR activators, 80.8%~85.0% of hPXR activators, 
61.2%~70.3% of PXR non-activators, and 67.7%~73.6% of hPXR non-activators. Our 
systems also correctly predicted 73.3%~86.7% of 15 newly published hPXR activators. 
The results from our study suggest that SLMs, especially SVM, are useful for in silico 
prediction of the activators of highly promiscuous proteins such as PXR and for 
characterizing the molecular features of PXR activation. By incorporating feature 
selection methods such as RFE into SVM, molecular descriptors relevant to the 
physicochemical properties of PXR activators can be identified. Most of these selected 
molecular descriptors are found to be consistent with those used in previous 
pharmacophore and QSAR studies and with the findings from X-ray crystallography 
studies. Moreover, we found that the number of selected descriptors in this study is 
substantially larger than the 22~39 molecular descriptors selected in the prediction of 
compounds of various other drug activities or properties. An examination of the selected 
descriptors shows that most of the “extra” sets of descriptors are properties such as 
electro-topological, connectivity and quantum chemical classes. Our selected descriptors 
are consistent with the molecular binding features derived from the study of the binding 
site of the ligand-free and drug-bound PXR receptor structures.  
In Chapter 3, we also examined whether proper selection of molecular descriptors 
could improve both the BBB- and the overall accuracy of SLMs. The methods used for 
this study are LR, LDA, k-NN, C4.5 DT, PNN and SVM. Molecular descriptors were 
selected by using RFE feature selection method. Our result by using 415 BBB+ and 
BBB- agents shows that RFE substantially improves both the BBB- and the overall 
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accuracy for all of the methods studied. RFE appears to be helpful in improving the 
performance of SLMs for the prediction of BBB penetration potential of chemical agents. 
This suggests that SLMs combined with proper feature selection is potentially useful for 
facilitating a more balanced and improved prediction of BBB+ and BBB- agents. In 
addition, we found that selected descriptors in this work are overlapped with those used 
in QSAR studies of BBB penetrating and non-penetrating agents. Particularly, the RFE 
selected molecular descriptors are consistent with the finding that less polar, more 
lipophilic compounds partition more readily into the brain and the greater binding of the 
solute to the membrane, the higher the BBB partitioning [Iyer et al. 2002]. 
 
6.1.4 The pharmacodynamic model: ER agonists 
 
In Chapter 4, we explored the employment of several SLMs, including of SVM, 
k-NN, PNN and C4.5 DT, for predicting ER agonists from a comprehensive set of known 
ER agonists and other compounds. The corresponding prediction systems were developed 
and tested by using 243 ER agonists and 463 ER non-agonists respectively; the sample 
size are significantly larger in number and structurally more diverse than those in 
previous studies. RFE feature selection method was used for selecting molecular 
descriptors responsible for distinguishing ER agonists from non-agonists. We found that 
most of selected discriptors were consistent with those used in other studies and the 
findings from X-ray crystallography data. The prediction accuracies of these methods are 
comparable to those of earlier studies despite the use of significantly more diverse range 
of compounds. SVM gives the best accuracy of 88.9% for ER agonists and 98.1% for 
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non-agonists. We found that in our independent validation set there were two 
environmental estrogenic compounds namely, kepone (chlordecone) and o p’-DDT, that 
have molecular structures very different from estradiol. This makes it difficult to deduce 
the estrogenic activity of these chemicals solely based on their molecular structures. 
However, we found that our SVM system is able to correctly predicate them as ER 
agonists. This ability of SVM clearly demonstrate its strength in the identification of 
classically difficult to characterize environmental estrogens at least for kepone and o p’-
DDT and its ability to deduce the estrogenic activity of chemicals based on the selected 
molecular descriptors. 
 
6.1.5 The toxicity models: Genotoxicity agents and TPT agents 
  
In Chapter 5, we tested several SLMs including SVM, PNN, k-NN and C4.5 DT 
using a more diverse set of 860 GT+ and GT- agents as compared with previous studies. 
RFE feture selection method was used for selecting molecular descriptors relevant to the 
genotoxicity model. The overall accuracy of SVM, k-NN and PNN is comparable to and 
those of DT lower than the results derived from earlier studies, with SVM giving highest 
accuracy of 77.8% for GT+ and 92.7% for GT- agents. Our study suggests that SLMs, 
particularly SVM and PNN, are able to facilitate the prediction of genotoxic potential of a 
diverse set of molecules without requiring the intrinsic mechanism knowledge of 
chemical compounds. Instead of focusing on specific structural feature or a particular 
group of related molecules, these methods classify molecules into genotoxic and non-
genotoxic agents based on their general structural and physicochemical properties 
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regardless of their structural and chemical types. Therefore, in principle, these methods 
are expected to be applicable to a diverse set of molecules. 
 
In Chapter 5, the Tetrahymena pyriformis toxicity model is constructed with the 
use of several SLMs, including LR, C4.5 DT, k-NN, PNN, SVM, and found that the 
model is able to classify successfully1129 compounds (841 TPT and 288 non-TPT agents) 
which are more structurally diverse than those in other studies. RFE feature selection 
method was used for improving prediction performance and selecting molecular 
descriptors responsible for distinguishing TPT and non-TPT agents. The prediction 
accuracy is 86.9% to 94.2% for TPT and 71.2% to 87.5% for non-TPT agents based on 5-
fold cross-validation studies. They are comparable to some of the earlier studies despite 
the use of more diverse sets of compounds. The selected molecular descriptors are 
consistent with those used in other studies and experimental findings. Our study suggests 
that SLMs, particularly SVM and PNN, are useful for facilitating the prediction of toxic 
potential to Tetrahymena pyriformis for a diverse set of molecules without requiring the 





This work, as far as we know, is the first study that applied SLMs, particularly 
SVM, PNN and k-NN, to build the prediction systems for PXR activators. The 
importance of PXR is realized currently for drug metabolism and drug-drug interactions, 
while insufficient computational methods have been applied to it. In this work we have 
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developed SVM, PNN and k-NN prediction systems, which were trained and tested by 
using significantly higher number of compounds than those in previous studies, for PXR 
activators. Our systems can correctly predict 73.3%~86.7% of 15 newly published hPXR 
activators. The three SLMs prediction systems, especially SVM, are useful for in silico 
prediction of the activators of highly promiscuous proteins such as PXR and for 
providing clues to physicochemical features of PXR activation.  
 
 This study pioneers the applicaton of SLMs, particularly SVM, PNN, k-NN and 
C4.5 DT, to build prediction systems for ER agonists. Identification of novel ER agonists 
from structurally diverse compounds is important for drug discovery and environmental 
safety evaluation. Previous knowledge of ER binding is insufficient for determining ER 
agonism, which is more relevant to drug discovery and safety evaluation. In this study, 
we have built SLMs prediction systems for predicting ER agonists and for characterizing 
molecular descriptors associated with ER agonism. The corresponding prediction systems 
have been developed and tested by using compounds significantly larger in number and 
higher in structural diversity than those of previous studies. Our systems can correctly 
predict 90.9% for ER agonists and 100% for ER non-agonists of 11 ER agonists and 16 
ER non-agonists reported in the literatures. Furthermore, our SVM model demonstrates 
its strength in identification of environmental estrogens, which are classically hard to 
characterize, and its ability to deduce the estrogenic activity of chemicals based on the 
selected molecular descriptors. 
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In addition, this work improves the quality of previous models for 
pharmacological properties prediction. All the pharmacological properties prediction 
models developed in this work have higher prediction capability than the corresponding 
models developed previously. The use of known, relative new SLMs such as SVM and 
PNN are found to be useful for improving prediction capability of pharmacological 
properties models for PXR activators, BBB agents, ER agonists, genotoxicity agents and 
TPT agents. Moreover, these models were also developed by using a significantly larger 
number and more diverse groups of compounds, as well as compounds with known 
human pharmacological properties data. Thus the models are expected to have better 
generalization ability than the previous models and are directly for the prediction of 
human pharmacological properties. Furthermore, RFE feature selection method is found 
to be helpful for facilitating a more balanced and improved overall prediction 
performance by properly selecting relevant molecular descriptors. Therefore, all the 
pharmacological properties models developed in this work are potentially useful to be 
incorporated as part of the strategy for reducing the cost and improving the speed in the 
drug discovery and development process. 
 
 This work also improves the interpretability of pharmacological properties 
prediction models developed by SLMs. By incorporating the RFE feature selection 
method into SVM, molecular descriptors relevant to PXR activators, BBB agents, ER 
agonists, genotoxicity agents and TPT agents are identified. Most of the selected 
molecular descriptors are consistent to those used in previous QSAR pharmacophore 
studies, and with the findings from X-ray crystallography studies. The selected molecular 
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descriptors provide particular structural information to identify the characteristics of a 
specific pharmacological property of pharmaceutical agents, and they are very helpful for 
the high throughput drug screening by using compounds from diverse structure dataset 





 Currently, three-levels of characterizing a mechanism of action from a 
pharmacological property model are reported in the literature. The first level states that 
specific groups in a molecule and their interaction with the target are responsible for 
activity. The second level is recommended that a pharmacophore is needed for expressing 
the activity, and the third level states the general molecular features that are often present 
in molecules that exhibit a given type of activity. All the pharmacological properties 
prediction models that were developed in this study fall into the third, the least specific 
category. 
 
 The performance of SLMs critically depends on the diversity of compounds in a 
training dataset and the appropriate representation of these compounds. The dataset used 
in this works are not expected to fully representative all of the compounds possessing and 
not possessing a specific pharmacological property. This is particularly true for 
compounds not possessing a specific property given the vast chemical space of several 
millions of compounds in currently available chemical databases. Hence inadequate 
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representation of compounds from vast chemical space in these studies to a certain extent, 
affect the performance of the models developed. 
 
 Both 1-D and 2-D molecular descriptors are used in these studies. 3-D molecular 
descriptors such as molecular dipole moment are also used. However, certain 
conformational properties such as conformational entropy are not considered. In addition, 
proper description of 3-D properties such as molecular dipole moment is poorly defined 
since the associated “active conformation” for the dipole is unknown. The deficiency of 
current 3-D molecular descriptors could have affect the performance and interpretation of 
the models developed. For example, in BBB penetration, transport across a series of 
tightly packed biological memberanes is involved. There are no meaningful 1-D and 2-D 
descriptors that can distinguish between a long, thin and flexible conformation of a 
molecule from a spherical, balled-up and rigid confirmation of a molecule and this 
difference in conformational preference is a controlling factor for BBB penetration. Some 
of the descriptors used in this study may be highly correlated and thus are very likely 
redundant in information content. Descriptors in the same class are not necessarily the 
same to a large information content regarding distinct molecular properties. Hence 
interpretation of the descriptors should be more appropriately conducted at the descriptor 
class level where redundant and overlapping descriptors are grouped into one class. 
 
 As shown in Figure 6.1, incorrectly classified compounds by models developed 
in this work suggest that the current molecular descriptors are not sufficient to adequately 
represent some of the compounds especially those contain long flexible chain, highly 
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polar tetrazole rings, multiple ionizable groups, polycyclic aromatic structures, complex 
two ring system with multiple heteroatoms and compounds with complicated ring 
structure. It appears that none of the currently available descriptors are capable to fully 
represent molecules containing a long flexible chain.  Due to the limited coverage of the 
number of bond links to a heteroatom loop, topological descriptors are not yet capable to 
describe special features of a complex multi-ring structure that contains multiple 
heteroatoms.  
 
The molecular descriptors use in this work is able to capture the overall molecular 
properties from structurally diverse chemical dataset that is useful for HTS in discovering 
novel drugs. However, they fail to capture atomic details of a compound required for 
binding to a target, which are generally useful in improving binding affinity and 
specificity. To accommodate this, knowledge for the binding site is required where in 
most cases it is lacking. Furthermore, the biological activity of a compound is an induced 
response that is influenced by numerous factors dictated by many levels of biological 
complexity. The relationship between structure and activity is thus more implicit and 
thereby requires a more thorough investigation and rigorous validation [Tong et al. 
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Figure 6.1 Examples of agents not-well-represented by some of the currently available 
molecular descriptors. The not-well-represented part of the structure is indicated by a 
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6.4 Suggestions for future studies 
 
 
In this work, it is assumed that sensitivity and specificity of the statistical learning 
classification systems such as SVM are equally important. However, in a drug discovery 
and development project, these accuracies may have different importance at different 
stages of the design cycle. This is particularly true in the initial phase of target and hit 
identification, it is more important to have a classification system that has high sensitivity 
(small number of false negatives) and reasonably good specificity. At later stage, it 
becomes increasingly important to focus on a manageable number of candidates to 
enhance binding specificity and reduce toxicity. Thus a classification system with high 
specificity (small number of false positives) and reasonably good sensitivity may become 
more important. By using different training error penalties, it is possible to modify the 
SVM classification system to suit these different needs. The first approach uses different 
training error penalties for D+ and D- (section 2.4.1.6 equation 2-20). For instance, a 
higher training error penalty for D+ and lower training error penlty for D- can be used to 
increase the sensitivity of the SVM classification system. The second approach adds a 
correction factor to the SVM decision function (section 2.4.1.6 equation 2-22). 
Consequently, a positive or negative correction factor will improve the sensitivity or 
specificity of the SVM classification system, respectively. 
 
The lack of structural diversity in the training sets may limit the applicability of 
the models developed by SLMs. However, it may be possible to use analog compound 
training sets to provide benchmarks as to what upper-level models are possible from a 
given method for a given endpoint. Furture studies can model high analog datasets as a 
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way to evaluate how much accuracy and reliability is lost in modeling structurally diverse 
data sets for a given SLMs. 
 
In addition, there is a need to explore different combination of descriptors and to 
select more optimum sets of descriptors by using more refined feature selection 
algorithms and parameters. However, indiscriminate use of many existing topological 
descriptors, which are overlapping and redundant to each other, may introduce noise as 
well as extending the coverage of some of the aspects of these special features. Thus, it 
may be necessary to introduce new descriptors for more appropriate representation of 
these special features. The new descriptors should ideally be able to translate back to the 
molecular structures. This will improve the interpretability of the developed SLMs 
classification systems. 
 
Finally, in this work, RFE feature selection method is incorporated into SVM 
classification system for dividing molecules into two classes according to a specific 
pharmacological property. This method can also be extended to the prediction of 
pharmacological properties in a continuous regression-based fashion. Future studies can 
combine RFE with support vector regression non-linear QSAR model on specific 
pharmacological properties prediction. Furthermore, efforts should be directed at the 
improvement of the efficiency and speed of RFE feature selection method, which can 
further help to optimally select molecular descriptors and enable the development of 
more accurate and efficient computational approaches for predicting  pharmacological 
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